<SEC-DOCUMENT>0001683168-21-003220.txt : 20210802
<SEC-HEADER>0001683168-21-003220.hdr.sgml : 20210802
<ACCEPTANCE-DATETIME>20210802171135
ACCESSION NUMBER:		0001683168-21-003220
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20210802
DATE AS OF CHANGE:		20210802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-255044
		FILM NUMBER:		211136918

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>pharmacyte_424b5.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: right; margin: 0pt 0; font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-255044</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #EE2724"><B>The information in this preliminary
prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not
an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale
is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>SUBJECT TO COMPLETION, DATED AUGUST
2, 2021 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Prospectus dated April 14, 2021) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 40px; width: 201px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Shares
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Pre-funded
Warrants to Purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Common
Warrants to Purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 14pt"><B>Underwriter
Warrants&nbsp;to Purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, par value
$0.0001 per share, and common warrants to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of our common stock (the &ldquo;Common Warrants&rdquo;) pursuant to this prospectus supplement and the accompanying prospectus. The
public offering price for each share of common stock and accompanying Common Warrant to purchase one share of common stock is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
.. The Common Warrants have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per share, are exercisable immediately and will expire years from the date of
issuance. We are also offering the shares of our common stock that are issuable from time to time upon exercise of the Common
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">We are also
offering pre-funded warrants (the &ldquo;Pre-funded Warrants&rdquo;) to purchase up to an aggregate of </FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="font-size: 10pt">shares of common stock (and the shares
of common stock issuable from time to time upon exercise of the Pre-funded Warrants), in lieu of shares of common stock, to those
purchasers whose purchase of shares of common stock in this offering would result in the purchaser, together with its affiliates and
certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of
common stock following the consummation of this offering. A holder of Pre-funded Warrants will not have the right to exercise any
portion of its Pre-funded Warrants if the holder, together with its affiliates and certain related parties, would beneficially own
in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after
giving effect to such exercise. Each Pre-funded Warrant will be exercisable for one share of common stock at an exercise price of
$0.001 per share of common stock. The public offering price is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Pre-funded Warrant and accompanying Common Warrant,
which is equal to the public offering price per share of common stock and accompanying Common Warrant less $0.001. Each Pre-funded
Warrant will be exercisable upon issuance and will expire when exercised in full. The shares of common stock or Pre-funded Warrants,
as applicable, and the accompanying Common Warrants, can only be purchased together in this offering but will be issued separately
and will be immediately separable upon issuance. There is no established public trading market for the Pre-funded Warrants or the
Common Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Pre-funded Warrants or the
Common Warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity
of the Pre-funded Warrants and the Common Warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s OTCQB Market Symbol is PMCB,
although as a result of the recent reverse split of the Company&rsquo;s common stock, until August 6, 2021, the Company&rsquo;s OTCQB
Market Symbol has temporarily been PMCBD. On July 30, 2021, the last reported sale price of our common stock was $12.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock has been approved for listing
on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;PMCB.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise indicated, all share and per
share information in this prospectus supplement gives effect to the reverse stock split of the Company&rsquo;s outstanding common stock,
which was effected at a ratio of 1-for-1,500 shares as of 12:01am Eastern Time on Monday, July 12, 2021. However, share and per share
amounts in the accompanying prospectus and certain of the documents incorporated by reference herein have not been adjusted to give effect
to the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The public offering price per share of common
stock, the public offering price per Pre-Funded Warrant and the public offering price per Common Warrant will be determined between us,
the underwriter, and investors based on market conditions at the time of pricing, and may be at a discount to the current market price
of our shares of common stock. Prior to this offering, there has been a limited public market for our common stock on the OTCQB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Investing in our securities involves significant
risks. Please read the information contained in or incorporated by reference under the heading &ldquo;<A HREF="#a_004">Risk Factors</A>&rdquo; beginning on
page <A HREF="#a_004">S-15</A> of this prospectus supplement and under similar headings in other documents filed after the date hereof and incorporated by
reference into this prospectus supplement and the accompanying prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the
accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Per Share and</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accompanying <BR>
Common</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrant</B></P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Per Pre-funded Warrant and<BR>
 Accompanying </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common<BR>
 Warrant</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; width: 63%"><FONT STYLE="font-size: 10pt">Public offering price<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 11%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 11%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 11%">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -13.7pt"><SUP>&nbsp;</SUP></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.3pt"></TD><TD STYLE="width: 13.7pt"><SUP>(1)</SUP></TD><TD>Includes $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per warrant for the accompanying Common Warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.3pt"></TD><TD STYLE="width: 13.7pt"><SUP>(2)</SUP></TD><TD>In addition, we have agreed to pay the underwriter a management fee equal
to 1.0% of the gross proceeds of this offering, to issue to the underwriter or its designees warrants to purchase shares of common stock
equal to 7.5% of the shares issued in this offering (including the shares of common stock issuable upon the exercise of the Pre-funded
Warrants) and to reimburse certain expenses of the underwriter in connection with this offering. This prospectus supplement and the accompanying
prospectus also covers the underwriter warrants and the shares of our common stock issuable upon exercise of the underwriter warrants. See &ldquo;<A HREF="#a_010">Underwriting</A>&rdquo; for additional disclosure regarding
                                            underwriting compensation. See &ldquo;<A HREF="#a_010">Underwriting</A>&rdquo; beginning
                                            on page <A HREF="#a_010">S-40</A> for additional disclosure regarding the compensation payable to the underwriter.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have granted the underwriter an option
for a period of up to 30 days from the date of this prospectus supplement to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock at the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , and/or Common Warrants to purchase up to shares of our common stock at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , less underwriting
discounts and commissions. If the underwriter exercises the option in full, the total underwriting discounts and commissions payable
by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , excluding potential proceeds from the exercise of the
Common Warrants included in such option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Delivery of the shares of common stock, Pre-Funded
Warrants and Common Warrants being offered pursuant to this prospectus supplement and the accompanying prospectus is expected to be made
on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, subject to the satisfaction of certain closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Sole Book-Running Manager </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>H.C. WAINWRIGHT
&amp; CO.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>The date of this prospectus
supplement is August__, 2021. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prospectus Supplement</P>


<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Page</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; width: 89%"><A HREF="#a_001">ABOUT THIS PROSPECTUS SUPPLEMENT</A></TD>
    <TD STYLE="text-align: center; width: 11%">S-ii</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_002">PROSPECTUS SUPPLEMENT SUMMARY</A></TD>
    <TD STYLE="text-align: center">S-1</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_003">THE OFFERING</A></TD>
    <TD STYLE="text-align: center">S-13</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_004">RISK FACTORS</A></TD>
    <TD STYLE="text-align: center">S-15</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_005">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: center">S-30</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_006">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: center">S-32</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_007">CAPITALIZATION</A></TD>
    <TD STYLE="text-align: center">S-33</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_008">DILUTION</A></TD>
    <TD STYLE="text-align: center">S-34</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_009">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS</A></TD>
    <TD STYLE="text-align: center">S-36</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_010">UNDERWRITING</A></TD>
    <TD STYLE="text-align: center">S-40</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_011">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></TD>
    <TD STYLE="text-align: center">S-46</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_012">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: center">S-49</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_013">EXPERTS</A></TD>
    <TD STYLE="text-align: center">S-50</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_014">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: center">S-51</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><A HREF="#a_015">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></TD>
    <TD STYLE="text-align: center">S-52</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><U>Page</U></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 89%; font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s1">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s2">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s3">THE OFFERING</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s4">OUR COMPANY</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s5">RISK FACTORS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s6">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s7">USE OF PROCEEDS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s8">DIVIDEND POLICY</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s9">DESCRIPTIONS OF THE SECURITIES WE MAY OFFER</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s10">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">27</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s11">LEGAL MATTERS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s12">EXPERTS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s14">INFORMATION INCORPORATED BY REFERENCE</A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">31</TD></TR>
</TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus supplement and the accompanying
prospectus are part of a shelf registration statement on Form S-3 (File No. 333-255044) that we filed with the Securities and Exchange
Commission, or SEC, on April 5, 2021 and that was declared effective by the SEC on April 14, 2021, pursuant to which we may from time
to time offer various securities in one or more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This document is in two parts. The first part
is this prospectus supplement, which describes the terms of this offering and also adds to and updates information contained in the accompanying
prospectus and the documents incorporated by reference herein or therein. The second part, the accompanying prospectus, including the
documents incorporated by reference into the accompanying prospectus, provides more general information. When we refer to this prospectus,
we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this
prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference herein or
therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided
that if any statement in one of these documents is inconsistent with a statement in another document having a later date - for example,
a document incorporated by reference in the accompanying prospectus - the statement in the document having the later date modifies or
supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have not and the underwriter has not authorized
anyone to provide information different from that contained in this prospectus supplement and the accompanying prospectus that we have
authorized for use in this offering. If anyone provides you with different or inconsistent information, you should not rely on it. We
do not and the underwriter does not take any responsibility for, and neither we nor the underwriter can provide assurance as to the reliability
of, any other information that others may give you. Neither the delivery of this prospectus supplement and the accompanying prospectus,
nor the sale of our common stock, Common Warrants and Pre-funded Warrants means that information contained in this prospectus supplement
and the accompanying prospectus, is correct after their respective dates. It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this
prospectus supplement and the accompanying prospectus in making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>This prospectus supplement does not contain
all of the information that is important to you. You should also read and consider the information in the documents to which we have referred
you in the sections entitled &ldquo;<A HREF="#a_014">Where You Can Find More Information</A>&rdquo; and &ldquo;<A HREF="#a_015">Incorporation of Certain Information by Reference</A>&rdquo;
in this prospectus supplement. You should rely only on the information contained or incorporated by reference in this document. You should
assume that the information in this prospectus supplement and the accompanying prospectus, as well as the information we have filed with
the SEC and incorporated by reference in this document, is accurate only as of its date or the date which is specified in those documents.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are offering to sell, and seeking offers to
buy, and the underwriter is soliciting offers to buy, these securities only in jurisdictions where offers and sales are permitted. The
distribution of this prospectus supplement and the accompanying prospectus and the offering of the securities in certain jurisdictions
may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying
prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution
of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying
prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities
offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such
person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus supplement and the information
incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service
marks and trade names included or incorporated by reference herein are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless the context otherwise requires, in this
prospectus supplement the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; and similar names refer to PharmaCyte
Biotech, Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>PROSPECTUS SUPPLEMENT SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This summary highlights certain information about
us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement and the
accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding
whether to invest in our common stock, Common Warrants and Pre-funded Warrants. For a more complete understanding of the Company and
this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying
prospectus, including the information incorporated by reference in this prospectus supplement and the accompanying prospectus, including
the information referred to under the heading &ldquo;<A HREF="#a_004">Risk Factors</A>&rdquo; in this prospectus supplement beginning
on page S-15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a biotechnology company focused on developing
cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as &ldquo;Cell-in-a-Box<SUP>&reg;.</SUP>.&rdquo;
The Cell-in-a-Box<SUP>&reg;</SUP> technology is intended to be used as a platform upon which therapies for several types of cancer, including
locally advanced, inoperable, non-metastatic pancreatic cancer (&ldquo;LAPC&rdquo;) will be developed. The current generation of our product
candidate is referred to as &ldquo;CypCaps&trade;.&rdquo; On September 1, 2020, we submitted an Investigational New Drug Application (&ldquo;IND&rdquo;)
to the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) for a planned Phase 2b clinical trial in LAPC. On October 1, 2020, the Company
received notice from the FDA that it had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to us setting forth
the reasons for the clinical hold and specific guidance on what we must do to have the clinical hold lifted. To lift the clinical hold,
the FDA has informed us that we need to conduct several additional preclinical studies and assays. The FDA also requested additional information
regarding several topics, including DNA sequencing data, manufacturing information and product release specifications. We are in the process
of conducting these studies and assays and gathering additional information to submit to the FDA. See &ldquo;Our Investigational New Drug
Application and the Clinical Hold&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The Cell-in-a-Box<SUP>&reg;</SUP> encapsulation
technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules.
The technology is intended to result in the formation of pinhead sized cellulose-based porous capsules in which genetically modified live
human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been
shown to create a micro-environment in which encapsulated cells survive and flourish. They are protected from environmental challenges,
such as the sheer forces associated with bioreactors and passage through catheters and needles, which we believe enables greater growth
and production. The capsules are largely composed of cellulose (cotton) and are bio inert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are developing therapies for pancreatic and
other solid cancerous tumors by using genetically engineered live human cells that we believe are capable of converting a cancer prodrug
into its cancer-killing form. We encapsulate those cells using the Cell-in-a-Box<SUP>&reg;</SUP> technology and place those capsules in
the body as close as possible to the tumor. In this way, we believe that when a cancer prodrug is administered to a patient with a particular
type of cancer that may be affected by the prodrug, the killing of the patient&rsquo;s cancerous tumor may be optimized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have also been considering ways to exploit
the benefits of the Cell-in-a-Box<SUP>&reg;</SUP>&nbsp;technology to develop therapies for cancer that involve prodrugs based upon certain
constituents of the&nbsp;<I>Cannabis</I>&nbsp;plant; these constituents are of the class of compounds known as &ldquo;cannabinoids&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Until: (i) the FDA allows us to commence a clinical
trial in LAPC described in our IND for which the FDA has placed a clinical hold; (ii) we validate our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation
technology in our planned Phase 2b clinical trial in LAPC and (iii) the availability of sufficient additional funding, we are not spending
any further resources developing this cannabinoid program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we have been exploring ways to delay
the production and accumulation of malignant ascites fluid that results from many types of abdominal cancerous tumors. Malignant ascites
fluid is secreted by abdominal cancerous tumors into the abdomen after the tumors have reached a certain stage of growth. This fluid contains
cancer cells that can seed and form new tumors throughout the abdomen. This fluid accumulates in the abdominal cavity, causing swelling
of the abdomen, severe breathing difficulties and extreme pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In our pancreatic cancer development program,
our plan is to determine whether our product candidate can prevent or delay the production and accumulation of malignant ascites fluid.
For the same reasons as those given above until: (i) the FDA allows us to commence a clinical trial in LAPC described in our IND for which
the FDA has placed a clinical hold; (ii) we validate our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology in our planned Phase 2b
clinical trial in LAPC and (iii) the availability of sufficient additional funding, we are not spending any further resources developing
this malignant ascites fluid program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have also been developing a potential therapy
for Type 1 diabetes and insulin-dependent Type 2 diabetes. Our product candidate for the treatment of diabetes consists of encapsulated
genetically modified insulin-producing cells. The encapsulation will be done using the Cell-in-a-Box<SUP>&reg;</SUP>&nbsp;technology.
Implanting these cells in the body is designed to function as a bio-artificial pancreas for purposes of insulin production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As with the two previous programs, until: (i)
the FDA allows us to commence a clinical trial in LAPC described in our IND upon which the FDA has placed a clinical hold; (ii) we validate
our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology in our planned Phase 2b clinical trial in LAPC and (iii) the availability of
sufficient additional funding, we are not spending any further resources developing the diabetes program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Cancer Therapy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Targeted Chemotherapy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our live-cell encapsulation technology-based potential
therapies consist of encapsulated genetically modified living cells, with the type of encapsulated cell dependent on the disease being
treated. For our lead product candidate, a therapy for pancreatic cancer, we propose that approximately 15,000-20,000 genetically modified
live cells that produce an enzyme (an isoform of cytochrome P450), which we believe will convert the chemotherapy prodrug ifosfamide into
its cancer-killing form, will be encapsulated using the Cell-in-a-Box<SUP>&reg; </SUP>technology. In the clinical trial, if the FDA allows
us to proceed, approximately 300 of these capsules will be placed in the patients&rsquo; blood supply and guided into place using interventional
radiography so that they finally reside as close to the tumor in the pancreas as possible. Low doses (one gram per square meter of body
surface area of the patient) of the chemotherapy prodrug ifosfamide will then be given to the patient intravenously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The prodrug ifosfamide is normally activated in
the patient&rsquo;s liver. By activating the prodrug near the tumor using the Cell-in-a-Box<SUP>&reg;</SUP> capsules, we believe our cellular
therapy will act as a type of &ldquo;bio-artificial liver.&rdquo; Using this type of &ldquo;targeted chemotherapy,&rdquo; we are seeking
to create an environment that enables optimal concentrations of the &ldquo;cancer-killing&rdquo; form of ifosfamide at the site of the
tumor. Because the cancer-killing form of ifosfamide has a short biological half-life, we believe that this approach will result in little
to no collateral damage to other organs in the body. We also believe this treatment will significantly reduce tumor size with no treatment-related
side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Figure 1: Proposed treatment for pancreatic
cancer by targeted deployment and activation of chemotherapy using Cell-in-a-Box<SUP>&reg; </SUP>encapsulated cells.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; border: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>Note</U>: Charts A and B are generalized graphic
    depictions of the principal hypothesized mechanisms of our proposed treatment for pancreatic cancer using our product candidate, the combination
    of Cell-in-a-Box<SUP>&reg;</SUP> encapsulated cells plus low-doses of ifosfamide, under expected conditions. This combination therapy
    will be the subject of a clinical trial we plan to conduct, subject to FDA approval allowing us to move forward with our clinical trial.
    No regulatory authority has granted marketing approval for the Cell-in-a-Box<SUP>&reg; </SUP>technology, the related encapsulated cells,
    or Cell-in-a-Box<SUP>&reg;</SUP> and encapsulated cells plus low-dose ifosfamide combination.</P></TD>
    <TD STYLE="width: 1%; text-indent: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 78%; text-indent: 0.25in"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 396px; width: 554px"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;<BR STYLE="clear: both">
</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><U>Chart (A)</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Cell-in-a-Box<SUP>&reg; </SUP>capsules containing
    live ifosfamide-activating cells (shown in white) will be implanted in the blood vessels leading to the tumor in the pancreas. Then low
    dose ifosfamide will be given intravenously.<BR>
    <BR>
    <BR>
    <BR>
    <BR>
    <BR>
    <BR>
    </P></TD>
    <TD STYLE="width: 7%; text-indent: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 45%; border: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><U>Chart (B)</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Chart B shows the human pancreas and generalized
    depictions of two pancreatic cancer tumors (shown in pink) as examples. In this chart, ifosfamide is converted to its cancer-killing form
    by the encapsulated live cells implanted near the tumors (shown in maroon).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><U>Legend</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Blue Arrows</I>: Ifosfamide enters capsules</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Red Arrows</I>: Conversion to active form</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>White Arrows</I>: Activated ifosfamide targets
    tumors</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Figure 2: Hypothesized mechanism of action
of treatment for pancreatic cancer by targeted deployment of the encapsulated live cells and activation of the chemotherapy prodrug drug
ifosfamide. The immune system cells are too large to enter the capsule.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><IMG SRC="image_003.jpg" ALT="" STYLE="height: 343px; width: 496px">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Pancreatic Cancer Therapy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe an unmet medical need exists for patients
with LAPC whose pancreas tumor no longer responds after 4-6 months of treatment with either Abraxane<SUP>&reg;</SUP> plus gemcitabine
or the 4-drug combination known as FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin). Both combinations are the current
standards of care for pancreatic cancer. We believe that these refractory patients have no effective treatment alternative once their
tumors no longer respond to these therapies. Two of the most commonly used treatments for these patients are 5-fluorouiracil (&ldquo;5-FU&rdquo;)
or capecitabine (a prodrug of 5-FU) plus radiation (chemoradiation therapy). We believe that both treatments are only marginally effective
in treating the tumor and both result in serious side effects. More recently, radiation treatment alone is being used at some cancer centers
in the United States (&ldquo;U.S.&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other treatments are being tried at various cancer
centers in the U.S. in an attempt to address this lack of an effective treatment for many LAPC patients, but their success is far from
certain. We are developing a therapy comprised of Cell-in-a-Box<SUP>&reg;</SUP> encapsulated live cells implanted near the pancreas tumor
followed by the infusion of low doses of the cancer prodrug ifosfamide. We believe that our therapy, if approved, can serve as a &ldquo;consolidation
therapy&rdquo; that can be used with the current standards of care for LAPC and thus address this critical unmet medical need. Two previous
human clinical trials of an encapsulated live cell and ifosfamide combination for LAPC were conducted in Germany by Bavarian Nordic during
1998 &ndash; 2000, and such trials were referenced in our IND for LAPC, submitted on September 1, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the FDA allowing us to move forward,
we plan to commence a clinical trial involving patients with LAPC whose tumors have ceased to respond to either Abraxane<SUP>&reg;</SUP>
plus gemcitabine or FOLFIRINOX after 4-6 months of either therapy. The trial would initially take place in the U.S. with possible study
sites in Europe at a later date.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Investigational New Drug Application
and the Clinical Hold</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">On
September 1, 2020, we submitted an IND to the FDA for a planned Phase 2b clinical trial in LAPC. Shortly thereafter, we received Information
Requests from the FDA related to the IND. We timely responded to all Information Requests.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">On
October 1, 2020, we received notice that the FDA had placed our IND on clinical hold.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">On
October 30, 2020, the FDA sent a letter to us setting forth the reasons for the clinical hold and providing specific guidance on what
we must do to have the clinical hold lifted.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">In
order to address the clinical hold, the FDA has requested that we:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide additional sequencing data and genetic stability studies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Conduct a stability study on the final formulated drug product candidate as
well as the cells from our Master Cell Bank;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Evaluate the compatibility of the delivery devices (the prefilled syringe and
the microcatheter used to implant the CypCaps<SUP>&trade;</SUP>) with our drug product candidate;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide additional detailed description of the manufacturing process;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide additional product release specifications for our encapsulated cells;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Demonstrate comparability between the 1<SUP>st</SUP> and 2<SUP>nd</SUP> generation
products and ensure adequate and consistent product performance and safety between the two generations of product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Conduct a biocompatibility assessment using the final finished capsules after
the entire drug product candidate manufacturing process (but without cells);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Address insufficiencies in Chemistry, Manufacturing and Controls information
in the cross-referenced Drug Master File;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Conduct an additional nonclinical study in a large animal (such as a pig) to
assess the safety, activity and distribution of the drug product candidate; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Revise the Investigators Brochure to include any additional preclinical studies
conducted in response to the clinical hold and remove any statements not supported by the data.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">The
FDA also requested that we address the following issues as an amendment to the IND:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for
assessing purity, safety, and potency;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Perform qualification studies for the drug substance filling step to ensure
that the product candidate remains sterile and stable during the filling process;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Submit an updated batch analysis for the drug product candidate for the specific
lot that will be used for manufacturing all future drug product candidate;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide additional details for the methodology for the Resorufin (CYP2B1) potency
and the PrestoBlue cell metabolic assays;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide a few examples of common microcatheters that fit the specifications
in our Angiography Procedure Manual;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Clarify the language in the Pharmacy Manual regarding proper use of the syringe
fill with the drug product candidate; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-style: normal; font-weight: normal">Provide a discussion with data for trial of the potential for cellular and humoral
immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in our study
population in the LAPC.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">We
have assembled a scientific and regulatory team of experts to address the FDA requests. That team is working to complete the items requested
by the FDA. We are in varying stages of addressing the studies and acquiring the information requested by the FDA. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">The
following provides a summary of the activities in which we are engaged to have the clinical hold lifted:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have completed a 3, 6, 9, and 12-month product stability study of our clinical trial product (CypCaps<SUP>&trade;</SUP>),
including container closure integrity testing for certain timepoints; the next time point in this ongoing study will be at 18 months of
product stability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have designed and commenced various additional studies required by the
FDA. These include</FONT> (<FONT STYLE="font-size: 10pt">i) a stability study on the cells from our Master Cell Bank (&ldquo;MCB&rdquo;)
used to make the CypCaps<SUP>&trade;</SUP>, which are already at the 3-year stability timepoint; (ii) further sequence analysis of the
DNA encoding of the Cyp2B1 gene in the cells in the CypCaps<SUP>&trade;</SUP>; and (iii) collated existing information on the reproducibility
and quality of the filling of the MCB cells into vials ready for CypCaps<SUP>&trade;</SUP> manufacturing. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We
have designed and commenced a Subchronic and Chronic Toxicity study.
We have also designed and are awaiting initiation of biocompatibility studies, including: (i) a Skin Sensitization study; (ii) an Acute
Systematic Toxicity study; (iii) an Ames test (Genotoxicity Bacteria and Reverse Mutation tests); (iv) an Intracutaneous test; (v) a Complement
Activation test; (vi) a Hemolysis test; (vii) an In Vitro Cytotoxicity test; and (viii) an In Vivo Micronucleus assay. Some of the data
being generated by these studies will also be used to demonstrate comparability with the CypCaps<SUP>&trade;</SUP> that were used in the two earlier German clinical trials over twenty years ago conducted by Bavarian Nordic.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">To enable the biocompatibility studies to be performed, we had Austrianova manufacture and deliver an
additional 400 syringes of empty capsules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We designed and will initiate studies to show that CypCaps<SUP>&trade;</SUP> are not in any way adversely
affected by the catheters used by interventional radiologists to deliver them, nor by the contract media used to visualize the blood vessels
during implantation of the CypCaps<SUP>&trade;</SUP>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We designed and will initiate studies to demonstrate how robust the CypCaps<SUP>&trade;</SUP> are during
delivery and use as well as to document that the syringes used to deliver the CypCaps<SUP>&trade;</SUP> will allow delivery consistently,
smoothly and safely.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">With our support, Austrianova is providing additional detailed confidential information to the FDA on
the manufacturing process, including information on the improvements made to the live cell encapsulated product since the last clinical
trials with respect to reproducibility and safety of the CypCaps<SUP>&trade;</SUP>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We plan to update our IND submission documents to include: (i) more pre-clinical data as discussed above,
(ii) some additional parameters for release of the CypCaps<SUP>&trade;</SUP>, (iii) a recommendation of the catheters and contrast medium
to be used to deliver the CypCaps<SUP>&trade;</SUP>; and (iv) an extensive discussion of the potential for cellular and humoral immune
reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in our study population
in the LAPC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have designed an abbreviated study in pigs to address biocompatibility and long-term implantation of
the capsules. This animal study will complement the positive data already available from the previous human clinical trials conducted
by Bavarian Nordic showing the safety of CypCaps<SUP>&trade;</SUP> implantation for up to two years in humans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Can<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal; color: black">n</FONT>abinoids
to Treat Cancer</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Numerous studies have demonstrated the therapeutic
potential of certain cannabinoids (constituents of Cannabis) in patients with cancer. Two of the most widely studied cannabinoids in this
regard are tetrahydrocannabinol (&ldquo;THC&rdquo;) and cannabidiol (&ldquo;CBD&rdquo;). Cannabinoids are potentially: (i) anti-proliferative
(slow tumor growth); (ii) anti-metastatic (slow tumor spread); (iii) anti-angiogenic (slowing blood vessel development); and (iv) pro-apoptotic
(initiate programmed cell death). In in vitro and in vivo models, the therapeutic potential of cannabinoids is broad. Results support
the therapeutic potential in lung, brain, thyroid, lymphoma, liver, skin, pancreas, uterus breast and prostate cancers. In a review of
51 scientific studies, among other properties, it was observed that cannabinoids can regulate cellular signaling pathways critical for
cell growth and survival. These properties indicate that cannabinoids could be useful in the treatment of cancer.</P>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">We
have many competitors that are developing Cannabis-based treatments for cancer. Jazz Pharmaceuticals has acquired GW Pharmaceuticals,
PLC who had an approved cannabinoid product for the treatment of multiple sclerosis spasticity and was developing a product portfolio
to treat a variety of illnesses, including glioblastoma (brain cancer). Cannabis Science, Inc. has been developing topical cannabinoid
treatments for basal and squamous cell skin cancers and Kaposi&rsquo;s sarcoma, and is exploring pre-clinical development of cannabinoid-based
anti-cancer drugs in a collaborative agreement with other entities. OWC Pharmaceutical Research Corp. is developing Cannabis-based products
targeting a variety of indications and has a collaborative agreement with an academic medical center in Israel to study the effects of
cannabinoids on multiple myeloma (a cancer of plasma cells). Cannabis Pharmaceuticals, Inc. is developing personalized anti-cancer and
palliative Cannabis-based treatments aimed mainly at improving the cachexia, anorexia syndrome and quality-of-life issues that are often
characteristic of patients with devastating diseases like cancer.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">In
contrast to the work being done by these companies, we plan to focus on developing specific therapies based on chosen molecules rather
than using complex Cannabis extracts. We intend to use the Cell-in-a-Box<SUP>&reg;</SUP> technology in combination with genetically modified
cell lines designed to activate cannabinoid molecules for the treatment of diseases and their related symptoms. Our initial target will
be glioblastoma, a very difficult-to treat form of brain cancer.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">In
May 2014, we entered into a research agreement with the University of Northern Colorado (&ldquo;UNC&rdquo;). The goal of the original
research was to develop methods for the identification, separation and quantification of constituents of Cannabis, some of which are prodrugs,
which could potentially be used in combination with the Cell-in-a-Box<SUP>&reg; </SUP>technology to treat cancer. &nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">In
January 2017, we entered into a second research agreement with UNC. The goal of this research is to assess the synthesis of the patG gene
and its incorporation into a vector, transfection of human embryonic kidney cells using this vector and assessment of cannabinoic acid
decarboxylase activity.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">During
2017, UNC identified an organism whose genome contains the genetic code for production of an enzyme capable of activating a cannabinoid
prodrug into its active cancer-killing form. Our Cannabis program now has two primary areas of focus. The first is evaluating the therapeutic
potential of cannabinoids, such as THC and CBD, particularly in our main &ldquo;target&rdquo; tumor &ndash; glioblastoma. UNC&rsquo;s
laboratory research has confirmed that a purified cannabinoid showed a potent dose-dependent decrease in cell viability for various cancers,
suggesting that this cannabinoid exhibits significant anti-proliferative effects (stops the growth and multiplication of cancer cells).
This activity has been demonstrated in brain (glioblastoma), pancreas, breast, lung, colon and melanoma cancer cells. The second area
of focus is in finding an enzyme capable of converting an inactive, side-effect-free, cannabinoid prodrug into its active cancer-killing
form.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Clinically,
targeted cannabinoid-based chemotherapy would be accomplished by implanting the encapsulated bio-engineered cells near the site of a tumor,
along with administration of a cannabinoid prodrug which would become activated at the site of the tumor by an enzyme produced by the
encapsulated cells. We believe this could lead to better efficacy than existing therapies with minimal treatment related adverse events.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Until:
(i) the FDA allows us to commence a clinical trial in LAPC described in our IND for which the FDA has placed a clinical hold; (ii) we
validate our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology in our planned Phase 2b clinical trial in LAPC and (iii) the availability
of sufficient additional funding occurs, we are not spending any further resources developing this program.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Malignant Ascites Fluid Therapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">We have been
exploring ways to delay the production and accumulation of malignant ascites fluid that results from many types of abdominal tumors. Malignant
ascites fluid is secreted by an abdominal tumor into the abdomen after the tumor reaches a certain stage of growth. This fluid contains
cancer cells that can seed and form new tumors throughout the abdomen. As this ascites fluid accumulates in the abdominal cavity, it can
cause gross swelling of the abdomen, severe breathing difficulties and extreme pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">Once an abdominal
tumor reaches a certain stage of development, the tumor secretes malignant ascites fluid into the abdominal cavity. When that occurs,
malignant ascites fluid must be removed by paracentesis on a periodic basis. This procedure is painful and costly. We know of no available
therapy that prevents or delays the production and accumulation of malignant ascites fluid. Preclinical studies were conducted by Translational
Drug Development (&ldquo;TD2&rdquo;), an early-stage Clinical Research Organization (&ldquo;CRO&rdquo;) specializing in oncology, to examine
whether the combination of Cell-in-a-Box<SUP>&reg;</SUP>&nbsp;encapsulated cells plus low doses of ifosfamide can delay the production
and accumulation of malignant ascites fluid. We believe the data from these studies support our plans to further explore whether the treatment
might play a role in malignant ascites fluid production and accumulation. However, the conclusions were difficult to interpret with certainty.
As a result, we plan to conduct another preclinical study in Germany to determine if our conclusions from the TD2 studies are valid. If
this study is successful, and subject to discussions with the FDA, we plan to submit an IND to seek approval from the FDA to conduct a
Phase 1 clinical trial in the U.S. to determine if our drug product candidate can delay the production and accumulation of malignant ascites
fluid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">Until: (i) the
FDA allows us to commence a clinical trial in LAPC described in our IND for which the FDA has placed a clinical hold; (ii) we validate
our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology in our planned Phase 2b clinical trial in LAPC and (iii) the availability of
sufficient additional funding occurs, we are not spending any further resources developing this program.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Diabetes Therapy</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A Bio-Artificial Pancreas to Treat
Diabetes</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">We
are developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes based upon the encapsulation of a human liver cell
line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body.
We are also considering an alternative route to bringing a biological treatment for diabetes into the clinic. We are exploring the possibility
of encapsulating human insulin-producing stem cells and then transplanting them into a diabetic patient. Our plans are subject to discussions
with the FDA.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">The
cell line we select will be encapsulated using the Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology. If appropriate animal testing
is completed successfully, and subject to discussions with the FDA, we intend to submit an IND to seek the FDA&rsquo;s approval to transplant
encapsulated insulin-producing cells into diabetic patients. The goal for these approaches is to develop a bio-artificial pancreas for
purposes of insulin production for diabetics who are insulin-dependent.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Our
diabetes program began with two of the most critical components of a biological diabetes therapy - a line of human cells which release
insulin in response to the blood glucose level in their environment and a technology to protect the cells from an attack by the immune
system once they are transplanted into a patient&rsquo;s body to replace his or her own destroyed insulin-producing cells. This technology
is the Cell-in-a-Box<SUP>&reg; </SUP>encapsulation technology. The cells used are called Melligen cells. They are patent-protected and
have been licensed to us by University of Technology Sydney (&ldquo;UTS&rdquo;).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Regulations
for the use of living cells as a medical product require that the potential of the cells to grow and form a tumor in a patient be assessed.
This so-called &ldquo;tumorigenicity study&rdquo; has been completed by the University of Veterinary Medicine Vienna (&ldquo;VetMed&rdquo;).
Melligen cells showed very low tumorigenicity at a level we believe would expect to pass regulatory scrutiny, although this is subject
to discussions with the FDA.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Putting
Melligen cells and the Cell-in-a-Box<SUP>&reg;</SUP> technology together, we conducted the first functional study in diabetic mice. The
results did not meet our expectations. We discovered that, contrary to what we had expected and what we had read in published scientific
papers on the Melligen cells published by UTS, the cells are not stable. With extensive testing and experiments, we discovered that the
Melligen cells lose some of their specific beneficial properties over time.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">We
entered into a new research agreement with UTS to create an advanced version of the Melligen cells for the treatment of diabetes. Under
the new research agreement, improvements will be made to the Melligen cells that we believe will increase their stability, increase their
insulin production and increase the bioactivity of the produced insulin.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Prof.
Ann Simpson, who created the Melligen cells, and her team of research scientists at UTS have been conducting this research project. The
work is being funded by the Company and UTS. Our portion of the funding was previously paid to UTS. The research to date has not produced
the results we had anticipated and is taking longer than we anticipated. It remains to be seen whether the Melligen cells are capable
of producing the required insulin to be a viable cell line for the treatment of diabetes.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Until:
(i) the FDA allows us to commence a clinical trial in LAPC described in our IND for which the FDA has placed a clinical hold; (ii) we
validate our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology in our planned Phase 2b clinical trial in LAPC and (iii) the availability
of sufficient additional funding occurs, we are not spending any further resources developing this program.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Impact of the COVID-19 Pandemic on
the Company&rsquo;s Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">The coronavirus
SARS-Cov2 pandemic (&ldquo;COVID-19&rdquo;) is causing significant, industry-wide delays in clinical trials. Although we are not yet in
a clinical trial, we have filed an IND with the FDA to commence a clinical trial in LAPC. While the IND has been placed on clinical hold
by the FDA, we have assessed the impact of COVID-19 on our operations. As of the date of this prospectus supplement, we believe the COVID-19
pandemic has had an impact upon our operations, primarily relating to delays in tasks associated with the preparation of the Company&rsquo;s
responses to the FDA&rsquo;s clinical hold, including all requested preclinical studies and assays. There may be further delays in generating
responses to the requests from the FDA related to the clinical hold. Many of these delays are due to the impact of the COVID-19 pandemic
in foreign countries where we are conducting these preclinical studies and assays, including India, Europe, Singapore and Thailand. There
have also been supply chain interruptions due to the COVID-19 pandemic. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">Further, many
clinical trials have been delayed due to COVID-19. There are numerous reasons for these delays. For example, patients have shown a reluctance
to enroll or continue in a clinical trial due to fear of exposure to COVID-19 when they are in a hospital or doctor&rsquo;s office. There
are local, regional and state-wide orders and regulations restricting usual normal activity by people. These discourage and interfere
with patient visits to a doctor&rsquo;s office if the visit is not COVID-19 related. Healthcare providers and health systems have shifted
their resources away from clinical trials toward the care of COVID-19 patients. The FDA and other healthcare providers are making product
candidates for the treatment of COVID-19 a priority over product candidates unrelated to COVID-19. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">As a result
of COVID-19 and the mitigation efforts to address it, we may experience additional disruptions that could adversely impact our business
and clinical trial, including: (i) delays or difficulties in enrolling patients in our Phase 2b clinical trial if the FDA allows us to
go forward with the trial; (ii) delays or difficulties in clinical site activation, including difficulties in recruiting clinical site
investigators and clinical site personnel; (iii) delays in clinical sites receiving the supplies and materials needed to conduct our clinical
trial, including interruption in global shipping that may affect the transport of our clinical trial product; (iv) changes in local regulations
as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trial is to be conducted,
which may result in unexpected costs, or to discontinue the clinical trial altogether; (v) diversion of healthcare resources away from
the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting
the conduct of our clinical trial; (vi) interruption of key clinical trial activities, such as clinical trial site monitoring, due to
limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial
subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; (vii) risk that participants
enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical
trial, including by increasing the number of observed adverse events; (viii) delays in necessary interactions with local regulators, ethics
committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;
(ix) limitations in employee resources that would otherwise be focused on the conduct of our clinical trial because of sickness of employees
or their families or the desire of employees to avoid contact with large groups of people; (x) refusal of the FDA to accept data from
clinical trials in affected geographies; and (xi) interruption or delays to our clinical trial activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">As a result
of the COVID-19 pandemic, commencement of our planned clinical trial to treat LAPC may be delayed beyond the lifting of the clinical hold
by the FDA should that occur. Also, enrollment may be difficult for the reasons discussed above. In addition, after enrollment in the
trial, if patients contract COVID-19 during their participation in the trial or are subject to isolation or shelter in place restrictions,
this may cause them to drop out of our clinical trial, miss scheduled therapy appointments or follow-up visits or otherwise fail to follow
the clinical trial protocol. If patients are unable to follow the clinical trial protocol or if the trial results are otherwise affected
by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data
from the clinical trial may be compromised or not be accepted by the FDA. This could further adversely impact or delay our clinical development
program if the FDA allows it to proceed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-weight: normal">It is highly
speculative in projecting the effects of COVID-19 on our proposed clinical development program and the Company generally. Moreover, the
various precautionary measures taken by many governmental authorities around the world in order to limit the spread of COVID-19 has had
and may continue to have an adverse effect on the global markets and global economy, including on the availability and pricing of employees,
resources, materials, manufacturing and delivery efforts and other aspects of the global economy. The continuation of the COVID-19 pandemic
could materially disrupt our business and operations, hamper our ability to raise additional funds or sell or securities, continue to
slow down the overall economy, curtail consumer spending, interrupt our sources of supply, and make it hard to adequately staff our operations.
The effects of COVID-19 quickly and dramatically change over time. Its evolution is difficult to predict, and no one is able to say with
certainty when the pandemic will cease to have an impact on our operations.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Recent Developments</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certificate of Amendment to Articles
of Incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June 30, 2021, at our Annual Meeting of Stockholders,
our stockholders approved a Certificate of Amendment to our Articles of Incorporation to increase the number of authorized shares of common
stock from 2,500,000,000 shares to 50,000,000,000 shares. Upon effectiveness of the 1:1,500 reverse stock split on July 12, 2021, the
number of authorized shares of our common stock was reduced proportionately to 33,333,334 shares by operation of Nevada law and the number
of outstanding shares of our common stock was reduced to 1,591,420 shares.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Reverse Stock Split</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June 30, 2021, our Board of Directors (&ldquo;<U>Board</U>&rdquo;)
approved a reverse stock split of 1:1,500 of our authorized and our issued and outstanding shares of common stock effective on July 12,
2021 pursuant to a Certificate of Change filed in Nevada. Except as otherwise indicated, all share and per share information in this
prospectus supplement gives effect to the reverse stock split of the Company&rsquo;s outstanding common stock, which was effected at
a ratio of 1-for-1,500 shares as of 12:01 a.m. Eastern Time on Monday, July 12, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Preliminary Fiscal Year 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 2, 2021, the Company announced selected
preliminary unaudited financial results for the fiscal year ended April 30, 2021. Complete audited financial information and operating
data for the fiscal year ended April 30, 2021, will not be available until after this offering is complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Preliminary (unaudited) Fiscal 2021 Financial
Results</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net loss for the fiscal year ended April 30, 2021
was approximately $3.6 million, or approximately $2.45 basic and diluted loss per share, compared with a net loss of approximately $3.8
million, or approximately $4.23 basic and diluted loss per share, for the fiscal year ended April 30, 2020. The losses per share amounts
are based on the basic weighted average number of shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Cash on Hand</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of April 30, 2021, we had approximately $2.2
million in cash in our bank account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preliminary fiscal year ended April 30, 2021
financial data is unaudited, preliminary, based upon the Company&rsquo;s good faith estimates and the information and data currently available
and subject to completion of the Company's financial closing procedures. While the Company expects that its final financial results for
the fiscal year ended April 30, 2021, following the completion of its financial closing procedures, will generally be consistent with
the amounts provided herein, the Company's actual results may differ materially from these estimates as a result of the completion of
its financial closing procedures, as well as final adjustments and other developments that may arise between now and the time that its
financial results for the fiscal year ended April 30, 2021 are finalized.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Summary of Risks Associated with Our Business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business is subject to numerous risks and
uncertainties that you should consider before investing in our company. These risks are described more fully in the section titled &ldquo;Risk
Factors&rdquo; in this prospectus supplement. These risks include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We are a biotechnology company with limited resources, a limited operating history and have no products approved for clinical trials
or commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>As a result of the clinical hold that has been placed on our IND by the FDA, it has taken and may continue to take considerable time
and expense to respond to the FDA and no assurance can be given that the FDA will remove the clinical hold in which case our business
and prospects will likely suffer material adverse consequences.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The recent and ongoing COVID-19 pandemic has affected and could continue to affect our operations, as well as the business or operations
of third parties with whom we conduct business. Our business could be adversely affected by the effects of other future health pandemics
in regions where we or third parties on which we rely have significant business operations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>If we are unable to successfully raise additional capital, our future clinical trials and product development could be limited and
our long-term viability may be threatened.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we
must prioritize development of certain product candidates. We may expend our limited resources on programs that do not yield a successful
product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater
likelihood of success.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We currently have no commercial revenue and may never become profitable.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to continue as a going concern.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>If we are unable to obtain, or if there are delays in obtaining, required approval from the applicable regulatory agencies, we will
not be able to commercialize our product candidates and our ability to generate revenue will be materially impaired.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>If allowed to proceed with our clinical development program, we intend to conduct clinical trials for certain of our product candidates
at sites outside of the U.S., and the U.S. regulatory agencies may not accept data from trials conducted in such locations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Promising results in previous clinical trials of our encapsulated live cell and ifosfamide combination for LAPC may not be replicated
in future clinical trials which could result in development delays or a failure to obtain marketing approval.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may not be able to protect our intellectual property rights throughout the world.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We rely and expect to continue to rely heavily on third parties to conduct our preclinical studies and clinical trials, and those
third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such studies and trials.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There are risks related to this offering, including risks that you will experience immediate and substantial dilution in the net tangible
book value per share of the common stock you purchase in this offering and the risk that substantial future sales or other issuances of
our common stock could depress the market for our common stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have broad discretion in the use of the net proceeds of this offering and, despite our efforts, we may use the net proceeds in
a manner that does not increase the value of your investment.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There has been no consistent active trading market for our common stock, and public trading of our common stock may continue to fluctuate
substantially.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A large number of shares may be issued and subsequently sold upon the exercise of existing options and warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We are a &ldquo;smaller reporting company&rdquo; under the SEC&rsquo;s disclosure rules and have elected to comply with the reduced
disclosure requirements applicable to smaller reporting companies.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>As a non-accelerated filer, we are not required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>As a result of our approval to be listed on Nasdaq concurrent with this offering, we will incur materially increased costs and become
subject to additional regulations and requirements.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq, including the ability to
continue to comply with the minimum bid price requirement of Nasdaq, a failure of which could result in a de-listing of our common stock,
limit investors&rsquo; ability to make transactions in our securities and subject us to additional trading restrictions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Following the reverse stock split, the resulting market price of our common stock may not attract new investors, including institutional
investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock
may not improve.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Corporate Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Nevada corporation incorporated in 1996.
In 2013, we restructured our operations to focus on biotechnology. The restructuring resulted in the Company focusing all of its efforts
upon the development of a novel, effective and safe way to treat cancer and diabetes. In January 2015, the Company changed its name from
Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our corporate headquarters is located at 23046
Avenida de la Carlota, Suite 600, Laguna Hills, California 92653, and our telephone number is (917) 595-2850. We maintain a website at
<U>www.pharmacyte.com</U>, to which we regularly post copies of our press releases as well as additional information about us. Our filings
with the SEC will be available free of charge through the website as soon as reasonably practicable after being electronically filed with
or furnished to the SEC. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus or
our other filings with the SEC, and should not be relied upon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A>THE OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-size: 10pt">Common stock offered by us</FONT></TD>
    <TD STYLE="width: 77%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Pre-funded Warrants offered by us</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-funded Warrants to purchase up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock. We are also offering to each purchaser the opportunity to purchase, if the purchaser so chooses, Pre-funded Warrants,
    in lieu of shares of common stock. Each Pre-funded Warrant will be exercisable for one share of our common stock. The purchase price
    of each Pre-funded Warrant will equal the price per share at which the shares of common stock are being sold to the public in this
    offering, minus $0.001, and the exercise price of each Pre-funded Warrant will be $0.001 per share. This offering also relates to
    the shares of common stock issuable upon exercise of any Pre-funded Warrants sold in this offering. The exercise price and number
    of shares of common stock issuable upon exercise will be subject to certain further adjustments as described herein. See &ldquo;<A HREF="#a_011">Description
    of Securities Offered</A>&rdquo; on page <A HREF="#a_011">S-45</A> of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Warrants offered by us</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Common Warrants to purchase an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
    common stock. Each share of our common stock and each Pre-funded Warrant to purchase one share of our common stock is being sold
    together with a Common Warrant to purchase one share of our common stock. Each Common Warrant has an exercise price of
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, is immediately exercisable and will expire on the
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;anniversary of the original issuance date. The shares of common stock or the Pre-funded
    Warrants, and the accompanying Common Warrants, as the case may be, can only be purchased together in this offering but will be
    issued separately and will be immediately separable upon issuance. This offering also relates to the offering of the shares of
    common stock issuable upon exercise of the Common Warrants. See &ldquo;<A HREF="#a_011">Description of Securities Offered</A>&rdquo;
    on page <A HREF="#a_011">S-45</A> of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s option to purchase additional shares and/or Common Warrants</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We have granted the underwriter an option for a period of up to 30 days from the date of this prospectus supplement to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock and/or Common Warrants to purchase additional  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock at the public offering price less the underwriting discounts and commissions. </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common stock to be outstanding after this offering</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares assuming the underwriter exercises in full its option to purchase additional shares and/or Common Warrants), assuming all of the Pre-funded Warrants issued in this offering are exercised and no exercise of any Common Warrants issued in this offering.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We intend to use the net proceeds of this offering (i) to complete activities
    requested by the FDA in order to address the FDA&rsquo;s clinical hold on our IND with respect to our planned Phase 2b
    clinical trial in LAPC, including conducting several additional preclinical studies and assays and providing the FDA with the
    additional information it requested, (ii) to begin to fund and conduct the Phase 2b clinical trial in LAPC, if and when the clinical
    hold on the IND is lifted, and (iii) for general working capital purposes. See &ldquo;<A HREF="#a_006">Use of
    Proceeds</A>.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">An investment in our common stock involves a high degree of risk. See &ldquo;<A HREF="#a_004">Risk
    Factors</A>&rdquo; beginning on page <A HREF="#a_004">S-15</A> of this prospectus supplement, and under similar headings in other documents filed after
    the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s Warrants</FONT></TD>
    <TD STYLE="width: 77%"><FONT STYLE="font-size: 10pt">We will issue to the underwriter, or its designees, at the closing of this offering common stock purchase warrants to purchase the number of shares of common stock equal to 7.5% of the aggregate number of shares of common stock and Pre-funded Warrants sold in this offering, including shares sold upon the underwriter&rsquo;s exercise of its option to purchase additional shares. The underwriter&rsquo;s warrants will be exercisable immediately and will expire three years from the issuance date and are registered on the registration statement of which this prospectus is a part. The exercise price of the underwriter&rsquo;s warrants will equal 125% of the public offering price per share and the accompanying warrant in this offering. See &ldquo;<A HREF="#a_010">Underwriting</A>.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OTCQB &reg; Market Symbol</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Company&rsquo;s OTCQB Market Symbol is PMCB, although as a result of
the recent reverse split of the Company&rsquo;s common stock, until August 6, 2021, the Company&rsquo;s OTCQB Market Symbol has been PMCBD.
Our common stock will continue to trade on the OTCQB Venture Market until trading commences on Nasdaq. There is no established trading
market for the Pre-funded Warrants or the Common Warrants, and we do not expect a trading market to develop. We do not intend to list
the Pre-funded Warrants or Common Warrants on any securities exchange or nationally recognized trading system. Without a trading market,
the liquidity of the Pre-funded Warrants and the Common Warrants will be extremely limited. </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Anticipated Nasdaq Symbol</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Our common stock has been approved for listing on the Nasdaq Capital Market
(&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;PMCB.&rdquo;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reverse Stock Split</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">On June 30, 2021, our Board approved a reverse stock split of 1:1,500 of our authorized and our issued and outstanding shares of common stock effective on July 12, 2021. Unless otherwise stated, all share and per share information in this prospectus supplement reflects the reverse stock split of the authorized and outstanding common stock of the Company at a ratio of 1:1,500. However, share and per share amounts in the accompanying prospectus and certain of the documents incorporated by reference herein have not been adjusted to give effect to the reverse stock split.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Outstanding Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The number of shares of our common stock to be
outstanding after this offering is based on 1,591,420 shares of our common stock outstanding as of July 31, 2021 (subject to adjustment
based on issuances of additional shares as applicable due to the rounding up on fractional shares resulting from the 1:1,500 reverse stock
split), and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>42,333 shares reserved for issuance upon the exercise of outstanding stock options at a weighted average exercise price of $78.63
per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>2,981 shares reserved for issuance upon the exercise of outstanding warrants at a weighted average exercise price of $58.70 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>166,667 shares of common stock reserved for future issuance under our 2021 Equity Incentive Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon exercise of the Common Warrants issued in this offering; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock (or if the underwriter exercises
its option to purchase additional shares of common stock in full, up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares
of common stock) issuable upon exercise of warrants with an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share to be issued to the underwriter or its designees as compensation in connection with this offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise indicated, all information
in this prospectus supplement assumes (i) no exercise by the underwriter of its option to purchase additional shares of our common stock
and/or Common Warrants; (ii) no exercise or conversion of the outstanding options or warrants described above; (iii) no exercise of the
Pre-funded Warrants and (iv) no exercise of the Common Warrants offered and sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Investing in our common stock involves a high
degree of risk. Before investing in our common stock, you should carefully consider the risks described below, together with all of the
other information contained in this prospectus supplement and the accompanying prospectus and incorporated by reference herein and therein,
including from our Annual Report on Form 10-K for the fiscal year ended April 30, 2020, our Quarterly Reports on Form 10-Q for the periods
ending October 31, 2020 and January 31, 2021 as well as any amendment or update to our risk factors reflected in subsequent filings with
the SEC. Some of these factors relate principally to our business and the industry in which we operate. Other factors relate principally
to your investment in our securities. The risks and uncertainties described therein and below are not the only risks facing us. Additional
risks and uncertainties not presently known to us or that we currently deem immaterial may also materially and adversely affect our business
and operations. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>If any of the matters included in the following
risks were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially and adversely
affected. In such case, you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Risks Related to Our Financial Position,
FDA Clinical Hold, Need for Additional Capital and Overall Business</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a biotechnology company with
limited resources, a limited operating history and have no products approved for clinical trials or commercial sale, which may make it
difficult to evaluate our current business and predict our future success and viability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a biotechnology company focused on developing
cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo;
In recent years, we have devoted substantially all our resources to the development of our product candidate for LAPC. We have limited
resources, a limited operating history, no products approved for clinical trials or commercial sale and therefore have not produced any
revenues. We have generated significant operating losses since our inception. Our net losses for the years ended April 30, 2020 and 2019
were approximately $3.8 million and $4.1 million, respectively. As of April 30, 2020, we had an accumulated deficit of approximately $104
million. As of January 31, 2021, we had an accumulated deficit of $106 million, and we reported a net loss of $2.6 million for the nine
months ended January 31, 2021. Substantially all our losses have resulted from expenses incurred relating to our research and development
programs and from general and administrative expenses and operating losses associated with our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect to continue to incur significant expenses
and operating losses for the foreseeable future. We anticipate these losses will increase as we continue our research and development
of, and, if approved by the FDA, commence clinical trials for, our product candidates. In addition to budgeted expenses, we may encounter
unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have no facilities to conduct fundamental research
and we have performed our research and development activities by collaboration with contract service providers and contract manufacturers,
and by designing and developing research programs in collaboration with university-based experts who work with us to evaluate mechanism(s)
of disease for which we have designed and developed product candidates. We have not maintained a principal laboratory or primary research
facility for the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Biotechnology product development is a highly
uncertain undertaking and involves a substantial degree of risk. We have not commenced or completed clinical trials for any of our product
candidates, obtained marketing approval for any product candidates, manufactured a commercial scale product, or arranged for a third party
to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Given the highly
uncertain nature of biotechnology product development, we may never commence or complete clinical trials for any of our product candidates,
obtain marketing approval for any product candidates, manufacture a commercial scale product or arrange for a third party to do so on
our behalf, or conduct sales and marketing activities necessary for successful product commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our limited operating history as a company makes
any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently
experienced by early-stage biotechnology companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully
overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business, operating results
and financial condition will suffer.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a result of the clinical hold that
has been placed on our IND by the FDA, it has taken and may continue to take considerable time and expense to respond to the FDA and no
assurance can be given that the FDA will remove the clinical hold in which case our business and prospects will likely suffer material
adverse consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On October 1, 2020, we received notice from the
FDA that it had placed our IND for a planned Phase 2b clinical trial in LAPC on clinical hold. As part of the clinical hold process, the
FDA has asked for additional information, tasks to be performed by us and new preclinical studies and assays. It has taken and may continue
to take a considerable period of time, the length of which is not certain at this time, for us to conduct such tasks and preclinical studies
and to generate and prepare the requested information. In addition, the significant expense of such work is likely to require us to raise
additional capital. It is possible that the service providers that we will utilize for such work may have considerable backlogs and/or
are suffering from slowdowns as a result of COVID-19 and may not be able to perform such work for an extended period of time. Even if
we are able to fully respond to the FDA&rsquo;s requests, they may subsequently make additional requests that we would need to fulfill
prior to the lifting of the clinical hold and we may never be able to begin our clinical trial in LAPC, obtain regulatory approval or
successfully commercialize our product candidates. An inability to conduct our clinical trial in LAPC as a result of the clinical hold
or otherwise, would likely force us to terminate our clinical development plans. It is possible that we will be unable to fully respond
to the FDA in a satisfactory manner, and as a result the clinical hold may never be lifted. If the clinical hold is not lifted or if the
lifting takes an extended period of time, our business and prospects will likely suffer material adverse consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>The recent
and ongoing COVID-19 pandemic could materially affect our operations, as well as the business or operations of third parties with whom
we conduct business. Our business could be adversely affected by the effects of other future health pandemics in regions where we or third
parties on which we rely have significant business operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business and its operations,
including, but not limited to, our proposed clinical development program, supply chain operations, research and development activities
and fundraising activities, has been and could continue to be adversely affected by the COVID-19 pandemic in areas where we have business
operations, including the U.S., India, Europe, Singapore and Thailand. Also, this pandemic could cause significant disruption in the operations
of third parties upon whom we rely on to conduct the Company&rsquo;s business. In March 2020, the World Health Organization declared the
COVID-19 outbreak a pandemic. Shortly thereafter, the U.S. government-imposed restrictions on travel between the U.S., Europe, and certain
other countries. The President of the U.S. declared the COVID-19 pandemic a national emergency. Since March 2020, numerous state, regional
and local jurisdictions, including the jurisdictions where our headquarters are located, as well as foreign jurisdictions, have imposed,
and others in the future may impose, quarantines, shelter-in-place orders, executive, and similar government orders for their residents
to control the spread of COVID-19.&nbsp;&nbsp; The COVID-19 pandemic has had an impact upon our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The effects of the executive
orders, the shelter-in-place orders and our work-from-home policies has and may continue to negatively impact productivity, disrupt our
business, and delay our proposed clinical development program and timeline, the magnitude of which will depend, in part, on the length
and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar,
and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Quarantines, shelter-in-place,
executive, and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business
operations could occur, related to COVID-19, could impact personnel at our third-party manufacturing facilities in Thailand, or the availability
or cost of materials we use or require to conduct our business, including product development, which would disrupt our supply chain. Some
of our suppliers and vendors of certain materials used in our operations and research and development activities are located in areas
that are subject to executive orders and shelter-in-place orders. While many of these materials may be obtained from more than one supplier,
port closures and other restrictions resulting from the COVID-19 pandemic may disrupt our supply chain or limit our ability to obtain
sufficient materials to operate our business. To date, we are aware of certain suppliers for our research and development activities that
have experienced operational delays directly related to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Depending upon the length
of the COVID-19 pandemic and whether the FDA lifts the clinical hold on our IND, we anticipate our planned clinical trial in LAPC may
be affected by the COVID-19 pandemic. If COVID-19 continues to spread in the U.S. and elsewhere, we may experience additional disruptions
that could adversely impact our business and proposed clinical trial, including: (i) delays or difficulties in enrolling patients in our
Phase 2b clinical trial if the FDA allows us to go forward with such trial; (ii) delays or difficulties in clinical site activation, including
difficulties in recruiting clinical site investigators and clinical site personnel; (iii) delays in clinical sites receiving the supplies
and materials needed to conduct our clinical trial, including interruption in global shipping that may affect the transport of our clinical
trial product; (iv) changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways
in which our clinical trial is to be conducted, which may result in unexpected costs, or to discontinue the clinical trial altogether,
if allowed to proceed; (v) diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trial; (vi) interruption of key clinical
trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments,
employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the
integrity of clinical trial data; (vii) risk that participants enrolled in our proposed clinical trials will acquire COVID-19 while the
clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse
events; (viii) delays in necessary interactions with local regulators, ethics committees, and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees; (ix) limitations in employee resources that would
otherwise be focused on the conduct of our clinical trial because of sickness of employees or their families or the desire of employees
to avoid contact with large groups of people; (x) refusal of the FDA to accept data from clinical trials in affected geographies; and
(xi) interruption or delays to our clinical trial activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The spread of COVID-19, which
has caused a widespread impact throughout the world, may materially affect us economically. The potential economic impact brought about
by the COVID-19 pandemic, and the duration of such impact, is difficult to assess or predict. The pandemic has resulted in significant
disruption of global financial markets, which could reduce our ability to access capital and negatively affect our future liquidity. Also,
a recession or market correction resulting from the spread of COVID-19 and related government orders and restrictions could materially
affect our business and the value of our common stock. The COVID-19 pandemic continues to evolve. The ultimate impact of the COVID-19
pandemic and the mitigation efforts to address it is highly uncertain and subject to change. We do not yet know the full extent of potential
delays or impacts on our business, our proposed clinical trial, healthcare systems or the global economy.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are unable to successfully raise
additional capital, our future clinical trials and product development could be limited and our long-term viability may be threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have experienced negative operating cash flows
since our inception and have funded our operations primarily through sales of our equity securities. We will need to seek additional funds
in the future through equity or debt financings, or strategic alliances with third parties, either alone or in combination with equity
financings to complete our product development initiatives. These financings could result in substantial dilution to the holders of our
common stock, or require contractual or other restrictions on our operations or on alternatives that may be available to us. If we raise
additional funds by issuing debt securities, these debt securities could impose significant restrictions on our operations. Any such required
financing may not be available in amounts or on terms acceptable to us, and the failure to procure such required financing could have
a material and adverse effect on our business, financial condition and results of operations, or threaten our ability to continue as a
going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our operating and capital requirements during
this fiscal year and thereafter will vary based on several factors, including whether the FDA allows us to commence our planned clinical
trial for LAPC, how quickly enrollment of patients in our such trial can be commenced, the duration of the clinical trial and any change
in the clinical development plans for our product candidates and the outcome, timing and cost of meeting regulatory requirements established
by the FDA and the EMA or other comparable foreign regulatory authorities. The proceeds of this proposed offering will not be sufficient
to complete our planned Phase 2b clinical trial for LAPC if the clinical hold is lifted by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our present and future capital requirements will
be significant and will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the FDA lifts the clinical hold on our IND filing for LAPC;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the progress and results of our development efforts for our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs, timing and outcome of regulatory review of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending any intellectual property-related claims;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the effect of competing technological and market developments;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>market acceptance of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rate of progress in establishing coverage and reimbursement arrangements with domestic and international commercial third-party
payors and government payors;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which we acquire or in-license other products and technologies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>legal, accounting, insurance and other professional and business-related costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be able to acquire additional funds
on acceptable terms, or at all. If we are unable to raise adequate funds, we may have to liquidate some or all of our assets, or delay
or reduce the scope of or eliminate some or all of our development programs. Further, if we do not have, or are not able to obtain, sufficient
funds, we may be required to delay development or commercialization of our product candidates. We also may have to reduce the resources
devoted to our product candidates or cease operations. Any of these factors could harm our operating results.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Due to the significant resources required
for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product
candidates. We may expend our limited resources on programs that do not yield a successful product candidate and fail to capitalize on
product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We seek to maintain a process of prioritization
and resource allocation to maintain an optimal balance between aggressively advancing lead programs and ensuring replenishment of our
portfolio. Until such time, if ever, as the FDA lifts its clinical hold on ou<FONT STYLE="font-family: Times New Roman, Times, Serif">r
I</FONT>ND related to our planned Phase 2b clinical trial in LAPC, our Cell-in-a-Box<SUP>&reg;</SUP> encapsulation technology is validated
in our planned Phase 2b clinical trial, and sufficient additional funding is available, we have halted spending on behalf of our other
development programs with respect to cannabinoids, malignant ascites fluid and diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Due to the significant resources required
for the development of our programs, we must focus our programs on specific diseases and decide which product candidates to pursue and
advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration,
management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable
commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or
collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss
valuable opportunities. We may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego
or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential
than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty
arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization
rights. If we make incorrect determinations regarding the viability or market potential of any or all of our programs or product candidates
or misread trends in the biotechnology industry, our business, prospects, financial condition and results of operations could be materially
adversely affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently have no commercial revenue
and may never become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Even if we can successfully achieve regulatory
approval for our product candidates, we do not know what the reimbursement status of our product candidates will be or when any of these
products will generate revenue for us, if at all. We have not generated, and do not expect to generate, any product revenue for the foreseeable
future. We expect to continue to incur significant operating losses for the foreseeable future due to the cost of our research and development,
preclinical studies and clinical trials and the regulatory approval process for our product candidates. The amount of future losses is
uncertain and will depend, in part, on the rate of growth of our expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our ability to generate revenue from our
product candidates also depends on numerous additional factors, including our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successfully complete development activities, including the remaining preclinical studies and planned clinical trials for our product
candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>complete and submit NDAs or BLAs to the FDA and MAAs to the EMA, and obtain regulatory approval for indications for which there is
a commercial market;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>complete and submit applications to, and obtain regulatory approval from, other foreign regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacture any approved products in commercial quantities and on commercially reasonable terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>develop a commercial organization, or find suitable partners, to market, sell and distribute approved products in the markets in which
we have retained commercialization rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>achieve acceptance among patients, clinicians and advocacy groups for any products we develop;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain coverage and adequate reimbursement from third parties, including government payors; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>set a commercially viable price for any products for which we may receive approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are unable to predict the timing or amount
of increased expenses, or when or if we will be able to achieve or maintain profitability. Even if we can complete the processes described
above, we anticipate incurring significant costs associated with commercializing our product candidates.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We face substantial competition, which
may result in others discovering, developing or commercializing competing products before or more successfully than we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The development and commercialization of new drug
products is highly competitive. We face competition with respect to our current product candidates. We will face competition with respect
to any product candidates that we may seek to develop or commercialize in the future. Such competition may arise from major pharmaceutical
companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology
companies that currently market products or are pursuing the development of products for the treatment of the disease indications for
which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that
are entirely different from our approach. Potential competitors also include academic institutions, government agencies and other public
and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Specifically, there are numerous companies developing
or marketing therapies for cancer and diabetes, including many major pharmaceutical and biotechnology companies. Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain
regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing
a strong market position before we can enter the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Many of the companies against which we are competing
or against which we may compete in the future have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we
do. Mergers and acquisitions in the pharmaceutical and biotechnology sectors may result in even more resources being concentrated among
a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining
qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additional Risks Related to Regulatory Matters</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are unable to obtain, or if
there are delays in obtaining, required approval from the applicable regulatory agencies, we will not be able to commercialize our product
candidates and our ability to generate revenue will be materially impaired.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our product candidates must obtain marketing approval
from the FDA for commercialization in the U.S. and from foreign regulatory agencies for commercialization in countries outside the U.S.
The process of obtaining marketing approvals in the countries in which we intend to sell and distribute our product candidates is expensive
and can take many years, if approval is obtained at all. This process can vary substantially based upon a variety of factors, including
the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will
prevent us from commercializing that product candidate. To date, we have not received approval to market any of our product candidates
from regulatory agencies in any jurisdiction. We have no experience in filing and supporting the applications necessary to gain marketing
approvals and expect to rely on third-party contract research organizations to assist us in this process. Securing marketing approval
requires the submission of extensive preclinical and clinical data and supporting information to the regulatory agencies for each product
candidate to establish the product candidate&rsquo;s safety and efficacy. Securing marketing approval also requires the submission of
information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our product candidates may not be effective, may
be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may
preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory agencies have substantial discretion in the approval
process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical,
clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay,
limit or prevent marketing approval of a product candidate. Changes in marketing approval policies during the development period, changes
in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may
also cause delays in or prevent the approval of an application. New cancer drugs frequently are indicated only for patient populations
that have not responded to an existing therapy or have relapsed after such therapies. If we experience delays in obtaining approval or
if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability
to generate revenues will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If allowed to proceed with our clinical
development programs, we intend to conduct clinical trials for certain of our product candidates at sites outside of the U.S., and the
U.S. regulatory agencies may not accept data from trials conducted in such locations.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although the FDA may accept data from clinical
trials conducted outside the U.S., acceptance of this data is subject to certain conditions imposed by the regulatory agencies outside
of the U.S. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance
with ethical principles. The trial population must also adequately represent the population in the country in which the clinical trial
is being conducted. The data must be applicable to the U.S. population and medical practice in the U.S. in ways that the FDA deems clinically
meaningful. Generally, the patient population for any clinical trial conducted outside of the U.S. must be representative of the population
for whom we intend to seek approval in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">In addition, while these clinical trials are subject
to the applicable local laws, the FDA acceptance of the data will be dependent upon its determination that the trials also complied with
all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the
U.S. If the FDA does not accept the data from any of our clinical trials that we determine to conduct outside the U.S., it would likely
result in the need for additional trials that would be costly and time-consuming and delay or permanently halt the development of our
product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the conduct of clinical trials outside
the U.S. could have a significant impact on us. Risks inherent in conducting international clinical trials include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Administrative burdens of conducting clinical trials under multiple foreign regulatory schemes;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Foreign exchange fluctuations; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Diminished protection of intellectual property in some countries.</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Promising results in previous clinical
trials of our encapsulated live cell and ifosfamide combination for LAPC may not be replicated in future clinical trials which could result
in development delays or a failure to obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Positive results in the previous Phase 1/2 and
Phase 2 clinical trials of the encapsulated live cell and ifosfamide combination product may not be predictive of similar results in future
clinical trials such as our planned Phase 2b clinical trial in LAPC for which the FDA has placed a clinical hold. The previous Phase 1/2
and Phase 2 clinical trials were done over twenty years ago in Germany by Bavarian Nordic and had a relatively limited number of patients
in each trial. These trials resulted in outcomes that were not statistically significant and may not be representative of future results.
In addition, interim results obtained after a clinical trial has commenced do not necessarily predict results in future clinical trials.
Numerous companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials
even after achieving promising results in early-stage clinical development. Our clinical trials may produce negative or inconclusive results
and we may decide, or regulatory agencies may require us, to conduct additional clinical trials. Moreover, clinical data are often susceptible
to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain the approval for their products by the regulatory agencies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Risks related to our Intellectual Property</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be able to protect our
intellectual property rights throughout the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Filing,
prosecuting and defending patents or establishing other intellectual property rights to our product candidates in all countries&nbsp;</FONT>throughout&nbsp;<FONT STYLE="background-color: white">the
world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive
than those in the United States or non-existent. For example, the Melligen cells are protected by patents only in the U.S. and Europe
and we are only pursuing patent protection for our pancreatic cancer product candidate in the U.S., Australia and Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the
enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our
patents or misappropriation of our intellectual property rights generally. Proceedings to enforce our patent and other intellectual property
rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our patents or intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications
at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate,
and the damages or other remedies awarded, if any, may not be commercially meaningful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Many
countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may
be compelled under specified circumstances to grant licenses to third parties. In those countries, we may have </FONT>limited <FONT STYLE="background-color: white">remedies
if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of
those patents. This could limit our ability to&nbsp;</FONT>pursue strategic alternatives, including identifying and
consummating&nbsp;<FONT STYLE="background-color: white">transactions with potential third-party partners, to further develop, obtain
marketing approval for and/or commercialize our product candidates, and consequently our potential revenue opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><B><I>Our intellectual property
and data and market exclusivity may not be sufficient to block others from commercializing identical or competing products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Our success
depends in large part on our ability to obtain and maintain both intellectual property rights and data and market exclusivity for our
product candidates in order to block others from commercializing identical or competing products.&nbsp; Establishing intellectual property
rights includes filing, prosecuting, maintaining, and enforcing patents that cover our product candidates and variations of our product
candidates and protecting our trade secrets and other proprietary information related to our product candidates from unauthorized use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">The foundational
patents relating to the Cell-in-the-Box&reg; technology that were formerly licensed from Bavarian Nordic/GSF covering capsules encapsulating
cells expressing cytochrome P450 and treatment methods using the same expired on March 27, 2017. Currently, we do not have any
issued patents in any countries covering our product candidate for the treatment of pancreatic cancer. We exclusively license from UTS
patented Melligen cells, which cover our product candidate for the treatment of diabetes, which are issued in the U.S. and Europe and
expire in August 2028. Currently, we do not have any issued patents or pending applications covering our product candidate for the
treatment of cancer using cannabinoids or our product candidate for the treatment of malignant ascites fluid therapy. We may not
be able to obtain protection for our product candidates or variations of our product candidates.&nbsp; Even if our owned and licensed
patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors
from competing with us or otherwise provide us with any competitive advantage or our patents may expire before or shortly after our product
candidate is approved. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies
or products in a non-infringing manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Confidential
know-how and trade secrets are only protectable to the extent a third party utilizes the confidential know-how or trade secret in an unauthorized
manner; however, if a third party is able to independently duplicate the technology, such as through reverse engineering, without access
to or use of our confidential know-how or trade secret, we would have no recourse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">In
addition, data exclusivity that is provided through the BPCIA in the U.S. and equivalents in foreign countries is limited in both
time and scope. The BPCIA bars the FDA from approving biosimilar applications for 12 years after an innovator biological product
receives initial marketing approval, however it does not bar the FDA from approving an identical or similar product that is the
subject of its own BLA. Finally, upon the approval of the first BLA for a biologic designated as an Orphan Drug for a specified
indication, the sponsor of that BLA is entitled to 7 years of exclusive marketing rights in the U.S. for biologic for the particular
indication unless the sponsor cannot assure the availability of sufficient quantities to meet the needs of persons with the disease.
In Europe, this exclusivity is 10 years. However, Orphan Drug status for an approved indication does not prevent another company
from seeking approval of a biologic that has other labeled indications that are not under orphan or other exclusivities. In
addition, in the U.S., the FDA is not prevented from approving another biologic for the same labeled Orphan indication if the
company can demonstrate that the other biologic is clinically superior to first approved product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Even if
we are able to obtain patents and maintain confidential information and trade secrets and obtain data and market exclusivity for our product
candidates, our competitors may be able to develop and obtain approval of identical or competing products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>If we do not obtain patent and/or data exclusivity
for our product candidates, our business may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Our commercial success
will largely depend on our ability to obtain and maintain patent and other intellectual property protection and/or data exclusivity
under the BPCIA in the U.S. and other countries with respect to our proprietary technology, product candidates and our target
indications. If we are unable to obtain patents covering our product candidates or obtain data and/or marketing exclusivity for our
product candidates, our competitors may be able to take advantage of our investment in development and clinical trials by
referencing our clinical and preclinical data to obtain approval of competing products, such as a biosimilar, earlier than might
otherwise be the case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>If we are unable to
protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In addition to seeking patents
for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other
proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering non-disclosure
and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific
collaborators, contract manufacturers, consultants, advisors and other third parties. We seek to protect our confidential proprietary
information, in part, by entering confidentiality and invention or patent assignment agreements with our employees and consultants; however,
we cannot be certain that such agreements have been entered with all relevant parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 22.5pt">Moreover, to the extent we
enter such agreements, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets
to unaffiliated third parties. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome is unpredictable. In addition,
some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be
lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate
them, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently
developed by a competitor, our competitive position would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The majority of the technology that we license
and use for our product candidates is not protected by patents, but rather is based upon confidential know-how and trade secrets. Confidential
know-how and trade secrets are only protectable to the extent a third party utilizes the confidential know-how or trade secret in an unauthorized
manner; however, if a third party is able to independently duplicate the technology, such as through reverse engineering, without access
to or use of our confidential know-how or trade secret, we would have no recourse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Risks Related to Our Dependence on Third
Parties</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely heavily on third parties to
conduct our preclinical studies and plan to rely on third parties to conduct our clinical trials, assuming they are allowed to proceed,
and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such studies and trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently rely heavily on third parties to
conduct our preclinical studies and plan to rely on third parties to conduct our clinical trials, assuming they are allowed to proceed,
including Austrianova in which we own an equity interest. We expect to continue to rely heavily on third parties, such as a CRO, a clinical
data management organization, a medical institution, a clinical investigator and others to plan for and conduct our clinical trials. Our
agreements with these third parties generally allow the third party to terminate our agreement with them at any time. If we are required
to enter alternative arrangements because of any such termination, the introduction of our product candidates to market could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our reliance on these third parties for research
and development (&ldquo;R&amp;D&rdquo;) activities will reduce our control over these activities but will not relieve us of our responsibilities.
For example, we design our clinical trials and will remain responsible for ensuring that each is conducted in accordance with the general
investigational plan and protocol for the trial. Moreover, regulatory agencies require us to comply with current good manufacturing practices
(&ldquo;cGMP&rdquo;) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties
that we do not control does not relieve us of these responsibilities and requirements. We also are required to register ongoing clinical
trials and post the results of completed clinical trials on a government-sponsored database of regulatory agencies within specified timeframes.
Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, these third parties may also have
relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual
duties, meet expected deadlines or conduct our clinical trials in accordance with the requirements of a regulatory agency or our protocols,
we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to,
or may be delayed in our efforts to, successfully commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We expect to rely on third parties to store
and distribute our product candidates for our clinical trials. Any performance failure on the part of such third parties could delay clinical
development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving
us of potential product candidate revenue. Our existing collaboration with universities and institutions is important to our business.
If we are unable to maintain these collaborations, or if these collaborations are not successful, our business could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely on numerous consultants for a substantial
portion of our R&amp;D related to our product candidates. If there are delays or failures to perform their obligations, our product candidates
would be adversely affected. If our collaboration with these consultants is unsuccessful or is terminated, we would need to identify new
research and collaboration partners for our preclinical and clinical development. If we are unsuccessful or significantly delayed in identifying
new collaboration and research partners, or unable to reach an agreement with such a partner on commercially reasonable terms, development
of our product candidates will suffer, and our business would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, if any of these consultants change
their strategic focus, or if external factors cause any one of them to divert resources from our collaboration, or if any one of them
independently develops products that compete directly or indirectly with our product candidates using resources or information it acquires
from our collaboration, our business and results of operations could suffer.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely on Prof. G&uuml;nzburg, Dr.
Salmons and Dr. L&ouml;hr for the development of our product candidates. If they decide to terminate their relationship with us, we may
not be successful in the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely on Prof. Walter H. G&uuml;nzburg and Dr.
Brian Salmons, officers of Austrianova, and Dr. L&ouml;hr, currently with the Karolinska Institute in Stockholm, Sweden, for the development
of our product candidates. If they decide to terminate their relationship with us, we may not be successful in the development of our
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prof. G&uuml;nzburg, Dr. Salmons and Dr. L&ouml;hr
are involved in almost all our scientific endeavors underway and being planned by us. These endeavors include preclinical and clinical
studies involving our cancer therapy for LAPC to be conducted in the U.S. and elsewhere on our behalf. They also provide professional
consulting services to us through the respective consulting agreements we have entered with the consulting companies through which they
provide services. The consulting agreements may be terminated for any reason at any time upon one party giving the other a written notice
prior to the effective date of the termination. If that occurs, we may not be successful in the development of our product candidates
which could have a material adverse effect on us.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Risks Related to this Offering</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You will experience immediate and
substantial dilution in the net tangible book value per share of the common stock you purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The effective public offering price per share
in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering, in which case
you may incur an immediate and substantial dilution in the net tangible book value of the shares of common stock you purchase in this
offering or the shares of common stock underlying the Pre-funded Warrants and the Common Warrants you purchase in this offering. After
giving effect to the sale by us of (i) shares of our common stock and accompanying Common Warrants to purchase shares of our common stock
at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per share of common stock and accompanying Common Warrant, and (ii) Pre-funded Warrants to purchase
shares of common stock and accompanying Common Warrants at an effective public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per Pre-funded Warrant and accompanying
Common Warrant, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us and assuming
full exercise of the Pre-funded Warrants, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per share, representing the difference between
the effective public offering price per share and our as adjusted net tangible book value per share as of January 31, 2021 after giving
effect to this offering. The exercise of warrants, including the Common Warrants issued in this offering, exercise of outstanding stock
options and vesting of other stock awards may result in further dilution of your investment. See &ldquo;<A HREF="#a_008">Dilution</A>&rdquo;
on page <A HREF="#a_008">S-34</A> of this prospectus supplement for a more detailed discussion of the dilution you will incur if you participate in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, as of July 31, 2021, we had outstanding
options to acquire 42,333 shares of our common stock and outstanding warrants to acquire 2,981 shares of our common stock, and pursuant
to this offering, we will issue underwriter warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 shares of our common stock. The issuance of shares of our common
stock upon exercise of the stock options or warrants could result in dilution to the interests of other holders of our common stock and
could adversely affect our stock price.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Substantial future sales or other
issuances of our common stock could depress the market for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sales of a substantial number of shares of our
common stock, or the perception by the market that those sales could occur, could cause the market price of our common stock to decline
or could make it more difficult for us to raise funds through the sale of equity in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with this offering, our directors
and executive officers have entered into lock-up agreements for a period of 90 days following this offering. Our directors and executive
officers may be released from such lock-up agreements prior to the expiration of the lock-up period at the sole discretion of H.C. Wainwright
&amp; Co. (See &ldquo;<A HREF="#a_010">Underwriting</A>&rdquo; beginning on page <A HREF="#a_010">S-40</A> of this prospectus supplement). Upon expiration
or earlier release of the lock-up, our directors and executive officers may sell shares into the market, which could adversely affect
the market price of shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Future issuances of our common stock or our other
equity securities could further depress the market for our common stock. We expect to continue costs associated with our R&amp;D programs,
such as preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates, and general and administrative
costs associated with our operations, and to satisfy our funding requirements, we may need to sell additional equity securities. The proceeds
of this offering will not be sufficient to conduct our planned clinical trial in LAPC should the FDA lift its clinical hold on our IND
and the Company may have to sell additional equity securities to fully fund such trial. The sale or the proposed sale of substantial amounts
of our common stock or our other equity securities may adversely affect the market price of our common stock and our stock price may decline
substantially. Our stockholders may experience substantial dilution and a reduction in the price that they are able to obtain upon sale
of their shares. New equity securities issued may have greater rights, preferences or privileges than our existing common stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no public market for the
Pre-funded Warrants or Common Warrants being offered in this offering.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">There
is no established public trading market for the Pre-funded Warrants or Common Warrants being offered in this offering, and we do not expect
a market to develop. In addition, we do not intend to apply to list the Pre-funded Warrants or Common Warrants on any securities exchange
or nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of the Pre-funded Warrants and the
Common Warrants will be limited.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Common Warrants being offered
may not have value.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">The
Common Warrants being offered by us in this offering have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per share, subject to certain adjustments, and expire
from the date of issuance, after which date any unexercised Common Warrants will expire and have no further value. In the event that the
market price of our common stock does not exceed the exercise price of the Common Warrants during the period when they are exercisable,
the Common Warrants may not have any value.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of Pre-funded Warrants and
Common Warrants purchased in this offering will have no rights as common stockholders until such holders exercise their Pre-funded Warrants
or Common Warrants and acquire our common stock.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal; font-weight: normal">Until
holders of Pre-funded Warrants or Common Warrants acquire shares of our common stock upon exercise of such warrants, holders of Pre-funded
Warrants and Common Warrants will have no rights with respect to the shares of our common stock underlying such Pre-funded Warrants and
Common Warrants. Upon exercise of the Pre-funded Warrants and Common Warrants, the holders will be entitled to exercise the rights of
a common stockholder only as to matters for which the record date occurs after the exercise date.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have broad discretion in the use
of the net proceeds of this offering and, despite our efforts, we may use the net proceeds in a manner that does not increase the value
of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management will have broad discretion in the application of our existing cash and the net proceeds from this offering, including for any
of the purposes described in the section titled &quot;Use of Proceeds,&quot; and you will not have the opportunity as part of your investment
decision to assess whether such proceeds are being used appropriately. Because of the number and variability of factors that will determine
our use of our existing cash and the net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. Our management might not apply our existing cash and the net proceeds from this offering in ways that ultimately increase the value
of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may
invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield
a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder
value, we may fail to achieve expected financial results,</FONT> which could cause our stock price to decline.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There has been no consistent active
trading market for our common stock, and public trading of our common stock ma<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal; color: black">y</FONT>
continue to fluctuate substantially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There has never been a consistent active trading
market for our common stock and trading has been limited and sporadic. The Company&rsquo;s OTCQB Market Symbol is PMCB, although as a
result of the recent reverse split of the Company&rsquo;s common stock, until August 6, 2021, the Company&rsquo;s OTCQB Market Symbol
has temporarily been &ldquo;PMCBD.&rdquo; Although our common stock sold in this offering has been approved for listing on Nasdaq under
the symbol &ldquo;PMCB&rdquo; it has not yet commenced trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no assurance that the trading market for our common stock will become more active or liquid. Furthermore,
there can be no assurance any market maker will be interested in trading our stock. Therefore, it may be difficult to sell your shares
of common stock if you desire or need to sell them. As a result, no assurances can be given that you will be able to readily sell your
common stock at a price equal to or above the price you paid. Our underwriter is not obligated to make a market in our securities, and
even if they make a market, they can discontinue market making at any time without notice. Neither we nor the underwriter can provide
any assurance that an active and liquid trading market in our securities will develop or, if developed, that such market will continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Moreover, the trading price of our common stock
has fluctuated substantially over the past few years, and there remains a significant risk that our common stock price may continue to
fluctuate substantially in the future in response to various factors, including any material developments in the FDA approval process
for our proposed Phase 2b clinical trial, material variations in our periodic operating results, departures or additions of management
or other key personnel, announcements of acquisitions, mergers, share consolidations, or new technology or patents, new product developments,
significant litigation matters, gain or loss of significant licensees, significant capital transactions, substantial sales of our common
stock in our trading market, and general and specific market and economic conditions.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be able to meet the continued
listing requirements for the Nasdaq Capital Market or another nationally recognized stock exchange, which could limit investors&rsquo;
ability to make transactions in our securities and subject us to additional trading restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock has been approved for listing
on Nasdaq under the symbol &ldquo;PMCB&rdquo; but has not yet commenced trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If and when our common stock is listed on the
Nasdaq Capital Market, in order to remain listed on the Nasdaq Capital Market, we will be required to meet the continued listing requirements
of the Nasdaq Capital Market or any other U.S. or nationally recognized stock exchange to which we may apply and be approved for listing.
We may be unable to satisfy these continued listing requirements, and there is no guarantee that our common stock will remain listed on
the Nasdaq Capital Market or any other U.S. or nationally recognized stock exchange. If, after listing, our common stock is delisted from
the Nasdaq Capital Market or any other U.S. or nationally recognized stock exchange, we could face significant material adverse consequences,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a limited availability of market quotations for our common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduced liquidity with respect to the market for our common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a determination that our common stock is a &ldquo;penny stock,&rdquo; which will require brokers trading in our common stock to adhere
to different rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a limited amount of news and analyst coverage; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>decreased ability to issue additional shares of our common stock or obtain additional financing in the future.</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A large number of shares may be issued
and subsequently sold upon the exercise of existing options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of July 31, 2021, there were 42,333 shares
of common stock issuable under outstanding options and 2,981 shares issuable upon exercise of outstanding warrants at various exercise
prices. To the extent that holders of existing options or warrants sell the shares of common stock issued upon the exercise of warrants,
the market price of our common stock may decrease due to the additional selling pressure in the market. The risk of dilution from issuances
of shares of common stock underlying existing options and warrants may cause shareholders to sell their common stock, which could further
decline in the market price. In addition, we will be issuing in this offering Common Warrants to purchase shares of common stock which
are immediately exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: white"><B><I>You may experience
future dilution as a result of future equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">In order to raise additional
capital, we may in the future offer additional common stock or other securities convertible into or exchangeable for our common stock
at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering
at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional shares of
our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the
price per share paid by investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We are a &ldquo;smaller reporting company&rdquo;
under the SEC&rsquo;s disclosure rules and have elected to comply with the reduced disclos<FONT STYLE="font-family: Times New Roman, Times, Serif">u</FONT>re
requirements applicable to smaller reporting companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a &ldquo;smaller reporting company&rdquo;
under the SEC&rsquo;s disclosure rules, meaning that we have either:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a public float of less than $250 million; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>annual revenues of less than $100 million during the most recently completed fiscal year; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>no public float; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a public float of less than $700 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a smaller reporting company, we are permitted
to comply with scaled-back disclosure obligations in our SEC filings compared to other issuers, including with respect to disclosure obligations
regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to
smaller reporting companies. Until we cease to be a smaller reporting company, the scaled-back disclosure in our SEC filings will result
in less information about our company being available than for other public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If investors consider our common stock less attractive
as a result of our election to use the scaled-back disclosure permitted for smaller reporting companies, there may be a less active trading
market for our common stock and our share price may be more volatile.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>As a non-accelerated filer, we
are not required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act.</I></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a non-accelerated filer under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, and we are not required to comply with the auditor attestation requirements of
Section 404(b) of the Sarbanes-Oxley Act of 2002. Therefore, our internal controls over financial reporting will not receive the level
of review provided by the process relating to the auditor attestation included in annual reports of issuers that are subject to the auditor
attestation requirements. In addition, we cannot predict if investors will find our common stock less attractive because we are not required
to comply with the auditor attestation requirements. If some investors find our common stock less attractive as a result, there may be
a less active trading market for our common stock and trading price for our common stock may be negatively affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B></B></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>If and when our common stock is listed on
Nasdaq, we will incur materially increased costs and become subject to additional regulations and requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If and when our common stock is listed on the
Nasdaq Capital Market, as a newly exchange-listed public company, we will incur material additional legal, accounting and other expenses,
including payment of annual exchange fees, to satisfy the continued listing standards for Nasdaq. If our common stock is listed on Nasdaq,
we must meet certain financial and liquidity criteria to maintain our listing. If we fail to meet any of Nasdaq&rsquo;s listing standards,
our common stock may be delisted. In addition, our Board may determine that the cost of maintaining our listing on a national securities
exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&rsquo;
ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We may experience volatility in our stock
price, which may adversely affect the trading price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have experienced significant volatility from
time to time in the market price of our shares of common stock. Over the past twelve months, shares of our common stock were quoted and
traded at a high of $55.50 per share and a low of $5.56 per share. In the future, the market price of our common stock may continue to
be volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Risks Related to our Reverse Stock Split</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>We cannot assure you that we will
be able to continue to comply with the minimum bid price requirement of Nasdaq</B><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There can be no assurance that the market price
of our common stock will remain at the level required for continuing compliance with Nasdaq&rsquo;s minimum bid requirement. It is not
uncommon for the market price of a company&rsquo;s common stock to decline in the period following a reverse stock split. If the market
price of our common stock declines following the effectuation of the reverse stock split, the percentage decline may be greater than would
occur in the absence of a reverse stock split. In any event, other factors unrelated to the number of shares of our common stock outstanding,
such as negative financial or operational results, could adversely affect the market price of our common stock and jeopardize our ability
to maintain compliance with Nasdaq&rsquo;s minimum bid price requirement.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>There can be no assurance that
we will be able to comply with the continued listing standards of Nasdaq, a failure of which could result in a de-listing of our common
stock</B><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Nasdaq requires that the trading price of its
listed stocks remain above one dollar in order for the stock to remain listed. If a listed stock trades below one dollar for more than
30 consecutive trading days, then it is subject to delisting from Nasdaq. In addition, to maintain a listing on Nasdaq, we must satisfy
minimum financial and other continued listing requirements and standards, including those regarding director independence and independent
committee requirements, minimum stockholders&rsquo; equity and certain corporate governance requirements. If we are unable to satisfy
these requirements or standards, we could be subject to delisting. This would have a negative effect on the price of our common stock
and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide
no assurance that any action we may take to restore our compliance with the listing requirements would allow our common stock to become
listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the
minimum bid price requirement, or prevent future non-compliance with the listing requirements.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>The reverse stock split may decrease
the liquidity of the shares of our common stock</I><FONT STYLE="font-style: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The liquidity of the shares of our common stock
may be affected adversely by the reverse stock split given the reduced number of shares that will be outstanding following the reverse
stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split. In addition,
the reverse stock split may increase the number of shareholders who own odd lots (less than 100 shares) of our common stock, creating
the potential for such shareholders to experience an increase in the cost of selling their shares and greater difficulty effecting such
sales.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Following the reverse stock split,
the resulting market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the
investing requirements of those investors. Consequen</I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal; color: black">tl</FONT><I>y,
the trading liquidity of our common stock may not improve</I><FONT STYLE="font-style: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we believe that a higher market price
of our common stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will
result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that
the market price of our common stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of
our common stock may not necessarily improve.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Risks Related to our Tax Matters </B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Our ability to use our net operating
loss carryforwards and certain other tax attributes may be limited. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of April 30, 2020, we had federal net operating
loss carryforwards of approximately $45 million, which will begin to expire in varying amounts beginning in 2020. Under Sections 382 and
383 of the United States Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation
undergoes an &ldquo;ownership change&rdquo; (generally defined as a greater than 50-percentage-point cumulative change (by value) in the
equity ownership of certain stockholders over a rolling three-year period), the corporation&rsquo;s ability to use its pre-change net
operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We
may have experienced ownership changes in the past and could experience one or more ownership changes in the future, including in connection
with this offering, some of which are outside our control. Our net operating loss carryforwards may also be subject to limitation under
state laws. Further, our ability to utilize net operating loss carryforwards of companies that we may acquire in the future may also be
subject to limitations. There is also a risk that due to tax law changes, such as suspensions on the use of net operating loss carryforwards,
or other unforeseen reasons, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to
offset post-change taxable income or taxes may be subject to limitation or expire.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Changes in U.S. tax law could adversely
aff</I>ect o<I>ur business and financial condition.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The laws, rules and regulations dealing with U.S.
federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal
Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely
affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to
continue to occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For example, the Tax Cuts and Jobs Act, or the
TCJA, was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a
top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable
income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable years beginning after
December 31, 2017 to 80% of current year taxable income and the elimination of net operating loss carrybacks generated in taxable years
ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), and the modification or repeal
of many business deductions and credits. In addition, on March 27, 2020, then President Trump signed into law the &ldquo;Coronavirus Aid,
Relief, and Economic Security Act&rdquo; or the CARES Act, which, among other things, suspends the 80% limitation on the deduction for
net operating losses arising in taxable years beginning before January 1, 2021, permits a five-year carryback of net operating losses
arising in taxable years beginning after December 31, 2017 and before January 1, 2021, and generally modifies the limitation on the deduction
for net interest expense to 50% of adjusted taxable income for taxable years beginning in 2019 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">It cannot be predicted whether, when, in what
form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under
existing or new tax laws, which could result in an increase in our or our shareholders&rsquo; tax liability or require changes in the
manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus supplement contains forward-looking
statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements
by the fact that they do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties
and include statements regarding, among other things, our projected revenue growth and profitability, our growth strategies and opportunity,
anticipated trends in our market and our anticipated needs for working capital. They are generally identifiable by use of the words &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
&ldquo;projects,&rdquo; &ldquo;continuing,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;expects,&rdquo; &ldquo;management believes,&rdquo; &ldquo;we
believe,&rdquo; &ldquo;we intend&rdquo; or the negative of these words or other variations on these words or comparable terminology. In
particular, these include statements relating to future actions, prospective products, market acceptance, future performance or results
of current and anticipated products, sales efforts, expenses, and the outcome of contingencies such as legal proceedings and financial
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Examples of forward-looking statements in this
prospectus supplement include, but are not limited to, our expectations regarding our business strategy, business prospects, operating
results, operating expenses, working capital, liquidity and capital expenditure requirements. Important assumptions relating to the forward-looking
statements include, among others, assumptions regarding demand for our products, the cost, terms and availability of materials related
to biopharma products, pricing levels, the timing and cost of capital expenditures, status of regulatory approvals, competitive conditions
and general economic conditions. These statements are based on our management&rsquo;s expectations, beliefs and assumptions concerning
future events affecting us, which in turn are based on currently available information. These assumptions could prove inaccurate. Although
we believe that the estimates and projections reflected in the forward-looking statements are reasonable, our expectations may prove to
be incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Important factors that could cause actual results
to differ materially from the results and events anticipated or implied by such forward-looking statements include, but are not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to conduct the preclinical studies and assays and provide the additional information requested by the FDA in order to
lift the clinical hold on our IND for LAPC;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to advance any product candidates into, and successfully complete, clinical studies and obtain regulatory approval for
them;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing or likelihood of regulatory filings and approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the commercialization, marketing and manufacturing of our product candidates, if approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to continue as a going concern;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the pricing and reimbursement of our product candidates, if approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the implementation of our strategic plans for our business, product candidates and technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope of protection we have and are able to establish and maintain for intellectual property rights covering our product candidates
and technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations related to the use of proceeds from this offering and our existing cash resources, and estimates of our expenses,
future revenues, capital requirements and our needs for additional financing;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to maintain and establish collaborations;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our financial performance;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to maintain compliance with the Nasdaq Capital Market&rsquo;s listing standards;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments relating to our competitors and our industry, including the impact of government regulation;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to retain and attract senior management and consultants; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>other risks and uncertainties, including those listed under the caption &ldquo;Risk Factors&rdquo; in this prospectus supplement and
the accompanying prospectus or any other documents incorporated by reference in this prospectus supplement and the accompanying prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We operate in a very competitive and rapidly changing
environment. New risks emerge from time to time. It is not possible for us to predict all of those risks, nor can we assess the impact
of all of those risks on our business or the extent to which any factor may cause actual results to differ materially from those contained
in any forward-looking statement. The forward-looking statements in this prospectus supplement are based on assumptions management believes
are reasonable. However, due to the uncertainties associated with forward-looking statements, you should not place undue reliance on any
forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and unless required by law, we
expressly disclaim any obligation or undertaking to publicly update any of them in light of new information, future events, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A>USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate that the net proceeds from our issuance
and sale of shares of our common stock, Pre-funded Warrants and Common Warrants in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriter exercises its option to purchase additional shares and/or Common Warrants to purchase additional shares in
full, after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. These estimates
exclude the proceeds, if any, from the exercise of the Pre-funded Warrants and Common Warrants sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We intend to use the net proceeds of this offering
(i) to complete activities requested by the FDA in order to address the FDA&rsquo;s clinical hold on our IND with respect to our
planned Phase 2b clinical trial in LAPC, including conducting several additional preclinical studies and assays and providing the FDA
with the additional information it requested, (ii) to begin to fund and conduct the Phase 2b clinical trial in LAPC, if and when the clinical
hold on the IND is lifted and (iii) for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The amounts and timing of our use of the net proceeds
from this offering will depend on a number of factors, such as the timing and progress of our efforts to lift the FDA&rsquo;s clinical
hold on our IND for a clinical trial for LAPC, our ability to conduct the clinical trial for LAPC if and when the FDA&rsquo;s clinical
hold is lifted, our R&amp;D efforts, the timing and progress of any collaborative or strategic partnering efforts, technological advances
and the competitive environment for our planned products. As of the date of this prospectus supplement, we cannot specify with certainty
all of the particular uses for the net proceeds to us from the sale of the shares of our common stock offered by us hereunder. Accordingly,
our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as
described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth our cash and our
capita<FONT STYLE="font-family: Times New Roman, Times, Serif">li</FONT>zation as of January 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on an actual basis; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on an as adjusted basis to reflect the sale by us in this offering of (i) shares of our common stock and accompanying Common Warrant
at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share and accompanying Common Warrant and (ii) Pre-funded Warrants and accompanying Common Warrant at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;per Pre-funded Warrant and accompanying Common Warrant, after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should read the data set forth in the table
below in conjunction with our financial statements, including the related notes, and &quot;Management's Discussion and Analysis of Financial
Condition and Results of Operations&quot; from our Quarterly Report on Form 10-Q for the quarter ended January 31, 2021, which is incorporated
by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center">As of January 31, 2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B>Actual</P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">As<BR>
Adjusted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">(in thousands, except share data)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">3,091</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">649</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding, actual and as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Common stock, $0.0001 par value; 1,666,667 shares authorized, 1,560,940 shares issued and outstanding, actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,084</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(106,471</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders' equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,613</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">114,092</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table and discussion above assumes the exercise
of the Pre-funded Warrants and no exercise of the Common Warrants offered and sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The number of shares of our common stock to be
outstanding after this offering is based on 1,560,940 shares of our common stock outstanding as of January 31, 2021 (subject to adjustment
based on issuances of additional shares as applicable due to the rounding up of fractional shares resulting from the 1:1,500 reverse stock
split), and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>41,734 shares of our common stock issuable upon the exercise of stock options outstanding as of January 31, 2021 at a
                                                                                                             weighted-average exercise price of $79.96 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>43,505 shares of our common stock issuable upon the exercise of outstanding warrants as of January 31, 2021 , at a weighted
                                                                                                             average exercise price of $16.54 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon exercise of the Common Warrants issued in this offering; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock (or if the underwriter exercises
its option to purchase additional shares of common stock in full, up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares
of common stock) issuable upon exercise of warrants with an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share to be issued to the underwriter or its designees as compensation in connection with this offering.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A>DILUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Purchasers of our common stock, Pre-funded Warrants
and Common Warrants in this offering will experience immediate dilution to the extent of the difference between the effective public offering
price per share of our common stock, Pre-funded Warrants and/or Common Warrants and the as adjusted net tangible book value per share
of our common stock immediately after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our net tangible book value as of January 31,
2021 was approximately $2.5 million, or $1.58 per share of our common stock. Net tangible book value per share of our common stock is
determined by dividing total tangible assets less total liabilities, excluding items such as intangibles, by the aggregate number of shares
of our common stock outstanding as of January 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">After giving effect to the sale of (i)
shares of our common stock and accompanying Common Warrants to purchase shares of common stock in this offering at a public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per share and accompanying Common Warrant and (ii) Pre-funded Warrants to purchase shares of common stock and
accompanying Common Warrants to purchase shares of common stock in this offering at a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 per Pre-funded
Warrant and accompanying Common Warrant, and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us, our as adjusted net tangible book value as of January 31, 2021 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. This represents an immediate increase
in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock to our
existing stockholders and an immediate dilution in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock to purchasers in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table illustrates this calculation
on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Offering price per share and accompanying Common Warrant in this offering</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of January 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Increase in net tangible book value per share attributable to purchasers in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">As adjusted net tangible book value per share immediately after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Dilution per share to purchasers in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the underwriter exercises its option in full
to purchase additional shares of our common stock and/or Common Warrants in this offering at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
the as adjusted net tangible book value per share after the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the decrease in the net tangible book value
per share to existing stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to new investors purchasing securities in this offering would
be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The discussion and table above assume no exercise
of Common Warrants and full exercise of the Pre-funded Warrants sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The above table is based on 1,560,940 shares of
our common stock outstanding as of January 31, 2021 (subject to adjustment based on issuances of additional shares as applicable due to
the rounding up of fractional shares resulting from the 1:1,500 reverse stock split), and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>41,734 shares of our common stock issuable upon the exercise of stock
options outstanding as of January 31, 2021, at a weighted-average exercise price of $79.96 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>43,505 shares of our common stock issuable upon the exercise of outstanding warrants as of January 31, 2021, at a weighted
                                                                                                             average exercise price of $16.54 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon exercise of the Common Warrants issued in this offering; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock (or if the underwriter exercises
its option to purchase additional shares of common stock in full, up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares
of common stock) issuable upon exercise of warrants with an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share to be issued to the underwriter or its designees as compensation in connection with this offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To the extent that options or warrants are exercised,
other equity awards vest, new equity awards are issued under the 2021 Equity Incentive Plan or pursuant to inducement awards, or we issue
additional shares of common stock in the future, there may be further dilution to investors participating in this offering. In addition,
we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient
funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities,
the issuance of these securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS
FOR NON-U.S. HOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following discussion is a summary of certain
material U.S. federal income tax considerations for non-U.S. holders (as defined below) with respect to their ownership and disposition
of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a &ldquo;non-U.S. holder is a beneficial
owner of our common stock that, for U.S. federal income tax purposes is neither a &ldquo;U.S. person&rdquo; nor an entity (or arrangement)
treated as a partnership. A &ldquo;U.S. person&rdquo; is any person that, for U.S. federal income tax purposes, is or is treated as any
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an individual who is a citizen or resident of the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States
or any political subdivision thereof, or otherwise treated as such for U.S. federal income tax purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an estate whose income is subject to U.S. federal income tax regardless of its source; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a trust (x) whose administration is subject to the primary supervision of a U.S. court and that has one or more U.S. persons who have
the authority to control all substantial decisions of the trust or (y) that has made a valid election under applicable Treasury Regulations
to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This discussion does not address the tax treatment
of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes or persons that hold their common
stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our
common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common
stock through a partnership or other pass-through entity, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This discussion is based on current provisions
of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations
promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and
all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation
could alter the tax consequences to non-U.S. holders described in this prospectus supplement. There can be no assurance that the Internal
Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this
discussion that a non-U.S. holder holds shares of our common stock as a capital asset within the meaning of Section 1221 of the Code,
generally property held for investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This discussion does not address all aspects of
U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&rsquo;s individual
circumstances nor does it address U.S. state, local or non-U.S. taxes, the alternative minimum tax, the rules regarding qualified small
business stock within the meaning of Section 1202 of the Code, the Medicare tax on net investment income or any other aspect of any U.S.
federal tax other than the income tax. This discussion also does not consider any specific facts or circumstances that may apply to a
non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>insurance companies;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>tax-exempt or governmental organizations;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>financial institutions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>brokers or dealers in securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulated investment companies;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pension plans;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;controlled foreign corporations,&rdquo; &ldquo;passive foreign investment companies,&rdquo; and corporations that accumulate
earnings to avoid U.S. federal income tax;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;qualified foreign pension funds&rdquo; as defined in Section 897(I)(2) of the Code and entities all of the interests of which
are held by qualified foreign pension funds;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons deemed to sell our common stock under the constructive sale provisions of the Code;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>certain U.S. expatriates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This discussion is for general information only
and is not tax advice. Accordingly, all prospective non-U.S. holders of our common stock should consult their tax advisors with respect
to the U.S. federal, state, local and non-U.S. tax consequences of the ownership and disposition of our common stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Distributions on Our Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As described in the &ldquo;Risk Factors&rdquo;
section above, we do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Distributions, if any, on
our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings
and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and
profits, the excess will be treated as a tax-free return of the non-U.S. holder&rsquo;s investment, up to such holder&rsquo;s tax basis
in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &ldquo;Gain
on Sale or Other Taxable Disposition of Our Common Stock.&rdquo; Any such distributions will also be subject to the discussions below
under the sections titled &ldquo;Backup Withholding and Information Reporting&rdquo; and &ldquo;FATCA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the discussion in the following two
paragraphs in this section, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at
a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the U.S. and such holder&rsquo;s country of
residence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dividends that are treated as effectively connected
with a trade or business conducted by a non-U.S. holder within the U.S. are generally exempt from the 30% withholding tax if the non-U.S.
holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified
deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code),
subject to an applicable income tax treaty providing otherwise. Any U.S. effectively connected income received by a non-U.S. holder that
is a corporation may also, under certain circumstances, be subject to an additional &ldquo;branch profits tax&rdquo; at a 30% rate, or
such lower rate as may be specified by an applicable income tax treaty between the U.S. and such holder&rsquo;s country of residence,
on its effectively connected earnings and profits that are not reinvested in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A non-U.S. holder of our common stock who claims
the benefit of an applicable income tax treaty between the U.S. and such holder&rsquo;s country of residence generally will be required
to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) to the applicable withholding agent and satisfy applicable
certification and other requirements. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits
under a relevant income tax treaty. A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax
treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Gain on Sale or Other Taxable Disposition
of Our Common Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the discussions below under &ldquo;Backup
Withholding and Information Reporting&rdquo; and &ldquo;FATCA,&rdquo; a non-U.S. holder generally will not be subject to any U.S. federal
income or withholding tax on any gain realized upon such holder&rsquo;s sale or other taxable disposition of shares of our common stock
unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the gain is effectively connected with the non-U.S. holder&rsquo;s conduct of a U.S. trade or business and, if an applicable income
tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained by such non-U.S. holder in the U.S., in
which case the non-U.S. holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable
to U.S. persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax described above
in &ldquo;Distributions on Our Common Stock&rdquo; also may apply;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the non-U.S. holder is a nonresident alien individual who is present in the U.S. for 183 days or more in the taxable year of the disposition
and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified
by an applicable income tax treaty between the U.S. and such holder&rsquo;s country of residence) on the net gain derived from the disposition,
which may be offset by certain U.S. source capital losses of the non-U.S. holder; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the non-U.S. holder&rsquo;s
holding period, if shorter) a U.S. real property holding corporation, unless our common stock is regularly traded on an established securities
market and the non-U.S. holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively,
during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock.
Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests
equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held
for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property
holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly
traded on an established securities market for purposes of the rules described above.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Backup Withholding and Information Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We must report annually to the IRS and to each
non-U.S. holder the gross amount of the distributions on our common stock paid to such holder and the tax withheld, if any, with respect
to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not
a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends
on our common stock. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above in &ldquo;Distributions
on Our Common Stock,&rdquo; generally will be exempt from U.S. backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Information reporting and backup withholding will
generally apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any
broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise
establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds
to a non-U.S. holder where the transaction is effected outside the U.S. through a non-U.S. office of a broker. However, for information
reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally
will be treated in a manner similar to dispositions effected through a U.S. office of a broker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Non-U.S. holders should consult their tax advisors
regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made
available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific
treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment
to a non-U.S. holder can be refunded or credited against the non-U.S. holder&rsquo;s U.S. federal income tax liability, if any, provided
that an appropriate claim is filed with the IRS in a timely manner.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">FATCA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Provisions of the Code commonly referred to as
the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a rate of 30% on payments of dividends
on our common stock paid to a foreign entity unless (i) if the foreign entity is a &ldquo;foreign financial institution,&rdquo; such foreign
entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii) if the foreign entity is not a &ldquo;foreign
financial institution,&rdquo; such foreign entity identifies certain of its U.S. investors, if any, or (iii) the foreign entity is otherwise
exempt under FATCA. Such withholding may also apply to gross proceeds from the sale or other disposition of our common stock, although
under recently proposed U.S. Treasury Regulations, no withholding would apply to such gross proceeds. The preamble to the proposed regulations
specifies that taxpayers (including withholding agents) are permitted to rely on the proposed regulations pending finalization. Under
certain circumstances, a non-U.S. holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement
between the U.A. and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult
their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through
which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to
prevent the imposition of the 30% withholding tax under FATCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>The preceding discussion of U.S. federal income
tax considerations is for general information only. It is not tax advice. Each prospective investor should consult its own tax advisor
regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing of our common
stock, including the consequences of any proposed change in applicable laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A>UNDERWRITING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into an underwriting
agreement with H.C. Wainwright &amp; Co., LLC, as underwriter, with respect to the shares of common stock, Pre-funded Warrants and
accompanying Common Warrants being offered in this offering. Subject to the terms and conditions of the underwriting agreement, we
have agreed to sell to the underwriter, and the underwriter has agreed to purchase from us, at the respective public offering price
less the underwriting discounts and commissions set forth on the cover page of this prospectus,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, Pre-funded Warrants to
purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock and accompanying Common
Warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-weight: bold; padding-bottom: 1pt">Underwriters</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Shares of Common Stock</B></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Pre-funded Warrants</B></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Common Warrants</B></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">H.C. Wainwright &amp; Co., LLC</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the underwriting agreement, the underwriter
has agreed to purchase all of the shares, Pre-Funded Warrants and accompanying Common Warrants sold under the underwriting agreement if
any of these shares, Pre-funded Warrants and accompanying Common Warrants are purchased, other than those shares covered by the underwriter&rsquo;s
option to purchase additional shares of common stock and/or Common Warrants described below. The underwriter has advised us that it does
not intend to confirm sales to any account over which it exercises discretionary authority. We have agreed to indemnify the underwriter
against certain liabilities, including liabilities under the Securities Act of 1933, as amended (&ldquo;Securities Act&rdquo;), or to
contribute to payments the underwriter may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The underwriter is offering the shares of common
stock, the Pre-Funded Warrants and the accompanying Common Warrants subject to its acceptance of the shares of common stock, Pre-funded
Warrants and accompanying Common Warrants from us and subject to prior sale. The underwriting agreement provides that the obligations
of the underwriter to pay for and accept delivery of the securities offered by this prospectus supplement are subject to the approval
of certain legal matters by their counsel and to certain other conditions specified in the underwriting agreement. If all of the shares
of common stock, the Pre-funded Warrants and the accompanying Common Warrants are not sold at the public offering prices, the underwriter
may change the offering price and other selling terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Commissions and Discounts; Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The underwriter has advised us that they propose
initially to offer the shares of common stock, the Pre-funded Warrants and the accompanying Common Warrants to the public at the public
offering price set forth on the cover of this prospectus supplement and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share and accompanying Common Warrant. After the initial offering, the public offering price, concession or any other term of the
offering may be changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table shows the public
offering price per share of common stock and accompanying Common Warrant and price per Pre-funded Warrant and accompanying Common
Warrant and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts
are shown assuming both no exercise and full exercise of the underwriter&rsquo;s option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock and Common
Warrants to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
(but without giving effect to any exercise of such additional Common Warrants issuable upon exercise of the underwriter&rsquo;s
option).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Share and accompanying Common Warrant</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Pre-funded Warrant and Accompanying Common Warrant</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">No Exercise</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Full Exercise</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 52%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discounts and commissions to be paid by us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we have agreed to issue to the
underwriter or its designees warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock (or if the underwriter exercises its option to purchase additional shares of common stock in full, up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 shares of
common stock) (representing 7.5% of the aggregate number of shares of common stock and Pre-funded Warrants sold in this offering),
at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (representing 125% of
the public offering price for a share of common stock and the accompanying warrant to be sold in this offering). The underwriter
warrants will be exercisable immediately and for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years from the date of
issuance of the underwriter warrants. The issuance of the underwriter warrants and the shares issuable upon exercise of the
underwriter warrants are registered on the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate expenses payable by us in connection
with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which includes
certain expenses incurred by the underwriter in connection with this offering that will be reimbursed by us. We have agreed to reimburse
the underwriter for certain expenses incurred by the underwriter in connection with this offering including certain fees and expenses
of counsel for the underwriter in an amount not to exceed $100,000, $50,000 for nonaccountable expenses and clearing fees of $15,950.
In addition, we have also agreed to pay the underwriter a management fee equal to 1% of the aggregate gross proceeds in this offering.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Option to Purchase Additional Shares and/or
Common Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have granted the underwriter an option to purchase
up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock and/or
Common Warrants (up to 15% of the shares of common stock and shares underlying the Pre-funded Warrants sold in this offering) at the public
offering price, less the underwriting discounts and commissions, within 30 days from the date of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have granted the underwriter a 18-month right
of first refusal to act as exclusive financial advisor, sole book-running manager, sole underwriter, or sole placement agent, as applicable,
if we or any of our subsidiaries decides to dispose or acquire businesses, finance or refinance any indebtedness or raise funds by means
of a public offering or a private placement or any other capital-raising financing of equity, equity-linked or debt securities using an
underwriter or placement agent other than with respect to certain excluded transactions. If the underwriter or an affiliate of the underwriter
accepts any such engagement, the agreement governing such engagement will contain, among other things, provisions for customary fees and
terms for transactions of similar size and nature, including indemnification, which are appropriate to such a transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Tail</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event that any investors that were contacted
or were introduced to us by the underwriter during the term of its engagement provide any capital to us in a public or private offering
or capital-raising transaction during the twelve-month period following the expiration or termination of the engagement of the underwriter,
we shall pay the underwriter the cash and warrant compensation provided above on the gross proceeds from such investors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No Sales of Similar Securities; Lock-ups</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have agreed to not sell any shares of our common
stock or any securities convertible into or exercisable or exchangeable into shares of common stock, subject to certain exceptions, for
a period of 90 days after the pricing of this offering unless we obtain prior written consent of the underwriter. This consent may be
given at any time without public notice, and the underwriter may consent in its sole discretion. The exceptions to the restriction include,
among other things, the issuance of any shares of our capital stock or securities convertible into shares of our capital stock that are
issued (i) pursuant to a stock or option plan, (ii) pursuant to the exercise or exchange of or conversion of any securities exercisable
or exchangeable for or convertible into shares of common stock issued and outstanding on the date of this prospectus supplement, and (iii)
as consideration in an acquisition, merger or similar strategic transaction approved by a majority of the disinterested directors, provided
that such securities are issued as &ldquo;restricted securities&rdquo; as defined in Rule 144 and carry no registration rights that require
or permit the filing of any registration statement in connection therewith within 90 days following the pricing of this offering, and
provided that any such issuance shall only be to a person providing us business synergies and additional benefits in addition to the investment
of funds, but shall not include a transaction in which we are issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have also agreed, subject to certain exceptions,
until the one-year anniversary of the first closing date of this offering, not to (i) issue or sell any debt or equity securities that
are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of common stock either (A) at
a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations
for the shares of common stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise
or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related to our business or the market for our common stock or
(ii) enter into, or effect a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby we may
issue securities at a future determined price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, each of our directors and executive
officers has entered into a lock-up agreement with the underwriter. Under the lock-up agreements, subject to certain limited circumstances,
the directors and executive officers may not, directly or indirectly, sell, offer to sell, contract to sell, or grant any option for the
sale (including any short sale), grant any security interest in, pledge, hypothecate, hedge, or otherwise dispose of, or enter into any
transaction which is designed to or could be expected to result in the disposition of, any shares of our common stock or securities convertible
into or exchangeable for shares of our common stock, or publicly announce any intention to do any of the foregoing, unless such directors
and executive officers obtain prior written consent of the underwriter for a period of 90 days from the date of this prospectus supplement.
This consent may be given at any time without public notice, and the underwriter may consent in its sole discretion. Such lock-up restriction
applies to all shares owned by our directors and executive officers whether owned as of the date of this prospectus supplement or subsequently
acquired.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Nasdaq Capital Market Listing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock has been approved for listing
on Nasdaq under the symbol &ldquo;PMCB.&rdquo; There is no established trading market for the Pre-funded Warrants or the Common Warrants,
and we do not expect a trading market to develop. We do not intend to list the Pre-funded Warrants or the Common Warrants on any securities
exchange or nationally recognized trading system. Without a trading market, the liquidity of the Pre-funded Warrants and the Common Warrants
will be extremely limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Price Stabilization, Short Positions and Penalty
Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with this offering, the underwriter
may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions and penalty bids in connection with
our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stabilizing transactions permit bids to purchase
shares of common stock so long as the stabilizing bids do not exceed a specified maximum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Overallotment transactions involve sales by the
underwriter of shares of common stock in excess of the number of shares the underwriter is obligated to purchase. This creates a syndicate
short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares
over-allotted by the underwriter is not greater than the number of shares that it may purchase in the overallotment option. In a naked
short position, the number of shares involved is greater than the number of shares in the overallotment option. The underwriter may close
out any short position by exercising its overallotment option and/or purchasing shares in the open market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Syndicate covering transactions involve purchases
of common stock in the open market after the distribution has been completed in order to cover syndicate short positions. Such a naked
short position would be closed out by buying securities in the open market. A naked short position is more likely to be created if the
underwriter is concerned that there could be downward pressure on the price of the securities in the open market after pricing that could
adversely affect investors who purchase in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Penalty bids permit the underwriter to reclaim
a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a stabilizing
or syndicate covering transaction to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These stabilizing transactions, syndicate covering
transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding
a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it
would otherwise be in the absence of these transactions. Neither we nor the underwriter make any representation or prediction as to the
effect that the transactions described above may have on the price of our common stock. These transactions may be effected on Nasdaq,
in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with this offering, the underwriter
also may engage in passive market making transactions in our common stock in accordance with Regulation M during the period before the
commencement of offers or sales of shares of our common stock in this offering and extending through the completion of the distribution.
In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for that security. However,
if all independent bids are lowered below the passive market maker&rsquo;s bid that bid must then be lowered when specific purchase limits
are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail
in the open market and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Electronic Distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A prospectus in electronic format may be made
available on the websites, if any, maintained by the underwriter participating in this offering and the underwriter may distribute prospectuses
electronically. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the
registration statement of which this prospectus form a part, has not been approved or endorsed by us or the underwriter, and should not
be relied upon by investors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other Relationships</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, certain of the underwriter
and its affiliates have provided, and may provide in the future, various advisory, investment and commercial banking and other services
to us in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The transfer agent and registrar for our common
stock is American Stock Transfer &amp; Trust Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s OTCQB Market Symbol is PMCB,
although as a result of the recent reverse split of the Company&rsquo;s common stock, until August 6, 2021, the Company&rsquo;s OTCQB
Market Symbol has temporarily been &ldquo;PMCBD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock has been approved for listing
on Nasdaq under the symbol &ldquo;PMCB.&rdquo; Our common stock will continue to trade on the OTCQB Venture Market until trading commences
on Nasdaq, which we expect to occur following the pricing of this offering. The offering, however, is subject to market and other conditions,
and there can be no assurance as to whether or when the offering may be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selling Restrictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>European Economic Area</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In relation to each Member State of the European
Economic Area (each a &ldquo;Relevant State&rdquo;), no securities have been offered or will be offered pursuant to the offering to the
public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent
authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in
that Relevant State, all in accordance with the Prospectus Regulation, except that the securities may be offered to the public in that
Relevant State at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">(a) to any legal entity which is a qualified
investor as defined under Article 2 of the Prospectus Regulation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">(b) to fewer than 150 natural or legal
persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent
of the representatives for any such offer; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">(c) in any other circumstances falling
within Article 1(4) of the Prospectus Regulation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">provided that no such offer of the securities
shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 23 of the Prospectus Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the purposes of this provision, the expression
an &ldquo;offer to the public&rdquo; in relation to the securities in any Relevant State means the communication in any form and by any
means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase
or subscribe for any securities, and the expression &ldquo;Prospectus Regulation&rdquo; means Regulation (EU) 2017/1129.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>United Kingdom</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No securities have been offered or will be offered
pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the securities which
has been approved by the Financial Conduct Authority, except that the securities may be offered to the public in the United Kingdom at
any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">(a) to any legal entity which is a qualified
investor as defined under Article 2 of the UK Prospectus Regulation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">(b) to fewer than 150 natural or legal
persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent
of the representatives for any such offer; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">(c) in any other circumstances falling
within Section 86 of the Financial Services and Markets Act 2000 (&ldquo;FSMA&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided that no such offer of the securities shall require us or any
underwriter to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus
Regulation. For the purposes of this provision, the expression an &ldquo;offer to the public&rdquo; in relation to the securities in the
United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any securities
to be offered so as to enable an investor to decide to purchase or subscribe for any securities and the expression &ldquo;UK Prospectus
Regulation&rdquo; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Canada</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The securities may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus
Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with
an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Securities legislation in certain provinces or
territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable
provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with
a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to section 3A.3 (or, in the case of securities
issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 Underwriting Conflicts
(&ldquo;NI 33-105&rdquo;), the underwriter is not required to comply with the disclosure requirements of NI 33-105 regarding underwriter
conflicts of interest in connection with this offering. Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by
the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriter
is not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Switzerland</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This document is not intended to constitute an
offer or solicitation to purchase or invest in the securities described herein. The securities may not be publicly offered, sold or advertised,
directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated
trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities constitutes
a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus
within the meaning of the listing rules of the SIX Swiss Exchange or any other regulated trading facility in Switzerland, and neither
this document nor any other offering or marketing material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neither this document nor any other offering or
marketing material relating to the offering, nor us nor the securities have been or will be filed with or approved by any Swiss regulatory
authority. The securities are not subject to the supervision by any Swiss regulatory authority, e.g., the Swiss Financial Markets Supervisory
Authority, and investors in the securities will not benefit from protection or supervision by such authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Israel</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This document does not constitute a prospectus
under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority.
In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the ordinary securities is directed
only at (i) a limited number of persons in accordance with the Israeli Securities Law and (ii) investors listed in the first addendum
(&ldquo;the Addendum&rdquo;) to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds,
insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriter, venture capital
funds, entities with equity in excess of NIS 50 million and &ldquo;qualified individuals,&rdquo; each as defined in the Addendum (as it
may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or,
where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to
it.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are offering shares of our common stock in
this offering. As of July 31, 2021, there were 1,591,420 shares of common stock issued and outstanding, held of record by approximately
35,000 stockholders. See &ldquo;Description of Securities we may Offer&rdquo; in our prospectus for more information regarding our shares
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Pre-funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following summary of certain terms and provisions
of the Pre-funded Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions
of the Pre-funded Warrant, the form of which will be filed as an exhibit to a Current Report on Form 8-K in connection with this offering
and incorporated by reference into the registration statement of which this prospectus supplement forms a part. Prospective investors
should carefully review the terms and provisions of the form of Pre-funded Warrant for a complete description of the terms and conditions
of the Pre-funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pre-funded warrants will be issued in certificated
form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Duration and Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each Pre-funded Warrant offered hereby will have
an initial exercise price per share equal to $0.001. The exercise price and number of shares of common stock issuable upon exercise is
subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common
stock and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Pre-funded Warrants will be exercisable, at
the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s Pre-funded Warrant to the extent that the
holder would own more than 4.99% (or at the election of the holder, 9.99%) of the outstanding shares of common stock immediately after
exercise, except that upon at least 61 days&rsquo; prior notice from the holder to us, the holder may increase the amount of ownership
of outstanding shares of common stock after exercising the holder&rsquo;s Pre-funded Warrants up to 9.99% of the number of shares of common
stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms
of the Pre-funded Warrants. No fractional shares of common stock will be issued in connection with the exercise of a Pre-funded Warrant.
In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise
price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Pre-funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Fundamental Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event of any fundamental transaction, as
described in the Pre-funded Warrants and generally including any merger with or into another entity, sale of all or substantially all
of our assets, tender offer or exchange offer, or reclassification of our shares of common stock, then upon any subsequent exercise of
a Pre-funded Warrant, the holder will have the right to receive as alternative consideration, for each share of common stock that would
have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common
stock of the successor or acquiring corporation or of our company, if it is the surviving corporation, and any additional consideration
receivable upon or as a result of such transaction by a holder of the number of shares of common stock for which the Pre-funded Warrant
is exercisable immediately prior to such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B></B></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to applicable laws, a Pre-funded Warrant
may be transferred at the option of the holder upon surrender of the Pre-funded Warrant to us together with the appropriate instruments
of transfer and payment of funds sufficient to pay any transfer taxes (if applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no established trading market for the
Pre-funded Warrants. We do not intend to list the Pre-funded Warrants on any securities exchange or nationally recognized trading system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Right as a Shareholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise provided in the Pre-funded
Warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders of the Pre-funded Warrants do not have
the rights or privileges of holders of our common stock, including any voting rights, until such Pre-funded Warrant holders exercise their
Pre-funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Common Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following summary of certain terms and provisions
of the Common Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions
of the Common Warrant, the form of which will be filed as an exhibit to a Current Report on Form 8-K in connection with this offering
and incorporated by reference into the registration statement of which this prospectus supplement forms a part. Prospective investors
should carefully review the terms and provisions of the form of Common Warrant for a complete description of the terms and conditions
of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Common Warrants will be issued in certificated
form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Duration and Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each Common Warrant offered hereby has an
initial exercise price per share equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The Common Warrants
are immediately exercisable and will expire on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anniversary of
the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the
exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Common Warrants will be exercisable, at the
option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the
number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder
(together with its affiliates) may not exercise any portion of such holder&rsquo;s Common Warrant to the extent that the holder would
own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding shares of common stock immediately after exercise, except
that upon at least 61 days&rsquo; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding shares
of common stock after exercising the holder&rsquo;s Common Warrants up to 9.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants. No
fractional shares of common stock will be issued in connection with the exercise of a Common Warrant. In lieu of fractional shares, we
will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If, at the time a holder exercises its Common
Warrants, a registration statement registering the issuance of the shares of common stock underlying the Common Warrants under the Securities
Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise
in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the
net number of shares of common stock determined according to a formula set forth in the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Fundamental Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event of any fundamental transaction, as
described in the Common Warrants and generally including any merger with or into another entity, sale of all or substantially all of our
assets, tender offer or exchange offer, or reclassification of our shares of common stock, then upon any subsequent exercise of a Common
Warrant, the holder will have the right to receive as alternative consideration, for each share of common stock that would have been issuable
upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor
or acquiring corporation of our company, if it is the surviving corporation, and any additional consideration receivable upon or as a
result of such transaction by a holder of the number of shares of common stock for which the Common Warrant is exercisable immediately
prior to such event. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the Common Warrants have
the right to require us or a successor entity to redeem the Common Warrants for cash in the amount of the Black Scholes Value (as defined
in each Common Warrant) of the unexercised portion of the Common Warrants concurrently with or within 30 days following the consummation
of a fundamental transaction. However, in the event of a fundamental transaction which is not in our control, including a fundamental
transaction not approved by our board of directors, the holders of the Common Warrants will only be entitled to receive from us or our
successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same
proportion), at the Black Scholes Value of the unexercised portion of the Common Warrant, that is being offered and paid to the holders
of our common stock in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination
of cash and stock, or whether the holders of our common stock are given the choice to receive alternative forms of consideration in connection
with the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to applicable laws, a Common Warrant may
be transferred at the option of the holder upon surrender of the Common Warrant to us together with the appropriate instruments of transfer
and payment of funds sufficient to pay any transfer taxes (if applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no trading market available for the Common
Warrants on any securities exchange or nationally recognized trading system. We do not intend to list the Common Warrants on any securities
exchange or nationally recognized trading system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Right as a Shareholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise provided in the Common Warrants
or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders of the Common Warrants do not have the rights
or privileges of holders of our common stock, including any voting rights, until they exercise their Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Underwriter Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also registering hereunder the Underwriter
Warrants and the shares of common stock issuable upon exercise thereof which we have agreed to grant to H.C. Wainwright &amp; Co., LLC,
or its designees, as partial consideration for the underwriting services. The Underwriter Warrants are exercisable for a number of our
shares equal to 7.5% of the aggregate number of shares and Pre-funded Warrants sold to the investors in this offering. The Underwriter
Warrants will have the same terms as the Common Warrants described above, except that the Underwriter Warrants will have an exercise price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (125% of the public offering price per share and the accompanying warrant) and will terminate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;years after the date of commencement
of sales in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Reference is hereby made to the &ldquo;&mdash;Common
Warrants&rdquo; description above and to the provisions of the Underwriter Warrant, the form of which will be filed with the SEC as an
exhibit to a Current Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement
of which this prospectus supplement and the accompanying prospectus form a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><A NAME="a_012"></A>LEGAL MAT<FONT STYLE="font-family: Times New Roman, Times, Serif">T</FONT>ERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain legal matters in connection with this
offering will be passed upon for us by Troutman Pepper Hamilton Sanders LLP, New York, New York. Certain legal matters governed by Nevada
law with respect to the validity of the offered securities will be passed upon for us by Ballard Spahr LLP, Las Vegas, Nevada. Haynes
and Boone, LLP, New York, New York, is acting as counsel for the underwriter in connection with certain legal matters related to this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The consolidated financial statements of PharmaCyte
Biotech, Inc. as of April 30, 2020 and 2019, and for each of the years in the two-year period ended April 30, 2020, have been incorporated
by reference herein in reliance upon the report of Armanino LLP, the Company&rsquo;s independent registered public accounting firm, incorporated
by reference herein and upon the authority of Armanino LLP as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A>WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed with the SEC a registration statement
on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us
to omit from this prospectus supplement certain information included in the registration statement. For further information about us and
the securities we are offering under this prospectus supplement, you should refer to the registration statement and the exhibits and schedules
filed with the registration statement. With respect to the statements contained in this prospectus supplement regarding the contents of
any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement
or document, a copy of which has been filed as an exhibit to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because we are subject to the information and
reporting requirements of the Exchange Act, we file annual, quarterly and current reports and other information with the SEC. Our SEC
filings are available to the public over the Internet at the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We make available free of charge on our
website our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we
electronically file such material with, or furnish such material to, the SEC. Please note, however, that we have not incorporated
any other information by reference from our website, other than the documents listed under the heading &ldquo;<A HREF="#a_015">Incorporation
of Certain Information by Reference</A>&rdquo; on page S-52 of this prospectus supplement. In addition, you may request copies of
these filings at no cost by writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PharmaCyte Biotech, Inc.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">23046 Avenida de la Carlota, Suite 600,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Laguna Hills, California 92653</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(917) 595-2850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">SEC rules permit us to incorporate information
by reference in this prospectus supplement. This means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus supplement, except
for information superseded by information contained in this prospectus supplement itself or in any subsequently filed incorporated document.
This prospectus supplement incorporates by reference the documents set forth below that we have previously filed with the SEC, other than
information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and
our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820002680/pharmacyte_10k-043020.htm">Annual Report on Form 10-K</A> for the fiscal year ended April 30, 2020, filed with the SEC on August 13, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Quarterly Reports on Form 10-Q for the fiscal quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820003111/pharmacyte_10q-073120.htm">July 31, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820004267/pharmacyte_10q-103120.htm">October 31, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316821000925/pharmacyte_10q-013121.htm">January 31, 2021</A>, filed with
the SEC on September 11, 2020, December 11, 2020 and March 12, 2021, respectively;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820003473/pharmacyte_8k.htm">October 16, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316821001793/pharmacyte_8k.htm">May 6, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316821002359/pharmacyte_8k.htm">June 4, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/pharmacyte_8k.htm">July 6, 2021</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/pharmacyte_8k.htm">July 13, 2021</A>;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The description of our common stock set for in the registration statement on Form 8-A registering our common stock under Section 12
of the Exchange Act, which was filed with the SEC on July 30, 2021, including any amendments or reports filed for purposes of updating
such description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All documents that we file (but not those that
we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of
which this prospectus supplement is a part shall be deemed to be incorporated by reference into this prospectus and will automatically
update and supersede the information in this prospectus supplement, and any previously filed documents. All documents that we file (but
not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus supplement
and prior to the termination of the offering of any of the securities covered under the prospectus shall be deemed to be incorporated
by reference into this prospectus supplement and will automatically update and supersede the information in this prospectus supplement
and any previously filed documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any statement contained herein or in a document
incorporated or deemed to be incorporated by reference in this prospectus supplement shall be deemed to be modified or superseded for
purposes of this prospectus supplement to the extent that a statement contained in the prospectus or this prospectus supplement, or in
any other subsequently filed document which also is or is deemed to be incorporated by reference in the prospectus and this prospectus
supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of the prospectus or this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To obtain copies of these filings, see &ldquo;<A HREF="#a_014">Where You Can Find More Information</A>&rdquo; on page <A HREF="#a_014">S-51</A> of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 76; width: 380">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$100,000,000.00</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PHARMACYTE BIOTECH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Debt Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>









<HR SIZE="2" ALIGN="CENTER" STYLE="width: 15%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer and sell, from time to time in one or more offerings,
up to $100,000,000.00 of our common stock, preferred stock, debt securities, warrants and rights, or any combination of these securities,
and/or units consisting of one or more of these securities. We may also offer common stock or preferred stock upon conversion of
debt securities or exercise of warrants and common stock upon conversion of preferred stock. All of the securities listed above
may be sold separately or as units with other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus describes some of the general terms that may
apply to these securities. When we decide to sell a particular class or series of securities, we will provide specific terms of
the offered securities in one or more prospectus supplements. We may also authorize one or more free writing prospectuses to be
provided to you in connection with these offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The prospectus supplement, and any documents incorporated by
reference, may also add, update or change information contained in or incorporated by reference into this prospectus. However,
no prospectus supplement shall offer a security that is not registered and described in this prospectus at the time of its effectiveness.
You should read carefully this prospectus and any prospectus supplement, as well as the documents incorporated by reference or
deemed to be incorporated by reference into this prospectus, and any free writing prospectus carefully before you invest. This
prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQB under the symbol &ldquo;PMCB.&rdquo;
Each prospectus supplement will contain information, where applicable, as to our listing on any securities exchange of the securities
covered by the prospectus supplement. The aggregate market value of our outstanding common stock held by non-affiliates was $76,316,030
based on 2,341,410,405 shares of outstanding common stock, of which 70,100,000 shares are held by affiliates, and a price of $.03360
per share, which was the last reported sale price of our common stock as quoted on the OTCQB on February 22, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These securities may be sold by us directly to purchasers, through
dealers or agents, or to or through underwriters, or through a combination of these methods. See &ldquo;<A HREF="#s10">Plan of Distribution</A>&rdquo;
in this prospectus. We may also describe the plan of distribution for any particular offering of our securities in a prospectus
supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect of which this prospectus
is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The net
proceeds we expect to receive from any such sale will also be included in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>An investment in our securities involves a high degree of
risk. See the sections entitled &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form 10-K, in any Quarterly Report
on Form 10-Q and in any Periodic Report on Form 8-K, as well as in any prospectus supplement or free writing prospectus related
to these specific offerings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may amend or supplement this prospectus from time to time
by filing amendments or supplements as required or related free writing prospectuses. You should read the entire prospectus and
any amendments or supplements carefully before you make your investment decision.<BR>
<BR>
Neither the Securities and Exchange Commission ( &ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved
of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is April
14, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="toc"></A><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right"><U>Page</U></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 85%; font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s1">ABOUT THIS PROSPECTUS</A></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s2">PROSPECTUS SUMMARY</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s3">THE OFFERING</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s4">OUR COMPANY</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s5">RISK FACTORS</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s6">FORWARD-LOOKING STATEMENTS</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s7">USE OF PROCEEDS</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s8">DIVIDEND POLICY</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s9">DESCRIPTIONS OF THE SECURITIES WE MAY OFFER</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s10">PLAN OF DISTRIBUTION</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">27</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s11">LEGAL MATTERS</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s12">EXPERTS</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in"><A HREF="#s14">INFORMATION INCORPORATED BY REFERENCE</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">31</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s1"></A>ABOUT THIS PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a Registration Statement that we
filed with the Securities and Exchange Commission using a &ldquo;shelf&rdquo; registration process. Under this shelf registration
process, we may offer from time to time securities described in this prospectus having a maximum aggregate offering price of $100,000,000.00
in one or more offerings. Each time we offer securities, we will prepare and file with the SEC a prospectus supplement or information
that is incorporated by reference into this prospectus that describes the specific amounts, prices and terms of the securities
we offer. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information
relating to these offerings and securities. The prospectus supplement also may add, update or change information contained in this
prospectus or the documents incorporated herein by reference. You should read carefully this prospectus, any applicable prospectus
supplement and any related free writing prospectus together with additional information described below under the caption &ldquo;Where
You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus does not contain all the information provided
in the Registration Statement we filed with the SEC. For further information about us or our securities offered hereby, you should
refer to that Registration Statement, which you can obtain from the SEC as described below under &ldquo;Where You Can Find More
Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information contained or incorporated
by reference in this prospectus, any prospectus supplement and any related free writing prospectus. We have not authorized any
other person to provide you with different information. If anyone provides you with different or inconsistent information, you
should not rely on it. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities,
in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus,
any prospectus supplement, any related free writing prospectus as well as information we have previously filed with the SEC and
incorporated by reference, is accurate as of the date of those documents only. Our business, financial condition, results of operations
and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free
writing prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are based on
independent industry publications and other publicly available information. Although we believe these sources are reliable, we
do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although
we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated
herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including
those discussed under the heading &ldquo;Risk Factors&rdquo; contained in this prospectus, the applicable prospectus supplement
and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into
this prospectus. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell securities through underwriters or dealers, through
agents, directly to purchasers or through any combination of these methods. We and our agents reserve the sole right to accept
or reject in whole or in part any proposed purchase of securities. The prospectus supplement, which we will prepare and file with
the SEC each time we offer securities, will set forth the names of any underwriters, agents or others involved in the sale of securities,
and any applicable fee, commission or discount arrangements with them. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In this prospectus, unless otherwise indicated, the &ldquo;<U>Registrant</U>,&rdquo;
&ldquo;<U>our company</U>,&rdquo; &ldquo;<U>we</U>,&rdquo; &ldquo;<U>us</U>&rdquo; or &ldquo;<U>our</U>&rdquo; refer to PharmaCyte
Biotech, Inc., a Nevada corporation and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We license the copyright for Cell-in-a-Box<SUP>&reg;</SUP> in
the United States from Austrianova Singapore Pte. Ltd. This prospectus contains references to our copyright. Solely for convenience,
copyrights and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without
the &reg; or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest
extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not
intend our use or display of other companies&rsquo; trade names or trademarks to imply a relationship with, or endorsement or sponsorship
of us by, any other company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s2"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This prospectus summary highlights certain information about
our company and other information contained elsewhere in this prospectus or in documents incorporated by reference. This summary
does not contain all of the information that you should consider before making an investment decision. You should carefully read
the entire prospectus, any prospectus supplement, including the section entitled &ldquo;Risk Factors&rdquo;, and the documents
incorporated by reference into this prospectus, before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s3"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a Registration Statement that we
filed with the SEC utilizing a shelf registration process. Under this shelf registration process, we may sell any combination of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>common stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>preferred stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>debt securities, in one or more series;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warrants to purchase any of the securities listed above;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>rights to purchase common stock, preferred stock or warrants; and/or&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>units consisting of one or more of the foregoing</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">in one or more offerings up to a total dollar amount of $100,000,000.00.
This prospectus provides you with a general description of the securities we may offer.&nbsp;Each time we sell securities, we will
provide a prospectus supplement that will contain specific information about the terms of that specific offering and include a
discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may also
add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement
together with the additional information described under the heading &ldquo;Where You Can Find More&nbsp;Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s4"></A>OUR COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biotechnology company focused on developing cellular
therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo;
The Cell-in-a-Box<SUP>&reg;&nbsp;</SUP>technology is intended to be used as a platform upon which therapies for several types of
cancer, including locally advanced, inoperable, pancreatic cancer (&ldquo;LAPC&rdquo;), and Type 1 and insulin dependent Type 2
diabetes will be developed. &nbsp;The current generation of our product candidate is referred to as &ldquo;CypCaps&trade;&rdquo;.
On September 1, 2020, we submitted an Investigational New Drug Application (&ldquo;IND&rdquo; to the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) for a planned Phase 2b clinical trial in LAPC, and on October 1, 2020, the Company received notice that the
FDA had placed the IND on clinical hold. See &ldquo;Clinical Hold.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing therapies for pancreatic and other solid cancerous
tumors by using genetically engineered live human cells that we believe are capable of converting a cancer prodrug into its cancer-killing
form, encapsulating those cells using the Cell-in-a-Box<SUP>&reg;</SUP>&nbsp;technology and placing those capsules in the body
as close as possible to the tumor. We believe that when the cancer prodrug is administered to a patient with a particular type
of cancer that may be affected by the prodrug, the killing of the patient&rsquo;s tumor may be optimized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also examining ways to exploit the benefits of the Cell-in-a-Box<SUP>&reg;</SUP>&nbsp;technology
to develop therapies for cancer that involve prodrugs based upon certain constituents of the&nbsp;<I>Cannabis</I>&nbsp;plant; these
constituents are of the class of compounds known as &ldquo;cannabinoids.&rdquo; Until the FDA allows us to commence the clinical
trial involving LAPC described in our IND for which the FDA has placed a clinical hold, we are not spending any further resources
developing this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we are developing a therapy to delay the production
and accumulation of malignant ascites fluid that results from many types of abdominal cancerous tumors. Malignant ascites fluid
is secreted by abdominal cancerous tumors into the abdomen after the tumors have reached a certain stage of growth. This fluid
contains cancer cells that can seed and form new tumors throughout the abdomen. This fluid accumulates in the abdominal cavity,
causing swelling of the abdomen, severe breathing difficulties and extreme pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are using our therapy for pancreatic cancer to determine
if it can prevent or delay the production and accumulation of malignant ascites fluid. As with our&nbsp;<I>Cannabis</I>&nbsp;program,
until the FDA allows us to commence the clinical trial involving LAPC described in its IND for which the FDA has placed a clinical
hold, we are not spending any further resources developing this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also developing a therapy for Type 1 diabetes and insulin-dependent
Type 2 diabetes. Our diabetes therapy consists of encapsulated genetically modified insulin-producing cells. The encapsulation
will be done using the Cell-in-a-Box<SUP>&reg;</SUP>&nbsp;technology. Implanting these cells in the body is designed to function
as a bio-artificial pancreas for purposes of insulin production. As with the two previous programs, we not spending any further
resources developing this program until the FDA allows us to commence the clinical trial involving LAPC described in its IND for
which the FDA has placed a clinical hold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Clinical Hold</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 1, 2020, the Company submitted an IND to the FDA
for a planned Phase 2b clinical trial in LAPC. Shortly thereafter, the Company received Information Requests from the FDA related
to the IND. The Company timely responded to all information requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 1, 2020, the Company received notice that the FDA
had placed the IND on clinical hold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 30, 2020, the FDA sent a letter to the Company setting
forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In order to address
the clinical hold, the FDA has requested that we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Provide additional sequencing data and genetic stability studies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct a stability study on the final formulated drug product as well as the cells from the Master Cell Bank;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Evaluate the compatibility of the delivery devices (i.e., the prefilled syringe and microcatheter) with our drug product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Provide additional detailed description of the manufacturing process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Provide additional product release specifications for the encapsulated cells;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Demonstrate comparability between the 1st and 2nd generation products and ensure adequate and consistent product performance
and safety between the two generations of product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct a biocompatibility assessment using the final finished capsules after the entire drug product manufacturing process
(but without cells);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Address insufficiencies in Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct an additional nonclinical study to assess the safety, activity and distribution of the drug product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold
and remove any statements not supported by the data; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Provide data from a new and extensive pig study.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The FDA also requested
that we address several issues not related to the clinical hold in an amendment to the IND, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Providing a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performing qualification studies for the drug substance filling step to ensure that the product remains sterile and stable
during the filling process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Submitting an updated batch analysis for the drug product for the specific lot that will be used for manufacturing all future
drug product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Providing additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Providing a few examples of common microcatheters that fit the specifications in the Angiography Procedure Manual;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Clarifying the language in the Pharmacy Manual regarding proper use of the syringe fill with the drug product; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Providing a discussion with data for the potential for cellular and humoral immune reactivity against the heterologous rat
CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in the Company&rsquo;s study population.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Since October
30, 2020, there has been no further communication with the FDA regarding the clinical hold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have assembled
a scientific team to address the FDA requests related to the clinical hold. That team is working to complete the items requested
by the FDA. We have not yet determined the estimated cost or the time necessary to complete these items. The cost and time associated
with completing these items will be significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Among other things, we completed a 12-month product
stability study, commenced physical parameter testing for CypCaps&trade; and commenced additional studies for the sequence of DNA
encoding of its encapsulated cells. We also designed the biocompatibility tests for cytotoxicity, sensitization, irritation, acute
systemic toxicity, material-mediated pyrogenicity, subacute/subchronic toxicity, genotoxicity and implantation. In addition, we
have begun a compression and swelling study of CypCaps&trade;, designed a study to determine if CypCaps&trade; are adversely affected
by contrast medium and designed a study to show the catheters used to implant CypCaps&trade; do not adversely impact the encapsulated
cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Impact of the COVID-19 Pandemic
on our Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The coronavirus SARS-Cov2 pandemic (&ldquo;COVID-19&rdquo;)
is causing significant, industry-wide delays in clinical trials. Although we are not yet in a clinical trial, we have filed an
IND with the FDA to commence a clinical trial in LAPC. While the IND has been placed on clinical hold by the FDA, we have assessed
the impact of COVID-19 on our operations. Currently, many clinical trials are being delayed due to COVID-19. There are numerous
reasons for these delays. For example, patients have shown a reluctance to enroll or continue in a clinical trial due to fear of
exposure to COVID-19 when they are in a hospital or doctor&rsquo;s office. There are local, regional and state-wide orders and
regulations restricting usual normal activity by people. These discourage and interfere with patient visits to a doctor&rsquo;s
office if the visit is not COVID-19 related. Healthcare providers and health systems are shifting their resources away from clinical
trials toward the care of COVID-19 patients. The FDA and other healthcare providers are making product candidates for the treatment
of COVID-19 a priority over product candidates unrelated to COVID-19. As of the date of this prospectus, the COVID-19 pandemic
has had an impact upon our operations, although we believe that impact is not material. The impact primarily relates to delays
in tasks associated with the preparation of our responses to the clinical hold, including all requested preclinical studies. There
may be further delays in generating responses to the requests from the FDA related to the clinical hold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the COVID-19 pandemic, commencement of our planned
clinical trial to treat LAPC may be delayed beyond the lifting of the clinical hold should that occur. Also, enrollment may be
difficult for the reasons discussed above. In addition, after enrollment in the trial, if patients contract COVID-19 during their
participation in the trial or are subject to isolation or shelter in place restrictions, this may cause them to drop out of our
clinical trial, miss scheduled therapy appointments or follow-up visits or otherwise fail to follow the clinical trial protocol.
If patients are unable to follow the clinical trial protocol or if the trial results are otherwise affected by the consequences
of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the
clinical trial may be compromised or not be accepted by the FDA. This could further adversely impact or delay our clinical development
program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">It is highly
speculative in projecting the effects of COVID-19 on our clinical development program and us generally. The effects of COVID-19
quickly and dramatically change over time. Its evolution is difficult to predict, and no one is able to say with certainty when
the pandemic will subside.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">COVID-19 could
materially affect our operations, as well as the business or operations of third parties with whom we conduct business. Our business
could be adversely affected by the effects of other future health pandemics in regions where we or third parties on which we rely
have significant business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were incorporated in 1996. In 2013, we restructured our operations
to focus on biotechnology, having been a nutraceutical products company before then. The restructuring occurred so we could develop
a unique, effective and safe way to treat cancer and diabetes. On January 6, 2015, we changed our name from &ldquo;Nuvilex, Inc.&rdquo;
to &ldquo;PharmaCyte Biotech, Inc.&rdquo; to reflect the nature of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The address of our corporate headquarters is 23046 Avenida de
la Carlota, Suite 600, Laguna Hills, CA 92653 and our telephone number is (917) 595-2850. We maintain a website at www.pharmacyte.com
where general information about us is available. The information on, or that may be accessed through, our website is not incorporated
by reference into and should not be considered a part of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have had a limited operating history with our current
business model and have not produced any revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s5"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our securities involves a high degree of risk.
Prior to making a decision about investing in our securities, you should carefully consider and evaluate the specific factors discussed
under the heading &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the fiscal year ended April 30, 2020 filed on
August 13, 2020, with the SEC, as amended, and any updates described in subsequent Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q and Periodic Reports on Form 8-K, all of which are incorporated herein by reference, and may be amended, supplemented
or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described
are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial
may also affect our operations. The occurrence of these known or unknown risks might cause you to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See also the statements contained under the heading &ldquo;Forward-Looking
Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s6"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and the documents incorporated by reference
herein contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act and Section 21E
of the Securities Exchange Act of 1934, as amended ( &ldquo;<U>Exchange Act</U>&rdquo;), that are intended to qualify for the &ldquo;safe
harbor&rdquo; created by those sections. In addition, we may make forward-looking statements in other documents filed with or furnished
to the SEC, and our management and other representatives may make forward-looking statements orally or in writing to analysts,
investors, representatives of the media and others. Forward-looking statements can generally be identified by the fact that they
do not relate strictly to historical or current facts and include, but are not limited to, statements using terminology such as
&ldquo;can&rdquo;, &ldquo;may&rdquo;, &ldquo;could&rdquo;, &ldquo;should&rdquo;, &ldquo;assume&rdquo;, &ldquo;forecasts&rdquo;,
&ldquo;believe&rdquo;, &ldquo;designated to&rdquo;, &ldquo;will&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;anticipate&rdquo;,
&ldquo;estimate&rdquo;, &ldquo;potential&rdquo;, &ldquo;position&rdquo;, &ldquo;predicts&rdquo;, &ldquo;strategy&rdquo;, &ldquo;guidance&rdquo;,
&ldquo;intend&rdquo;, &ldquo;budget&rdquo;, &ldquo;seek&rdquo;, &ldquo;project&rdquo; or &ldquo;continue&rdquo;, or the negative
thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future, including risks
relating to the recent outbreak of the coronavirus (COVID-19). You should read statements that contain these words carefully because
they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>discuss our future expectations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>contain projections of our future results of operations or of our financial condition; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>state other &ldquo;forward-looking&rdquo; information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe it is important to communicate our expectations.
However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our business
and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results and
the timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to a
variety of factors and risks, including, but not limited to, those set forth under &ldquo;Risk Factors&rdquo; and &ldquo;Our Company&rdquo;
set forth in this prospectus and the documents incorporated herein by reference<FONT STYLE="background-color: white">, including
among others, our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; whether
the FDA approves our IND and lifts its clinical hold so that we can commence our planned clinical trial involving LPAC; there is
substantial doubt about our ability to continue as a going concern; the success and timing of our preclinical studies and clinical
trials; the potential that results of preclinical studies and clinical trials may indicate that any of our technologies and product
candidates are unsafe or ineffective; our dependence on third parties in the conduct of our preclinical studies and clinical trials;
the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates; the material
adverse impact that the coronavirus pandemic may have on our business, including our planned clinical trial involving LAPC, which
could materially affect our operations as well as the business or operations of third parties with whom we conduct business; and
whether the FDA will approve our product candidates after our clinical trials are completed, assuming the FDA allows our clinical
trial to proceed for LAPC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All forward-looking statements and risk factors included in
this prospectus are made as of the date hereof, and all forward-looking statements and risk factors included in documents incorporated
herein by reference are made as of their original date, in each case based on information available to us as of the date hereof,
or in the case of documents incorporated by reference, the original date of any such document, and we assume no obligations to
update any forward-looking statement or risk factor, unless we are required to do so by law. If we do update one or more forward-looking
statements, no inference should be drawn that we will make updates with respect to other forward-looking statements or that we
will make any further updates to those forward-looking statements at any future time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements may include our plans and objectives
for future operations, including plans and objectives relating to our products and our future economic performance, projections,
business strategy and timing and likelihood of success. Assumptions relating to the foregoing involve judgments with respect to,
among other things, future economic, competitive and market conditions, future business decisions, and the time and money required
to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict
accurately and many of which are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of the assumptions underlying the forward-looking statements
contained in this prospectus could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated
in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking
statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives
or plans will be achieved, and we caution you against relying on any of the forward looking-statements contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s7"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as otherwise provided in the applicable prospectus supplement,
we intend to use the net proceeds from the sale of the securities covered by this prospectus for general corporate purposes, which
may include, but are not limited to, working capital, capital expenditures, clinical trials, business development and research
and development expenditures and acquisitions of new technologies or businesses. The precise amount, use and timing of the application
of such proceeds will depend upon our funding requirements and the availability and cost of other capital. Additional information
on the use of net proceeds from an offering of securities covered by this prospectus may be set forth in the prospectus supplement
relating to the specific offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s8"></A>DIVIDEND POLICY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never declared or paid any cash dividends on our common
stock. We do not anticipate paying any cash dividends to stockholders in the foreseeable future. In addition, any future determination
to pay cash dividends will be at the discretion of our Board of Directors (&ldquo;Board&rdquo;) and will be dependent upon our
financial condition, results of operations, capital requirements, and such other factors as our Board deems relevant.<BR STYLE="clear: both">
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s9"></A>DESCRIPTIONS OF THE SECURITIES WE MAY
OFFER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The descriptions of the securities contained in this prospectus,
together with any applicable prospectus supplement, summarize all the material terms and provisions of the various types of securities
that we may offer. We will describe in the applicable prospectus supplement relating to a particular offering the specific terms
of the securities offered by that prospectus supplement. We will indicate in the applicable prospectus supplement if the terms
of the securities differ from the terms we have summarized below. We will also include in the prospectus supplement information,
where applicable, regarding material United States federal income tax considerations relating to the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell from time to time, in one or more offerings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>shares of our common stock;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>shares of our preferred stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warrants to purchase any of the securities listed above;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>rights to purchase common stock, preferred stock or warrants; and/or&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>units consisting of one or more of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus may not be used to consummate a sale of securities
unless it is accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description of common stock and preferred stock,
together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and
provisions of the common stock and preferred stock that we may offer under this prospectus but is not complete. For the complete
terms of our common stock and preferred stock, please refer to our articles of incorporation, as may be amended from time to time
(&ldquo;<U>Articles of Incorporation</U>&rdquo;), any certificates of designation for our preferred stock, that may be authorized
from time to time, and our bylaws, as amended from time to time. Nevada Law may also affect the terms of these securities. While
the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will
describe the specific terms of any series of these securities in more detail in the applicable prospectus supplement. If we so
indicate in a prospectus supplement, the terms of any common stock or preferred stock we offer under that prospectus supplement
may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 1, 2021, our authorized capital stock consists of
2,490,000,000 shares of common stock, par value $0.0001 per share, of which 2,341,410,405 shares were issued and outstanding, and
10,000,000 shares of preferred stock, par value $0.0001 per share, of which no shares were issued and outstanding. The actual number
of stockholders is greater than the number of stockholders of record and includes stockholders who are beneficial owners but whose
shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders
whose shares may be held in trust by other entities. In addition, as of April 1, 2021, there were issued and outstanding options
to purchase 62,600,000 shares of our common stock and warrants to purchase 4,472,129 shares of our common stock. The authorized
and unissued shares of common stock and preferred stock are available for issuance without further action by our stockholders,
unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Unless
approval of our stockholders is so required, our Board will not seek stockholder approval for the issuance and sale of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Common Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of our common stock are entitled to one vote for each
share issued and outstanding held on all matters to be voted upon by the stockholders. Our shares of common stock have no preemptive,
conversion, or redemption rights. The rights, preferences, and privileges of the holders of common stock are subject to, and may
be adversely affected by, the rights of the holders of shares of any series of preferred stock we may issue in the future. Upon
the sale of substantially all of our stock or assets or dissolution, liquidation or winding up, and after all liquidation preferences
payable to any series of preferred stock entitled thereto have been satisfied, our remaining assets shall be distributed to all
holders of common stock and any similarly situated stockholders who are not entitled to any liquidation preference or, if there
be an insufficient amount to pay all such stockholders, then ratably among such holders. All of our issued and outstanding shares
of common stock are fully paid and non-assessable. The holders of shares of our common stock will be entitled to such dividends
and other distributions in cash, stock or property from our assets or funds legally available for such purposes as may be declared
from time to time by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on OTCQB under the symbol &ldquo;PMCB.&rdquo;
American Stock Transfer &amp; Trust Company is the transfer agent and registrar for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Articles of Incorporation provides that our Board may, by
resolution, designate classes of preferred stock in the future. The designated series of preferred stock will have such powers,
designations, preferences and relative participation or optional or other special rights and qualifications, limitations or restrictions
as expressed in the related resolution adopted by the Board. Once designated by our Board, each series of preferred stock will
have specific financial and other terms that will be described in a prospectus supplement. The description of the preferred stock
that is set forth in any prospectus supplement is not complete without reference to the documents that govern the preferred stock.
These include our Articles of Incorporation and any certificates of designation that our Board may adopt. Before the issuance of
shares of each series of preferred stock, the Board is required by the Nevada Revised Statutes and our Articles of Incorporation
to adopt resolutions and file a certificate of designations with the Secretary of State of the State of Nevada. The related certificate
of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions,
including, but not limited to, some or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number of shares constituting that series and the distinctive designation of that series, which number may be increased
or decreased (but not below the number of shares then outstanding) from time to time by action of the Board;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will
be cumulative, and, if so, from which date;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such
voting rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether that series will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision
for adjustment of the conversion rate in such events as the Board may determine;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms
and amount of such sinking fund;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not the shares of the series will have priority over or be on a parity with or be junior to the shares of any other
series or class in any respect;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of
the corporation, and the relative rights or priority, if any, of payment of shares of that series; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other relative rights, preferences and limitations of that series.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Although our Board has no intention at the present time of doing
so, it could authorize the issuance of a series of preferred stock that could, depending on the terms of such series, impede the
completion of a merger, tender offer or other takeover attempt. All shares of preferred stock offered hereby will, when issued,
be fully paid and non-assessable, including shares of preferred stock issued upon the exercise of preferred stock warrants or subscription
rights, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">We have authorized
10,000,000 shares of preferred stock, with a par value of $0.0001, of which one share has been designated as &quot;Series A Preferred
Stock&quot; and 13,500 shares have been designated as &ldquo;Series E Preferred Stock.&rdquo; The one share of Series A Preferred
Stock was issued on October 30, 2019 and repurchased by the Company on December 3, 2019. As of April 30, 2020, there are no shares
of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">The descriptions
of the Series A Preferred Stock and the Series E Preferred Stock below is qualified in its entirety by reference to the Company&rsquo;s
Articles of Incorporation, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Series A Convertible Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Series A Preferred
Stock has the following features:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There is one share of preferred stock designated as Series A Preferred Stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders
of the Company having a right to vote on any matter plus one.&nbsp;&nbsp;The Certificate of Designations that designated the terms
of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series
A Preferred Stock; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation
in any distributions to shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Series E Convertible Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series E Convertible Preferred Stock have the following
features:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The holders of Series E Convertible Preferred Stock are entitled to receive cash out of our assets before any amount is paid
to the holders of any capital stock of any class junior in rank to the shares of Series E Convertible Preferred Stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Each share of Series E Convertible Preferred Stock is convertible, at the holder's option, into shares of common stock at the
average closing bid price of the common stock for five trading days prior to the conversion date;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have the right, in our sole discretion, at any time 110 days after issuance of shares of Series E Convertible Preferred
Stock, to redeem all of the shares of Series E Convertible Preferred Stock upon thirty days advance written notice at a redemption
price equal to the par value of the shares of the Series E Convertible Preferred Stock; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>At every meeting of stockholders every holder of shares of Series E Convertible Preferred Stock is entitled to 50,000 votes
for each share of Series E Convertible Preferred Stock with the same and identical voting rights as a holder of a share of common
stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The &ldquo;business combination&rdquo;
provisions of Sections 78.411 to 78.444, inclusive, of the NRS, generally prohibit a Nevada corporation with at least 200 stockholders
of record from engaging in various &ldquo;combination&rdquo; transactions with any interested stockholder for a period of two years
after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved by the
Board prior to the date the interested stockholder obtained such status or the combination is approved by the Board and thereafter
is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding
voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the combination was approved by the Board prior to the person becoming an interested stockholder or the transaction by which
the person first became an interested stockholder was approved by the Board before the person became an interested stockholder
or the combination is later approved by a majority of the voting power held by disinterested stockholders; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per
share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination
or in the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common
stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is
higher, or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">A &ldquo;combination&rdquo; is generally
defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in
one transaction or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate market value
equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to 5% or
more of the aggregate market value of all outstanding shares of the corporation, (c) 10% or more of the earning power or net income
of the corporation, and (d) certain other transactions with an interested stockholder or an affiliate or associate of an interested
stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In general, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s
voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may
discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock
at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The provisions of Nevada law could have
the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations
in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may
also have the effect of preventing changes in the composition of our Board and management. It is possible that these provisions
could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In addition, the NRS provides for statutes,
Sections 78.378 to 78.3793, inclusive, of the NRS, that limit the voting rights of the acquisition of a &ldquo;controlling interest&rdquo;
defined to occur at three ownership thresholds of one-fifth, one-third and a majority of the corporation&rsquo;s voting power.
Although our Articles of Incorporation have not opted out of these statutes, the limitations on voting rights apply only to a corporation
with 200 or more stockholders of record, at least 100 of whom have addresses in the State of Nevada appearing on the corporation&rsquo;s
stock ledger during the 90 days immediately preceding the date of the acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we may include in any applicable prospectus supplement or free writing prospectus, summarizes the material terms and provisions
of the warrants that we may offer under this prospectus and any related warrant agreement and warrant certificate. While the terms
summarized below will apply generally to any warrants that we may offer, we will describe the specific terms of any series of warrants
in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants
offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional
important terms and provisions and will be incorporated by reference as an exhibit to the Registration Statement which includes
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;<U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue warrants for the purchase of common stock, preferred
stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred
stock and/or debt securities, and the warrants may be attached to or separate from these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will evidence each series of warrants by warrant certificates
that we may issue under a separate agreement. We may enter into a warrant agreement with a warrant agent. Each warrant agent may
be a bank or trust company that we select which has its principal office in the United States. We may also choose to act as our
own warrant agent. We will indicate the name and address of any such warrant agent in the applicable prospectus supplement relating
to a particular series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the
terms of the series of warrants, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the offering price and aggregate number of warrants offered;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
with each such security or each principal amount of such security;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the date on and after which the warrants and the related securities will be separately transferable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one
warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase common stock or preferred stock, the number or amount of shares of common stock or preferred
stock, as the case may be, purchasable upon the exercise of one warrant and the price at which and currency in which these shares
may be purchased upon such exercise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the manner of exercise of the warrants, including any cashless exercise rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the warrant agreement under which the warrants will be issued;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>anti-dilution provisions of the warrants, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms of any rights to redeem or call the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the dates on which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable
during that period, the specific date or dates on which the warrants will be exercisable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the manner in which the warrant agreement and warrants may be modified;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the identities of the warrant agent and any calculation or other agent for the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>federal income tax consequences of holding or exercising the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms of the securities issuable upon exercise of the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants
may be listed or quoted; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><BR>
</P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or
interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon
our liquidation, dissolution or winding up or to exercise voting rights, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Exercise of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant will entitle the holder to purchase the securities
that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement.
Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time
up to 5:00 P.M. eastern time on the expiration date that we set forth in the applicable prospectus supplement. After the close
of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of the warrants may exercise the warrants by delivering
the warrant certificate representing the warrants to be exercised together with specified information and paying the required exercise
price by the methods provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate,
and in the applicable prospectus supplement, the information that the holder of the warrant will be required to deliver to the
warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon receipt of the required payment and the warrant certificate
properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable
prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants
represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Enforceability of Rights by Holders of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any warrant agent will act solely as our agent under the applicable
warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single
bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility
in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate
any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related
warrant agent or the holder of any other warrant, enforce by appropriate legal action the holder&rsquo;s right to exercise, and
receive the securities purchasable upon exercise of, its warrants in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Warrant Agreement Will Not Be Qualified Under Trust Indenture
Act</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No warrant agreement will be qualified as an indenture, and
no warrant agent will be required to qualify as a trustee, under the Trust Indenture Act of 1939, as amended (&ldquo;Trust Indenture
Act&rdquo;). Therefore, holders of warrants issued under a warrant agreement will not have the protection of the Trust Indenture
Act with respect to their warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Governing Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant agreement and any warrants issued under the warrant
agreements will be governed by New York law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Calculation Agent</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any calculations relating to warrants may be made by a calculation
agent, an institution that we appoint as our agent for this purpose. The prospectus supplement for a particular warrant will name
the institution that we have appointed to act as the calculation agent for that warrant as of the original issue date for that
warrant, if any. We may appoint a different institution to serve as calculation agent from time to time after the original issue
date without the consent or notification of the holders. The calculation agent&rsquo;s determination of any amount of money payable
or securities deliverable with respect to a warrant will be final and binding in the absence of manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Outstanding Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 1, 2021, we had outstanding four warrants to purchase
4,472,129 shares of our common stock at a weighted average exercise price of $0.039.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we include in any applicable prospectus supplement or free writing prospectus, summarizes certain general terms and provisions
of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we
will describe the specific terms of the series in a supplement to this prospectus. We will also indicate in the supplement to what
extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. To the extent
the information contained in the prospectus supplement differs from this summary description, you should rely on the information
in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue debt securities either separately, or together
with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities
may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus,
the debt securities will be our direct, unsecured obligations and may be issued in one or more series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The debt securities will be issued under an indenture between
us and a trustee named in the prospectus supplement. We have summarized select portions of the indenture below. The summary is
not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture
for provisions that may be important to you. In the summary below, we have included references to the section numbers of the indenture
so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings
specified in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of each series of debt securities will be established
by or pursuant to a resolution of our Board and set forth or determined in the manner provided in a resolution of our Board, in
an officer&rsquo;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities
will be described in a prospectus supplement relating to such series (including any pricing supplement or term sheet).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We can issue an unlimited amount of debt securities under the
indenture that may be in one or more series with the same or various maturities, at par, at a premium, or at a discount. (Section
2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt
securities being offered, the aggregate principal amount and the following terms of the debt securities, if applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title and ranking of the debt securities (including the terms of any subordination provisions);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any limit on the aggregate principal amount of the debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date or dates on which the principal of a particular series of debt securities is payable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any
commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date
or dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular record
date for the interest payable on any interest payment date;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such
payment), where the debt securities of such series may be surrendered for registration of transfer or exchange, and where notices
and demands to us in respect of the debt securities may be delivered;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the
debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at
the option of a holder of debt securities and the period or periods within which, the price or prices at which and the terms and
conditions upon which the debt securities of a particular series shall be redeemed or purchased, in whole or in part, pursuant
to such obligation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt
securities and other detailed terms and provisions of these repurchase obligations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple
thereof;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the debt securities will be issued in the form of certificated debt securities or global debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other
than the principal amount;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the currency of denomination of the debt securities, which may be U.S. dollars or any foreign currency, and if such currency
of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation of the currency, currencies or currency units in which payment of principal of, and premium and interest on,
the debt securities will be made;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if payments of principal of, or premium or interest on, the debt securities will be made in one or more currencies or currency
units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect
to these payments will be determined;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the manner in which the amounts of payment of principal of, and premium, if any, and interest on, the debt securities will
be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to
a commodity, commodity index, stock exchange index or financial index;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions relating to any security provided for the debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture with respect
to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect
to the debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the
debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt
securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if applicable,
the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring
an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies
to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the
marketing of the securities; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of
subordination, if any, of such guarantees. (Section 2.2)</TD></TR></TABLE>

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue debt securities that provide for an amount less
than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms
of the indenture. We will provide you with information on the federal income tax considerations and other special considerations
applicable to any of these debt securities in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we denominate the purchase price of any of the debt securities
in a foreign currency or currencies or a foreign currency unit or units, or if the principal of, and premium, if any, and interest
on, any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide
you with information on the restrictions, elections, general tax considerations, specific terms and other information with respect
to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P></DIV>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Transfer and Exchange </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each debt security will be represented by either one or more
global securities registered in the name of The Depository Trust Company (&ldquo;<U>DTC</U>&rdquo; or the &ldquo;<U>Depositary</U>&rdquo;)
or a nominee of the Depositary (we will refer to any debt security represented by a global debt security as a &ldquo;book-entry
debt security&rdquo;), or a certificate issued in definitive registered form (we will refer to any debt security represented by
a certificated security as a &ldquo;certificated debt security&rdquo;) as set forth in the applicable prospectus supplement. Except
as set forth under the heading &ldquo;Global Debt Securities and Book-Entry System&rdquo; below, book-entry debt securities will
not be issuable in certificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Certificated Debt Securities</I>. You may transfer or exchange
certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. (Section
2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of
a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange. (Section 2.7)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may effect the transfer of certificated debt securities
and the right to receive the principal of, premium and interest on certificated debt securities only by surrendering the certificate
representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder
or the issuance by us or the trustee of a new certificate to the new holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Global Debt Securities and Book-Entry System</I>. Each global
debt security representing book-entry debt securities will be deposited with, or on behalf of, the Depositary, and registered in
the name of the Depositary or a nominee of the Depositary. Please see the section entitled &ldquo;Global Securities&rdquo; for
more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Covenants </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will set forth in the applicable prospectus supplement any
restrictive covenants applicable to any issue of debt securities. (Article IV)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>No Protection in the Event of a Change of Control </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we state otherwise in the applicable prospectus supplement,
the debt securities will not contain any provisions that may afford holders of the debt securities protection in the event we have
a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control)
which could adversely affect holders of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Consolidation, Merger and Sale of Assets </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not consolidate with or merge with or into, or convey,
transfer or lease all or substantially all of our properties and assets to, any person (a &ldquo;<U>successor person</U>&rdquo;)
unless:</P>

</DIV>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we are the surviving corporation or the successor person (if other than our company) is a corporation organized and validly
existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under
the indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>certain other conditions are met.</TD></TR></TABLE>

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding the above, any of our subsidiaries may consolidate
with, merge into or transfer all or part of its properties to us. (Section 5.1)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P></DIV>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Events of Default </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Event of Default&rdquo; means with respect to any series
of debt securities, any of the following:</P>

</DIV>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>default in the payment of any interest upon any debt security of that series when it becomes due and payable, and continuance
of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a
paying agent prior to the expiration of the 30-day period);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>default in the payment of principal of any debt security of that series at its maturity;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>default in the performance or breach of any other covenant or warranty by us in the indenture or any debt security (other than
a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than
that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or our company
and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities
of that series as provided in the indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of our company; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other Event of Default provided with respect to debt securities of that series that is described in the applicable prospectus
supplement. (Section 6.1)</TD></TR></TABLE>

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Event of Default with respect to a particular series of debt
securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default
with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration
under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will provide the trustee written notice of any Default or
Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe
in reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect
thereof. (Section 6.1)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an Event of Default with respect to debt securities of any
series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount
of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities,
that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if any,
on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency
or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt
securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any
holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities of any series
has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a
majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events
of Default, other than the non-payment of accelerated principal and interest, if any, with respect to debt securities of that series,
have been cured or waived as provided in the indenture. (Section 6.2) We refer you to the prospectus supplement relating to any
series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the
principal amount of such discount securities upon the occurrence of an Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indenture provides that the trustee may refuse to perform
any duty or exercise any of its rights or powers under the indenture, unless the trustee receives indemnity satisfactory to it
against any cost, liability or expense that might be incurred by it in performing such duty or exercising such right or power.
(Section 7.1(e)) Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt
securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section
6.12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No holder of any debt security of any series will have any right
to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee,
or for any remedy under the indenture, unless:</P>

</DIV>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>that holder has previously given to the trustee written notice of a continuing Event of Default with respect to debt securities
of that series; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request,
and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee
has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series
a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7)</TD></TR></TABLE>

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding any other provision in the indenture, the holder
of any debt security will have an absolute and unconditional right to receive payment of the principal of, and premium and any
interest on, that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement
of payment. (Section 6.8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indenture requires us, within 120 days after the end of
our fiscal year, to furnish to the trustee a statement as to compliance with the indenture. (Section 4.3) If a Default or Event
of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of
the trustee, the trustee shall mail to each holder of the securities of that series notice of a Default or Event of Default within
90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default.
The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any Default or Event
of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee
determines in good faith that withholding notice is in the interest of the holders of those debt securities. (Section 7.5)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Modification and Waiver </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We and the trustee may modify, amend or supplement the indenture
or the debt securities of any series without the consent of any holder of any debt security:</P>

</DIV>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to cure any ambiguity, defect or inconsistency;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with covenants in the indenture described above under the heading &ldquo;Consolidation, Merger and Sale of Assets&rdquo;;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to provide for uncertificated securities in addition to or in place of certificated securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to add guarantees with respect to debt securities of any series or secure debt securities of any series;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to surrender any of our rights or powers under the indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to add covenants or Events of Default for the benefit of the holders of debt securities of any series;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with the applicable procedures of the applicable depositary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to make any change that does not adversely affect the rights of any holder of debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted
by the indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change
any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture
Act. (Section 9.1)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom-width: 0in; border-bottom-color: Black">We may
also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding
debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without
the consent of the holders of each affected debt security then outstanding if that amendment will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom-width: 0in; border-bottom-color: Black">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone
the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduce the principal amount of discount securities payable upon acceleration of maturity;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>waive a Default or Event of Default in the payment of the principal of, or premium or interest on, any debt security (except
a rescission of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal
amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>make the principal of, or premium or interest on, any debt security payable in currency other than that stated in the debt
security;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities
to receive payment of the principal of, and premium and interest on, those debt securities and to institute suit for the enforcement
of any such payment and to waivers or amendments; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>waive a redemption payment with respect to any debt security. (Section 9.3)</TD></TR></TABLE>

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for certain specified provisions, the holders of at least
a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities
of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount
of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any
past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal
of, or any interest on, any debt security of that series; provided, however, that the holders of a majority in principal amount
of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment
default that resulted from the acceleration. (Section 6.13)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Defeasance of Debt Securities and Certain Covenants in Certain
Circumstances </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Legal Defeasance</I>. The indenture provides that, unless
otherwise provided by the terms of the applicable series of debt securities, we may be discharged from any and all obligations
in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the deposit with
the trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency
other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency, that, through
the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount
sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge
each installment of principal of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities
of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This discharge may occur only if, among other things, we have
delivered to the trustee an opinion of counsel stating that we have received from, or there has been published by, the U.S. Internal
Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal
income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities
of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance
and discharge and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as
would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Defeasance of Certain Covenants</I>. The indenture provides
that, unless otherwise provided by the terms of the applicable series of debt securities, upon compliance with certain conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may omit to comply with the covenant described under the heading &ldquo;Consolidation, Merger and Sale of Assets&rdquo;
and certain other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable
prospectus supplement; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to the debt securities
of that series (&ldquo;covenant defeasance&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The conditions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities denominated in a single
currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency, that,
through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the
opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment
of principal of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities of that series
on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not
recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance
and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been
the case if the deposit and related covenant defeasance had not occurred. (Section 8.4)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom-width: 0in; border-bottom-color: Black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom-width: 0in; border-bottom-color: Black"><U>No
Personal Liability of Directors, Officers, Employees or Securityholders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of our past, present or future directors, officers, employees
or securityholders, as such, will have any liability for any of our obligations under the debt securities or the indenture or for
any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder
waives and releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities.
However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view
of the SEC that such a waiver is against public policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Governing Law </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indenture and the debt securities, including any claim or
controversy arising out of or relating to the indenture or the debt securities, will be governed by the laws of the State of New
York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indenture will provide that we, the trustee and the holders
of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities
or the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indenture will provide that any legal lawsuit, action or
proceeding arising out of or based upon the indenture or the transactions contemplated thereby may be instituted in the federal
courts of the United States of America located in the City of New York or the courts of the State of New York in each case located
in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance of the debt securities)
irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The indenture will
further provide that service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute
or rule of court) to such party&rsquo;s address set forth in the indenture will be effective service of process for any suit, action
or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt
securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue
of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to
plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section 10.10)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue rights to purchase common stock, preferred stock
or warrants that we may offer to our security holders in one or more series. The rights may or may not be transferable by the persons
purchasing or receiving the rights. In connection with any rights offering, we may enter into a standby underwriting or other arrangement
with one or more underwriters or other persons pursuant to which such underwriters or other persons would purchase any offered
securities remaining unsubscribed for after such rights offering. Each series of rights will be issued under a separate rights
agent agreement to be entered into between us and a bank or trust company, as rights agent, that we will name in the applicable
prospectus supplement. The rights agent will act solely as our agent in connection with the rights and will not assume any obligation
or relationship of agency or trust for or with any holders of rights certificates or beneficial owners of rights. A copy of the
form of rights agent or subscription agent agreement, including the form of rights certificate representing a series of rights,
will be filed with the SEC in connection with the offering of a particular series of rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The prospectus supplement relating to any rights that we offer
will include specific terms relating to the offering, including, among other matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of the rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the securities for which the rights are exercisable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date of determining the security holders entitled to the rights distribution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the aggregate number of rights issued and the aggregate number of shares of common stock or preferred stock or warrants purchasable
upon exercise of the rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which the rights are transferable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the exercise price;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the conditions to completion of the rights offering;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any applicable federal income tax considerations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the material terms of any standby underwriting or other purchase arrangement that we may enter into in connection
with the rights offering;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date on which the right to exercise the rights will commence and the date on which the rights will expire; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other terms of the rights, including terms, procedures and limitations relating to the exchange and exercise of the rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each right would entitle the holder of the rights to purchase
for cash the amount of shares of common stock or preferred stock or warrants at the exercise price set forth in the applicable
prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided
in the applicable prospectus supplement. After the close of business on the expiration date, all unexercised rights will become
void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may determine to offer any unsubscribed securities directly
to persons other than our security holders, to or through agents, underwriters or dealers or through a combination of such methods,
including pursuant to standby arrangements, as described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Until a holder exercises the rights to purchase shares of our
common stock or preferred stock or warrants, the holder will not have any rights as a holder of shares of our common stock or preferred
stock or warrants, as the case may be, by virtue of ownership of the rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units consisting of one or more of the other securities
described in this prospectus, in any prospectus supplement or a free writing prospectus in any combination. Each unit will be issued
so that the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the
unit. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred
separately, at any time or at any time before a specified date or upon the occurrence of a specified event or occurrence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The applicable prospectus supplement or free writing prospectus
will describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any unit agreement under which the units will be issued;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the
units; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the units will be issued in fully registered or global form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Book-Entry, Delivery and Form </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we indicate differently in any applicable prospectus
supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more
global notes or global securities (collectively, &ldquo;<U>global securities</U>&rdquo;). The global securities will be deposited
with, or on behalf of, DTC and registered in the name of Cede &amp; Co., the nominee of DTC. Unless and until it is exchanged for
individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred
except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or its nominee to
a successor depositary or to a nominee of the successor depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC has advised us that it is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a limited-purpose trust company organized under the New York Banking Law;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a &ldquo;banking organization&rdquo; within the meaning of the New York Banking Law;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a member of the Federal Reserve System;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a &ldquo;clearing corporation&rdquo; within the meaning of the New York Uniform Commercial Code; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a &ldquo;clearing agency&rdquo; registered pursuant to the provisions of Section 17A of the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC holds securities that its participants deposit with DTC.
DTC also facilitates the settlement among its participants of securities transactions, such as transfers and pledges, in deposited
securities through electronic computerized book-entry changes in participants&rsquo; accounts, thereby eliminating the need for
physical movement of securities certificates. &ldquo;Direct participants&rdquo; in DTC include securities brokers and dealers,
including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary
of The Depository Trust &amp; Clearing Corporation (&ldquo;<U>DTCC</U>&rdquo;). DTCC is the holding company for DTC, National Securities
Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the
users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect
participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly.
The rules applicable to DTC and its participants are on file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchases of securities under the DTC system must be made by
or through direct participants, which will receive a credit for the securities on DTC&rsquo;s records. The ownership interest of
the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect
participants&rsquo; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases.
However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic
statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership
interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of beneficial
owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except
under the limited circumstances described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate subsequent transfers, all global securities deposited
by direct participants with DTC will be registered in the name of DTC&rsquo;s partnership nominee, Cede &amp; Co., or such other
name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the
name of Cede &amp; Co. or such other nominee will not change the beneficial ownership of the securities. DTC has no knowledge of
the actual beneficial owners of the securities. DTC&rsquo;s records reflect only the identity of the direct participants to whose
accounts the securities are credited, which may or may not be the beneficial owners. The participants are responsible for keeping
account of their holdings on behalf of their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So long as the securities are in book-entry form, you will receive
payments and may transfer securities only through the facilities of the depositary and its direct and indirect participants. We
will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices
and demands in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered
for payment, registration of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Conveyance of notices and other communications by DTC to direct
participants, by direct participants to indirect participants and by direct participants and indirect participants to beneficial
owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redemption notices will be sent to DTC. If less than all of
the securities of a particular series are being redeemed, DTC&rsquo;s practice is to determine by lot the amount of the interest
of each direct participant in the securities of such series to be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither DTC nor Cede &amp; Co. (or such other DTC nominee)
will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon
as possible after the record date. The omnibus proxy assigns the consenting or voting rights of Cede &amp; Co. to those direct
participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached
to the omnibus proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 0in 0in 12pt; border-bottom-width: 0in; border-bottom-color: Black"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So long as securities are in book-entry form, we will make payments
on those securities to the depositary or its nominee, as the registered owner of such securities, by wire transfer of immediately
available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless
if otherwise provided in the description of the applicable securities herein or in the applicable prospectus supplement, we will
have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank
accounts in the United States designated in writing to the applicable trustee or other designated party at least 15 days before
the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee
or other designated party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redemption proceeds, distributions and dividend payments on
the securities will be made to Cede &amp; Co., or such other nominee as may be requested by an authorized representative of DTC.
DTC&rsquo;s practice is to credit direct participants&rsquo; accounts upon DTC&rsquo;s receipt of funds and corresponding detail
information from us on the payment date in accordance with their respective holdings shown on DTC records. Payments by participants
to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for
the account of customers in bearer form or registered in &ldquo;street name.&rdquo; Those payments will be the responsibility of
participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of
redemption proceeds, distributions and dividend payments to Cede &amp; Co., or such other nominee as may be requested by an authorized
representative of DTC, is our responsibility; disbursement of payments to direct participants is the responsibility of DTC; and
disbursement of payments to the beneficial owners is the responsibility of direct and indirect participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except under the limited circumstances described below, purchasers
of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities.
Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights under the securities
and the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The laws of some jurisdictions may require that some purchasers
of securities take physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge
beneficial interests in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC may discontinue providing its services as securities depositary
with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor
depositary is not obtained, securities certificates are required to be printed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As noted above, beneficial owners of a particular series of
securities generally will not receive certificates representing their ownership interests in those securities. However, if:</P>

</DIV>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities representing
such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required
to be registered and a successor depositary is not appointed within 90 days of the notification to us or of our becoming aware
of DTC&rsquo;s ceasing to be so registered, as the case may be;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we determine, in our sole discretion, not to have such securities represented by one or more global securities; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an Event of Default has occurred and is continuing with respect to such series of securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom-width: 0in; border-bottom-color: Black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom-width: 0in; border-bottom-color: Black">we will
prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any beneficial
interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable
for securities in definitive certificated form registered in the names that the depositary directs. It is expected that these directions
will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests
in the global securities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s10"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities offered pursuant to this prospectus
from time to time in one or more transactions, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to or through underwriters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through broker-dealers (acting as agent or principal);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through agents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>directly by us to one or more purchasers (including our affiliates and stockholders), through a specific bidding or auction
process, a rights offering or otherwise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through a combination of any such methods of sale; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through any other methods described in a prospectus supplement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The distribution of securities may be effected, from
time to time, in one or more transactions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>block transactions (which may involve crosses) and transactions on any national exchange or any other organized market where
the securities may be traded;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>sales &ldquo;at the market&rdquo; to or through a market maker or into an existing trading market, on an exchange or otherwise;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>sales in other ways not involving market makers or established trading markets, including direct sales to purchasers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The applicable prospectus supplement will describe the terms
of the offering of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the name or names of any underwriters, if, and if required, any dealers or agents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchase price of the securities and the proceeds we will receive from the sale;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any underwriting discounts and other items constituting underwriters&rsquo; compensation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any discounts or concessions allowed or re-allowed or paid to dealers; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any securities exchange or market on which the securities may be listed or traded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may distribute the securities from time to time in one or
more transactions at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a fixed price or prices, which may be changed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>market prices prevailing at the time of sale;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prices related to such prevailing market prices; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Only underwriters named in the prospectus supplement are underwriters
of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If underwriters are used in an offering, we will execute an
underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including
any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement.
The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly
by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s)
will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will
be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering
price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise
set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject
to conditions precedent, and the underwriters will be obligated to purchase all of the offered securities, if any are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may grant to the underwriters options to purchase additional
securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts,
as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus
supplement for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a dealer is used in the sale of the securities, we, or an
underwriter, will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying
prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement,
document incorporated by reference or free writing prospectus, as applicable, the name of the dealer and the terms of the transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities directly or through agents we designate
from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions
we will pay the agent in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may authorize agents or underwriters to solicit offers by
institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant
to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of the securities, underwriters,
dealers or agents may receive compensation from us or from purchasers of the securities for whom they act as agents, in the form
of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for
whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any
institutional investors or others that purchase securities directly for the purpose of resale or distribution, may be deemed to
be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the common stock by
them may be deemed to be underwriting discounts and commissions under the Securities Act. No FINRA member firm may receive compensation
in excess of that allowable under FINRA rules, including Rule 5110, in connection with the offering of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may provide agents, underwriters and other purchasers with
indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect
to payments that the agents, underwriters or other purchasers may make with respect to such liabilities. Agents and underwriters
may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the public offering of a series of securities,
persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price
of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons participating
in the offering of more securities than have been sold to them by us. In addition, those persons may stabilize or maintain the
price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling
concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are
repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the
market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced,
may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect that the
transactions described above, if implemented, may have on the price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise specified in the applicable prospectus supplement,
any common stock sold pursuant to a prospectus supplement will be eligible for trading as quoted on the OTCQB. Any underwriters
to whom securities are sold by us for public offering and sale may make a market in the securities, but such underwriters will
not be obligated to do so and may discontinue any market making at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to comply with the securities laws of some states,
if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed
brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required, this prospectus may be amended or supplemented
from time to time to describe a specific plan of distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s11"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain legal matters governed by New York law with respect
to the validity of certain of the offered securities will be passed upon for us by Troutman Pepper Hamilton Sanders LLP, New York,
New York. Certain legal matters governed by Nevada law with respect to the validity of certain of the offered securities will be
passed upon for us by Ballard Spahr LLP, Las Vegas, Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s12"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Armanino </FONT>LLP, independent
registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K
for the year ended April 30, 2020, as set forth in their report, which is incorporated by reference in the prospectus and elsewhere
in this registration statement. Our consolidated financial statements are incorporated by reference in reliance on <FONT STYLE="background-color: white">Armanino
</FONT> LLP&rsquo;s report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s13"></A>WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and any subsequent prospectus supplements do
not contain all of the information in the Registration Statement. We have omitted from this prospectus some parts of the Registration
Statement as permitted by the rules and regulations of the SEC. Statements in this prospectus concerning any document we have filed
as an exhibit to the Registration Statement or that we otherwise filed with the SEC are not intended to be comprehensive and are
qualified in their entirety by reference to these filings. In addition, we file annual, quarterly and current reports and other
information with the SEC. The SEC maintains a website that contains reports and information statements and other information that
registrants file electronically with the SEC, including us. The SEC&rsquo;s website can be found at <U>http://www.sec.gov</U>.
In addition, we make available on or through our website copies of these reports as soon as reasonably practicable after we electronically
file or furnished them to the SEC. Our website can be found at <U>http:www.pharmacyte.com</U>. Our website is not a part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s14"></A>INFORMATION INCORPORATED BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have elected to incorporate certain information by reference
into this prospectus. By incorporating by reference, we can disclose important information to you by referring you to other documents
we have filed or will file with the SEC. The information incorporated by reference is deemed to be part of this prospectus, except
for information incorporated by reference that is superseded by information contained in this prospectus. This means that you must
look at all of the SEC filings that we incorporate by reference to determine if any statements in the prospectus or any document
previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents
set forth below that we have previously filed with the SEC, except in each case the information contained in such document to the
extent &ldquo;furnished&rdquo; and not &ldquo;filed&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820002680/pharmacyte_10k-043020.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal year ended April 30, 2020, filed with the SEC on August 13, 2020.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Quarterly Report on Form 10-Q for the quarterly period ended <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820003111/pharmacyte_10q-073120.htm" STYLE="-sec-extract: exhibit">July 31, 2020</A>, filed with the SEC on September 11, 2020.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Quarterly Report on Form 10-Q for the quarterly period ended <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820004267/pharmacyte_10q-103120.htm" STYLE="-sec-extract: exhibit">October 31, 2020</A>, filed with the SEC on December 11, 2020.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Quarterly Report on Form 10-Q for the quarterly period ended <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316821000925/pharmacyte_10q-013121.htm" STYLE="-sec-extract: exhibit">January 31, 2021</A>, filed with the SEC on March 12, 2021.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1157075/000168316820003473/pharmacyte_8k.htm" STYLE="-sec-extract: exhibit">Form 8-K</A> filed with the SEC on October 16, 2020.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also incorporate by reference all documents we file in the
future pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus and prior to the sale
of all the securities covered by this prospectus (including all such documents filed with the SEC after the date of the initial
filing of the Registration Statement that contains this prospectus and prior to effectiveness of the Registration Statement or
after such effectiveness), except in each case the information contained in such document to the extent &ldquo;furnished&rdquo;
and not &ldquo;filed.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may&nbsp;obtain copies of these documents on the website
maintained by the SEC at <U>http://www.sec.gov</U>, or from us without charge (other than exhibits to such documents, unless such
exhibits are specifically incorporated by reference into such documents) by writing us at Corporate Secretary, PharmaCyte Biotech,
Inc., 23046 Avenida de la Carlota, Suite 600, Laguna Hills, California 92653 or visiting our website at http://www.pharmacyte.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any statement contained in a document incorporated or deemed
to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for the purposes of this prospectus
to the extent that a statement contained herein, any prospectus supplement or in any other subsequently filed document which also
is or deemed to be incorporated by reference herein modifies or supersedes that statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 40px; width: 201px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Shares of Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Pre-funded Warrants
to Purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B><FONT STYLE="font-size: 14pt"><B>Common Warrants
to Purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Underwriter Warrants&nbsp;to
Purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Sole Book-Running Manager </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>H.C. WAINWRIGHT &amp; CO.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  H ,D# 2(  A$! Q$!_\0
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M/PM:Z=;V%ZLU[Y<-XVS!@CX\P]>3C(X]:Z+5+Y[011VZ"2YN'V1*QP,]23[
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M>=$KA'3/9UP1^%8'CZWNK_P=J%E8VTMQ<W"!$1!_M \GMQ6SJ=\NG63SE"[
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M6Z'R3""/]60 5]N***N;O%$4X\LG8@U:Q:_L6BC?9*K!XVQD!@<C-5%U6[1
MD^E71G'!$>"A/LV>E%%.F^9<K0JBY7S)FLI)4%A@D=/2L_5[5[DV06+S%2Y5
MG&. N#UHHK.#Y971I.*E&S([ZP!N["2VMD'ES[G9% PNTUJ4442DY)7",5%N
#Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &, BH# 2(  A$! Q$!_\0
M'    00# 0                $$!08" P<(_\0 21   0," @4'"0<# 0<%
M 0$  @ ! P0%$1(&$R$B,10R04)14G('%18T4V%QD;(C,S5B@8*2)%1S0P@E
M)F.AHL(V1+'!T1?A_\0 &P$  04! 0                (#! 4& 0?_Q  R
M$0 ! P($! 4$ @,! 0$      0(#!!$%$B$Q!A,R4105(C-!(V%B<1920E.!
M)$.A_]H # ,!  (1 Q$ /P#U0CJI'=$CY10APQ;8*7%L%2JG26NAJIXACCP
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MZOEN%$,LS,QX]"2^%[$U'8:Z*9<K"80A";)HJ$(0 (0A  A"$ "$(0 (0A
MA"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$
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MIS!\! ^E7@7Q87[=Y:;#:A9F:GFW$%"RGESM2UQ4(0K,SH(0A  A"$ "$(0
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M>9/L=<XU1^LBX[=GR3>LAJ:Z0F[%G [AGD)2--B%$<A<XU.$(F8:Z'%R&]E
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MQ6FU4#YZB W \AY6;I9199\O27U%AZ21+GW,[1/20/61C42G]IFWU+12!-M
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MC#:21"%?_!B?@$)-O507Q7-SC69U](JW4,VIK(#[#'%8!'(?- R+H?(L^2U
M;XTYYO\ HDN5ME0E012(]-"_5]LI;K P54>+X;#;BRJ=3H;6TLAR6^HB/'G,
M3;75RM9/)21$?.PVI\J=^YK8KY/4<<ET3NL=^B.;51'6,X&8EFX*VVW0>FC
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MM3I!UR726X@^D51+4.0C&>J9=97*+A103:1UH3!C]OF;XI;!$I9K51,81.3
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MW\E;<$8(\3+_ &.^4TG^M"I>A5'[67^2/0ND]O-_)6W*R,K+OBI?['/**/\
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ML:"DSY^30MCTY-JS*G@<Q,HHG)N&(<%(^;:W^SE^2/-M?_:2_P 4FT8O)/\
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..*$ 9(6*$ 9(6*$ ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %7 ? # 2(  A$! Q$!_\0
M'0 !  $% 0$!              4! @0&!P,("?_$ $D0  $# P(# P<, 0,#
M P$)  $  @,$!1$&$B$Q00<34105(E)A<9$6,C9"57)S@9*3L=$C)*'!"#-B
M%T.R5"4G-#538W2"X?_$ !L! 0 # 0$! 0             ! @,$!08'_\0
M,Q$  @(!!  & 0($!04       $" Q$$$B$Q!1,B05%A,@840G&AL14C4M'A
M)#.1P?#_V@ , P$  A$#$0 _ /JE$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$R
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M05'=U4)+HW>FQPP3CHOJF1T=SUO74A8_-.&N+]H+#PY9\5#]HW9M1Z@I'U5
MUE/=&-RQW20>#ECK=$FE;3^9]IX%^H(PA^TUOJK?&7[&1IBHTSK[1L-N\DA,
M, ;OI' !T;F]0MSD;#24T<=*V.(X#6@MX8]J^2:*KNVD=0-DA=)25\#\.:[@
M'8\1U'M7=-&ZL^65&6=^R"J9DRT^<.)\6^Q6T.J5SV6<-'-XUX"]'_U&G]53
MYX_L;W)--'"[_,USSQ )QP'@O.AK6.<2X-:3\XN/#"TZ:N8Z>0-VOD:.[:PG
MB?<HZOWTS(14[QD\B>('N7NQTRQ@^7W?U.A32L<7P%D<NSUQGA[%H/:5HFTZ
MWMDL3Z)AN36%D54XX[H^/M"E8+Y;9"T!\U14M;AOU0/;^2Y]VC]H68W6O3\S
M@XMVU-1CG_XM7%JKJ]+!N9Z/AGAMWB5JKH7'NS@-%I!UON51%<2'>3R.CPTY
M#R.H]BV&3<V)PA: [@&^"D:.UUM=2NJH(9'4S'['2@9&3[5%WVM%I?W7=][*
MTCT>A7AU:6>MEYEG$?8^SUFMTWZ>T_[;1^JU]O\ ]L^Q>SBR4=GTE;FTD+(W
MRPLEE<T9+G$<>*E*'Z2W'\)B:0D,FE;0\MV%U+&=OAZ*K0_26X_AL7HQBH\(
M_.;K9W3\R;RV3*JJ*J@J44'<_I3:?N2_P%.*#N?THM/W)?X"M'LI+HG4Z*B\
MWR!C27.P ,DE1R6;QV0/R2M0O(NG<GR@'=S]'=XX4XQS7$M!;N',!06IKQW&
MFJVKMTK)'L& YASM/M]JX]:+O7TMUIZJ*IF=*YX#]SLAV2NRO3V:B+DW^)Q6
M7PHDDEV=]GD9#!)+*<,8"YQ]BTC2M;I^\:AJJBBHG15XR[>[DX<MP6Z/:RJH
MBR9N62LPX>\<5 Z;TA16"MFJH'R22O&UNX_-;X+&N481DF^36R$K)1:7!KM#
MH6MIM6MKW5##3-F,P=]<D]"H+M2J*B74CX9BX01Q@QLSP=[5UJZ5D=OM]15R
MY+(6;B M%M%7;M?22QW*B[J> ;V.8X@EGO731?+<K)K*CP8W5+&R+Y9X]E\U
M9/:KI2QR.+6?]ESCD-)'(*_L\LMYH+[62W!LD<!SNWOW=XXG@0MYLUJH[32M
MIZ",1Q?[D^U>>H[FVRV6IKN[,G=#(;XE8ROW2DH+LTC3B*<WT9-=5P4-')45
M<C8H6#)<[HO&S76BN]/WUOF$D8.#XA:72UT^OM.5M,]K:>IB>T@@Y8? *5T1
M89-+VZJ?<9XPZ1V]Q;P: %6548Q]7Y(LKG*7I7!N&%=A1]KNU'=(G24$[)F-
M."6GDL_*PQM[.A-/E%41$)(^[6Z"Z4-11U32Z"=N'@'!_(]%#?(RT.K!431S
M2^CZ<4DA+'NQC>X<B['5;06@IM!XH#6[?I.UT-)60L9-(RK9W,AFD+B(^C1X
M!8KM!V(W"2L-._O7L+#E^6C(QR]P6V/X8QP]JT;4-TNU/JDPQ^5LI64Y?31T
M\.]M2_'I-<[ZI'! >-9V>BIUJ;V*TMIGPB"2FV9)C QLSX%3=-I"U4]EGM4;
M)/)IG!Y =Z3,'+<'V+G5+JK4[+;&VZ3UE,)JPLBE;1ETKF;<X#>OI<,J8CO>
MJHYG-GBJ)7^0MEV-I_180X;BX]7D<@$!M]+I6U4EYCKFB0U )D;&Z0EF_&"\
M-]8CF5:=&6<UUPJ1"YKJX'OF X!)XDCX+3JZX7ZOJF76@H:HR0MJ12MFB+,#
M:-I<WQSGFMH[-ZR\5E@[Z_2=Y4&0ACG1&-Q;X$'VH"0JM,6ZJG[Z1KQ)WPF)
M#R-Q#=N#[,+QM6CK3;>[\EB>T1R]]&">##X!;&!P/%780!H Y*J 81 $1$ 1
M$0!,(B IM";1PX*J(,# 5-H\%5$!3:/!4(R%<>2QZF4Q1/>UNX@94/A9"[P>
MQ'!6AP! Z^U0M3=R^*-T&=P.7#_A>%-<2*A\TV=SAAK0> 6'GQR;JB>#8\#P
M3 \%BQUT) !E9D^!RO5T[&R,C<X!SN7M6^Y&#BSUPJGDL2&L9++*UI&UAQD^
M*RL@A1%IDM-=D<::&.I?*V-@D=Q<0,$^]1-YJQ'.R(D,]JE*V=L+W%QP>@\5
MI==5BHKYGY)[OQ7H:>MS>6:9PN#5^TBQ4NH8F@/:VNCR&3M'SO8[V+B)\OL-
MU:YIDIZR$^BYO#/N]B[S=:R.64/GQ31!O![6Y+EK&J;-1W2WNE=.'[!_CD:/
M2;[%CK_"E:O-IXFCZ?P+]1/2/]MJ?54_GV_X,KLZU##>Y',<Z""Y<"3*<;_'
M:LS4=725-UEC=/W!A:6S.D)()'0+BM1#56FO;NWPSQN#HY>1/M"D[YJFMO%'
MY/4,C;QW/<T8<\^*X:/&G5!QO7K1ZFK_ $E#571NT+7E2[^C(ONI)9'R04$A
M9& 6ND;P)]WL4?IZSR72I:=S8Z=C@7EYQO\ 8$L%EGN3R]D4CH8SR:W)=[ M
MUEMLMMI0V:#NSEI$)X$!1IM)9XA9Y^H_'V-/$?%=/X'1^QT&'/W?Q_,WJ>"W
M#33[?0!D+'1X:UA]$. Z_P!KY7UQ:[O:9'U%TIW1P3./<S Y:_!Z>"^CI[C!
M;HG0UC1+!)&Q[6LX8=U&?@N']O-Y-74T='&R5L<;=YW\N/@O<U%<57Z>C\_L
MME;-SD\MGVCH([]$V)QXDT<7'_\ J%[4/TEN/X;%C]GOT&L/_P#"B_\ B%[T
M/TEN/X;%Y:,F32JJ*JJ244'<_I1:?N2_P%.*#N8SJFU#_P#;E_@*T>RLNC,O
M5T@M-NEK*DGNX^@YD^"T1VK6:HIZFU1QOHJFH:6P.<[@X^"VG7%HFO-@FIJ;
M F:=[0?K>Q<]T;I6YOU!!-54SZ:&F?O+WCF? +MT\:O+<Y/U(X]3*WS%&*X-
MAT#I6LH(*^.\,:(:@;.Y#MP(\5GV[L]M='<15;Y96L=N9$_&UI6UUE5%24TD
M]0_9$QI<XGH%&:?U)07ULOF]SBZ(^DQPP<>*P=MTLS7"-555'$7RR:(X >"8
M ZIE<[[0M5W.RW2"GH QD99N+GMSN.>06=54K);4:VS5:3D;_4PLJ('Q2M#H
MWC:6GJ%S:\72AT/624=BI&OG?_DF=*XD > ZKH5KJ7UEMIJA\99++&'%IZ%<
M^[0=*U]7<S<+9%W_ '@#7M!PX'Q]RWTFQ3V6/@PU&YQWUKDVG1FI6Z@HY'/A
M$-3"<2L'$>\+TUE=:.UV@NN$)GCE.P1#ZRT>F=6Z#LKJB6%CJVLDVM:X^C&T
M#J5M45/3:YTM325S'PE_$%AXM=XA6LJA7/>OP*UV2LK<)?D9FB3;);,R:ST_
MD\,CCN;C!#O J1U#;O.MGJ:(/+#*S =X%0_EEFT7;X:.6;NP22 >+B>I*GK9
M<*:YTK*FBD$D3NH6-BDI>9'KY-H.+CY;[-:[/],5&GVU3ZR5CYIL#$?!N!_R
MMR5,*Y4G-V2W,TK@H1P@$1%0N$1$!1S0586X'#/Q5Y*U;7MYJ;';*>OI1O;'
M.ULL?KL/ J8Q<GA%9S4%EF?<+I2-N-N@VLDGFD<V,XR68^<0IAN>1\5\ZPWF
ML@O/E\,CR))'B+?Q[AC_ )R[OI^X4=?01NM]2VIBC&PR#J1S71J-.Z,9,*-0
MK<X)&1P8USW'#0,D^P+4]2ZVMUHIVN9()I)X72T^TY#W#ACV+,UQ=)K38IJB
MEDIV3#DV;_W!U ]JX4V-I!))(<#P/$#/$CCR6FDTKOY]C/5:I4\+L^@=.7:.
MZT$<C7M?*&-[TLXM#B.(!4ST"Y5V06^<P2U+:RHCHX9"UE*W_MN)'%V>JZGQ
M7/=!0FXHZ*9N<%)ER($61J$1$ 1$0!$3* (F53.>2C(*Y5.*97C//%#&Y\KP
MQC1DN)P IPWT1G!ZD\%K5XG8^0]S*_(X.9G 4QYRIG0LFCE:^)QV[V'(!4+>
MIV/JVL8Z$N S@$97/J,[#ITV/,630-8U=?#=X8Z9SV1X!;M'!WO6:[5M+%4L
MBDB>78:))!R!6R1TOE1[EK6DEI +AR_-<RK[+<:>XS4<E+*^8N.W:TEK@>N5
MZ&A5&MAB:Q@XM=*[1SS!YR=FE_QVUDE/#$Z)[<G'@1S7/M87NXT-;30TKW-B
M RWKGV*0[-8[C-/5TU>*@T,3=H9)D8=X+:JFT-=4Q"1D;@7< 1G:N:R'[>UI
M+<C:JSSZO],B+I9Y###,[+'N:'.!/7VK;Z)[Y*=KI"QQ_P#%1-/:G_/=\YC\
M8/(A3<4;8V@-: /8N>F,MSD^#HOE%Q44:)J*ZQLU3Y&Z9IDV99&#QSCJM?N,
M\D$7E;!A\K7%X_VPM4U4ZX?^N%6ZVQO+(&L=*XC+<8XA;-<F.KZQU-%GNWMW
M,=T;[%]'I<;$<[ZP0'G"K\U5L\)W,8T0'< >!Y >U85_NE'YGME-WCH0P@5;
M!P<,=5FZZLS;#INIEFJS&Z4-?#$#Q+_%<DNETJ+CW3IR"6-VDCF_VGQ7'K_$
MJ]+'/<G['M>#^!W>)V8Z@NV9>J+JRY5[S3.<:./A&Z0>D0HJ:"6&..21CFLD
M^:['-2UAH:=\%?77,.;34+0XM'UG'D%XUUQ=>*(RQQNBIJ<<&XX,SR&5X"T%
MVJ4K[>)/H^UN_46C\(E#1:>.8Q_)_P#WN9MEO]?%4P14\[:>3>&M>> Q[5FW
M6X5T->RHGE-3&Y[B]X=D.QX'P6H->TDXZ\N/$!953<*N6"BIP&O@@<0&8P"#
MSRNO0^(NI^1J.&>7XWX##50_Q#0<Q?+1N5UO!U'%1T<41B&'!C@WI[2N9]I,
M#:BV-:^<35-&<'9QP/:5NUUOD=BI8HJ"IA>YP&^';\SV@KC6KKH:VOF? PQ1
MR'+VAQPX^*]>^S,,,^$::[[/T,[/OH-8<?\ T47_ ,0O>A^DMQ_#8L?L]X:&
ML.?_ **+_P"(7O0_26X_AL7G(JR:55154$E.B@KIGY3VK X]W+_ 4[T4'<_I
M1:?PY?X"M'LJ^C1Z/4M\EUQY(_>8.^+# 6< WULKJ6,#'1>0IHA,9A$P2'F[
M;Q^*]@%I;8IXVK!G56X9W/)AW2@CN5!/2S9#)6%IQT6E,TW4:2L-SJ+;,^IK
M'-PT[?FM'@/%="QPYK&KI1!233.&X1M+L>. E=CB]OL+*XR633>S"NNM;0U1
MN;I9(PX".248+O%;?54%-5EKJF&*5S?FES<X7%/E==Q<#6,J7-:'9[D ; W/
M@NW6^H%5103@%O>,#L>\+;553JEOZR8Z:R-D7#O!9<)7TEOGEA9O?'&7-:.I
M X+1^SO4]SO-RJH:\!T;6[PX-QL.?FKH+FEQ()X$<5XTU%3TN_R>&.,O.7%H
MQDKGC.,8M-<FTJY.2:?!XW6UTETIQ#7PMFC!R >B]J2FBHZ9D%/$UD+!AK0.
M "]SPX+1.U"MNM'!2^;3,V%Q/>/B&7 ] IKC*W%><(625:<\&G]I4,T6JYI9
MP>[D8-CB,C"VKL@AGCM]9(\.%/))F/<,9]H4]IF&2Z:<HW7NF;)/C)$C>(\%
ML$43(6-9&T-8. :T8 73=J_\OR&NCGHT^)^;GL]>JJJ%5"X4=P1$4@(BH4!1
MRX]VL&-U^I^ZJC*XLQ) U_!A'(D+L#@<M7&>U.&DI]41NIVED\L6Z<X]%QZ?
MFNO0I>:LG)K?^VVC4'@ENW;D/(:0.9X]%]"V.CAH;73PTT#:=C6 E@'(XZ^U
M<)TY:JC4%>V*E<^.G8_:ZIC&0Q_,9]B[Y;VSQ4,#*M[7SM:&O<WDXCJNCQ*Q
M2DDCG\/K:B\D#V@6M]VT]+#3TT<]0P[XB\X[LCFX>U<ELFGKM?)&BCIWPP..
M#4R#(X<"0/#*ZKK_ %G1:2I:5U<SO75,HC[IIX[3S=[@MAMSH'4,#Z/9Y,Y@
M<S9RVE<5&L=2=<3OO\.E)0U$UZ7U]X(O2&FVZ=HC##422,D <]CCD"3JX>P^
M"V/"HTDCB,*JR<G)Y9>*27 ')$102$1$ 1$0!6;V;L9X^"NZ*&OD[8FC>"P'
MYLF['%5DVN46A'<\$MO:7;0>/-84M6=KGPD>@>(<<97+M;:@N$=PCIH)W1;(
M\N>W@2O71=UJ:X34E6]TI8 6.)\?%:V:>V-'GKHRKNJ>H\E]FX7C5U);# ^<
M/Q)]4#BHF\U+M2::J(J!^9*AP<S+L<!T6-J&QB[-C#Y2R6/DYHSP6;9;:VCI
M*>EB)+ 2-[NI7)^XC"$90_/)U2T\I3E"?X$5;:2OL.FJV*H<QSBTR-A:<AOY
M^*T..KJ(YQ4B9_>;@=Y=G.>BZ+JJ\0V6I9#44Q<96Y<W/ CQ6-;-)4-4Z.N@
M;(:=Y#@T\A[UZ.GU&S=.Z'Y='#J-/O<:Z)_CV8NJYK@^W43Z(3#>,O[KF#T7
M0-(LJO,%(ZO:?*RWTB_G[,JZFMC8&.>]X;(.#2#PV]."US4FMS;:L4/DI>_@
M9) [@ L:IRMAY48\\OCX-+8PA-6.7'"Y-Y.UF-V!Q]V2O"EK:2KE<VFGCE?&
M<.#3DM6J5=V;*R,U52(FS1D1G.#DC@5$]G=BJK5>)JBLE8UCF%K6L.[>2?G%
M4K<)1;F\/VS[EK5*N24.?G!TP-.1R5>(56\D/)"3YLUW=Q;NUJZ1UU;-34&Q
MIV1C_N.QP!*R*/5SX].S7)S(VM$VUI=S=&.>/:M7[;.[E[2+M%*_:P,8<=>7
M1:9+,^5K8LN[MIP&CD?R5]1XDM-4H1YD?1^ ^ V>)3\R?IK7;,F^72:Z5TD[
MY9S%NS''*\NV@J&\Y-I9WF-P[R(\"X9P5-3/I[#;Q75#H9ZTG_' UV2P>T>*
MU"62@F?,^W-J*F:8E[VNX!IZKATVCE9/SK^7\'L^,^/5Z2O]AX>L)<-H]F76
M>;O:<SN=%4O#GQGD\K+N=?24C&11MGC=M#*BE<<!QZ.411RQ4-RIJF5C7.B<
M).Y>.#AX%3W:%+3WJ6UW2B,$3ZB(1O&<#(7L1SMRCX1O+Y]R+DKXA34CH&AD
MPRV7CG< I6"HBEC8X/ <_P":W/$J!GIX;7J&"FJWM%+W8<YQXY!'0K!K:V)M
M,QD+7>61.+C(WD6=/S7#K-+'41S_ !'N>">-V^&367F'NO\ 8VGR9G>S/V!Y
MF;M?N_X6E5MI@:Z;O9GMVG@ ,K:;%<FW"E!=@/;P*R:NDADBF(CS(1P'BO.T
M^KG2_*O/I/%_!:/$Z?WWAW#[:^?^3[8T$ W1-C =N:*.+!/7T0O6A^DMQ_#8
MO'0LD4FCK,8W-+12QC@<\<+VH?I+<?PV+TUCV/SV:<7A\$TJJBJJDE.A4'<O
MI3:/N2_P%.*#N7THM/W)?X"M'LJ^B<R4544%B@7E*QDC'LD'H.!!!ZA>JPKP
M";56AI()A?C'/D5*Y9$FDC03V=TKKH9!7M\BW;^[X9Y\L^"Z)"888VQL<P-:
M  ,\@OAY]9<F3RM-QKO1>[_WG#J?:KFUMPS_ /F-;^^[^U[$M!9<DY3/'AKH
M5-J,3[B[V/UV?%7![79VN!QX%?#PK+@3QN-;^^[^UVW_ *;*J>1][CJ*F:8C
M8X"60NQ[LKDOT+IBY9.FG7*V6W!W,'=CAP\4>QKQAS0X>!&5<%<N!9._"^"U
MK<<@KL(B8)&$1%("(B *F%5$!:1P6LZVL(OU+24Q8W9Y0PRNQZ6SJ >BVA62
M\ ,#B2IC)Q>45E%26&1EGM5!:(13V^..(!H!#>9]I6=43,@A?+*[#6-+B3X!
M<>UA55VA^T6GOSYIIK'<L0S,<?1A/B%UQABJZ0/]&2&9F?2Y%I']*BMWMY[.
MV_1_MX5V+F,EW_='RSVAW&NUC=)[T066MDXHZ7/(\<9_,KJG8E?JF(U6E+P7
M>6T'I1%WUHSQQ[EB]MEOI*#3=FIK=!&R 5S7;(F\.?/ 73[?:Z%M1#<&TT3:
MY\+6F4-])PP%PTTRC<Y-GT?B/B5=OAU=.S$>=ORFO]_<F?#"JJ855Z!\B$1$
M 1$0!$1 6NY%<Z[3+-=;E5T<E!')- T8+&NQ@^*Z,0J$#\U>N?ERW8R9VPWQ
MPG@YS7Z-DN45'%4S=W6LBP96\1CP4EIG2K+53M?&3+*\XEW#'#V*<O%[MMGD
MA\XSMCDE.UG4J5B>R5@?&X%KAD.'50W:X;6_2R5Y>_<EZE[F(*"-LL1:T!K,
M\/>KV4L$43FX&W)<,]%[RO,<4C\9+03CQ7+1K^XU1KXHZ5KO1=W8:,E@'4I3
MI79G8NA=J?+PI/LFM86RANDC7W"5[1 TELD9!X>!4/2:YIHVTU&VE>VDB(;O
M!QN]J\-/3UM\LE<VI))=Z+),8))Z+6X-.W26MCI&TK]SG?./+ 7717&2E7J)
M==&%\W';.B/?9UBJKHJNG])K@\\6%AZ=%I=[ELM1>HX:T/\ *6X!>WEGH"MR
MMEMD\W,BC>UNT!KMPX\%"2:(%PNK:\RF-F_+HSUQU7EZ>*4_4VL9/1OE_EI1
MP^B&U38JFXUT$E)M+0P-V$XV#Q"Z+IJG;3VN"/<U[V-#7. XDJ^EM,<.QSCE
M[#P/BI-D;&G+6@9YK166SBHSY2Z,G"J+<H+E]E[/FA4D+MCMF-V#C/BJDAHX
MKPDG\%9LB*^#Y$[0XKO4Z[K1=J39<)WX9'&,[QR&/%0-VT+KR=NRBTS<6MY]
MX!@GW<5]DU%KH*VM@K9Z6*2JA^9(YN2U2C#D8\%QUZ1*QV2>6?2ZK]266:2.
MDHCL2[Q[GY_2=F/:(9"\Z9NKCXD9S_NKAV==I/D[86Z7N3 ..6L /QROT":.
M"KA=SE)\MGS.6^SX*M_9UKTT<]/5:4N1<_C'(YH):5F1=FNM(;'44D^E[E4/
M8[_%Z(X$]0ONE%96-+ /A7_TSUM>*<4==IFX0U$#/]/.\#:0/JDJ+MO9CKVF
MJ"Y^D[B['SLM&'+[^PJ(YL'PE'V4ZW96N[G3M?'!(-Q& ,%3\VAM56VV&JN-
MFJHHV [CC):/%?9I5DD;'@M>W+3SSQ!6&HIAJ(XDCU?"?&-1X79OJ>5[KV9R
M'_I]M5[HK5-4U\LC+;, ZFIY.>/6]@*Z10_26X_AL4JQC6,#6 -:.  &  HJ
M@^DMQ_#8IIK\N.U''K]9+6WRODL-_!-#DJJBJK',44'<_I1:?N2_P%.*#N?T
MHM/W)?X"M'LK+HG41%!8HO.5HD8]F.8(7JA0C'&#XFO]"ZBU#=*9[<%E2\8_
M-8S8<8X+H/;):?-^OJV0-_QU;6S-/M/ K3&Q'AD<5])58I5IGS=M;A8T8S81
MX+JO_3Q,*?5-?3N..^I\M'B05SAL/'DMK[-*WS7K:VS'@V1_<N)Y8<L]3ZJV
MC73O;8F?4+?]E>K6JY?/(^@"(BD!$1 $1$ 1$* *R7HK\*UX'!",D+J>V4-U
MM$T-SB9+3LQ(0[H6\<KA>O=7W:\S^362H%):(VDQF-Q:Z0-X$G')=ZU)"^IL
M%PAA)$DD+FM(\<+C-JUM#;[;3T51IACI:=O<O+MH)+>!SE4L2/I? 4TW-5^8
MT^$WPOO#.=4<U\HQ%615^_T.];WKN\;@'J"N_=G>J&:E93&3:ROIV%D[&DXX
MCF%I[>T.WOVEFF(3DAF!M'-2_9Q7B]ZOK+I!;Q04K8C3", >F\<R".:RA%)Y
M3R>EXVYZC3N5U*@XKO*_L=;55JFJ-=6#337"XUS#4 <((CN>3[NBYK=>VVJG
M=(RRVKNHQ\V6H/'X!;Y/B4LG=47S#-VDZRK'9\YQ4X\(X@%X_+[6+> O+\CJ
M6@Y3).&?4B+YMMW:KJZD</*'T]8SKOCV_P"X6\V3MGMLTS8+W3243B!_E9Z3
M,_\ "G)&#K*+!M=SHKK3MJ+=515,)^M$[(6<@!Y*AY*J% :)KO2,]_K*>HI9
MV1.8.[=O\,J(U=>KMI^X6ZW6YQ$,43 WT-W?N\,KI-:]L<#G/:7-\ %SK6U]
MFHZ:&"F#2^1V622-RZ/'AX+HIME*<:VLG/;3&$)6)X.@PU&^.G[UNV65@<6'
MIPXK!I=/VVAGJ*BDIHV33?/<>(*Y_I#4M?65KX:V=SI-G^.1PR0NB4DPJJ!S
M9(GX QDGB2L+MU%CKR;51C=6K/8U+66II;%%#36ZDABD?N)<YN6_DI.TW=E5
M1T,XC=& S<6^#NJA=9VRHJ+4]D<1,S3O8''TL+'T?2UE/;)(ZQCFG=ED;N):
M/$K.V49Z93_BR:U1<=0X?P-'2*&1DT8>T .>,D9RLD- Y<E$V6%T<;7EC2'<
M=X*ENJB'*Y$^'P5PK7O#!DKSEF:SGS6%),7..>(/)3.6!"ML]Y)B2>"\3(O$
MR*TR+%S-U#X/=DQ8[+>7(K.BD$K0YAR%#N<KZ:J[AXS\PJ(7<XD)TY643816
M1O#P".JN73G/1RXP514;R55("(B %4540%%"T/TEN/X;%-J%HOI+<?PV*459
M,JJHJJI8HH.Y_2BT_<E_@*<4'<_I1:?N2_P%:/9671.HB*"P0\D1 <D[>[(:
MBVT=VB9EU,_NY,#ZIY? KBPAP[!YA?6=]MT5VM550SC,<["P^PGD5\Q5MNDM
M]=/1S#;)3N+3GF0.J]/1VIQ<6>7K*?5N1'"(97O$UT<C)(\A['!S2.A'$+);
M%[UZ-B\.BZI/*P<B6#Z3TM=&W>PT5:P\98QN'@[JIC*Y-V-W@1F>T2GT23-"
M3_N NK@KQK8[98/;IEN@BY$"+,T"(B (B90!4*JK2@(FKN[:.Z-@GX1/ P[P
M/M4F3N +2"/'/-:=K,?ZT9Y;!D!8>G-3"AE91W%Q\G)Q'*?J>PKH\EN&Y&/F
MXEAF[58?)32-BX2'(;[US'6O9T[4LSJN.D=0UV.+XYQM?[2,+J@VR!KFX+>8
M(_E654\5)3RSU#VQQ1-+GO)P&M',KFDE+AG;I=5;I)^;3+#/EBHTDW3^JJ:U
MZK,T5+,-[)HI (SCF"?%3%WUQ55=+';-&4SK=;J8.8Z8<729X$@]/>K];:F.
MM[LV:2)K;!1O+(!CTZAYX948R"21NQ@CCB:,"&,\6CV^U4JK:;PLGH>(^+V:
M]05KZ[7L0S;?+++WLQ$DV/2>\Y)/O6=!;Y'-9AFX@9):/Y6R-MD,5(:NH#V0
MM:-L1(WR'Q'L5=,U])554E <TQJ7 >D<_ KLJTTI1W-'A3U,(/!$QVB0MSW0
M'#QYJTVP@9=EGO"E[A)4"\SM,GD]/$2&@]5C6O4L=17LI:F&-T4CN[$K>A\5
MK+122R5CJXMXR1KZ![8RUP.T^ YK!GMYVX?'Z*WE\,#GN .S#BW#O8L&KH-A
M.<X\>BX<8X.K^1K-FNUSTS5NJ+)4.AY;HW<6.X\L+O/9WV@T>JX?)YP*6[QC
M_) X_.]K?$+BM;0MR2\8;U(40\3T53%44;S%4Q.W1SM^<,?\*0XL^N0<JY:7
MV9ZO9JJS!TQ:RXP>A41@\SZP]A6Y90J>=3D1.P0#[5HFKM-FY4H,+\2Q'<)'
M<CGHMXK213N/\J+,O ;AEO4%9.;KFIKM&L:U9!Q?3-1TOI&HMU3,^>1CJES,
ML\,+>K72MAA:YH>TXXM)ZKWIWQRM#F@%V,>Y9('!7FW=+S)]F<4J8>5'HPJV
MF;41O&W+R,95S*2,2"3'$,V$>*RP$ YJ-BR%)X/.&)L; U@PWH%>\':=N 5<
M$*G&$1DP'4LKCET@RL.<=T\M)R5+RN$;"X] M>EG[Q[G'J5A=PCIIW29Z%ZL
M=(O$O5CI%S.1UJ)DLW22-8SYSO%91MDI&=[?@K;+$7N=*[D.#5.8X+HJK4EE
MG+;:XRQ$PK?!+3C;(\.;T]BS%7"+I2P<S>7D!$120$1$ 1$0!0M%])KC^&Q3
M2A:+Z37'\-BE$,F554554DHH.Y_2BT_<E_@*<4'<_I1:?N2_P%:/9671.HB*
M"P1$0%NWQ7+>UW36XLO-*P%S1W=1@=/%=47C501U,$D,S0^*1I:YIZ@JU<]C
MRBED-ZP?,K8LX(X@\EZ-BP>2V75>G7V*ZOCVDTTAS _ICP*B1#QQA>DK-RR>
M;Y;B\,LMLLM!6P55.<20OWC'AX+O]CN45UML-7 06R-XCP/4+A#8>7#BMLT)
M>W6>L,$[O]',>(/U#XA<UT=RRCHHEM>#K@16->' %I!:1D'Q5X7&=H1$4@+P
MG>02 2O=8U0/2*E$,P)ZB5OS7E1T]?5-SMF(694\U%5/5=$8IF;9&76HEJ'%
M\SBYP&,K4+ER=CJMIKCZ#EJURSQ\5W4\=''>VR7T3K7S=,RW79Y\D<=L4Q/S
M?85B]L^HC7U<>EZ&H$<;F>45LK3G#!R9^:T2[O$<3W/QAH)XJ$M,O?P/FJ=T
MCIGX<2<G:.0RN;6U1A)->YIH;)33W=$C3N:^>-\;=M/" V)HX</%8=7')8IJ
MFXG+I'.Q <\.*E(('$ M8[N\XX<@/#*EYK73W&C%'7QO[K(VNY%@6>EM53>3
M?45N:;1J-'<G7J"*>J,NV G>X'GGJLJFHGFM@EIR?2<"S/,\>:JYU!I:[.I8
M:>:?>X<'C#"/<NM44,=2V"6&CIVDQ@M<&C+1[%WV7J$<G%&ES>8\$!=;)%<R
M'2/?'*1Q(&1^:C*#2<-'61SOG[W8[<V,# RNB,H"PY /N'C[5@W%D=)3RSS%
MH;&-Y/M\%Q+46/TKW.K]M6GN?L:C>9:6C!DK9&L#CG YJVW7"*X6^;S:6SSP
M.&62\ 6'FM*N<K:Z]OJZF.25KG?]L'./!;;V;VN>FN%3+/3EE-4,(:Q_,^!6
MLJ8QCSV1"QREPS*K*,.B:61[ X9+>@6NUM+S#N+3R.%OU;"X'<1AASQ'+'@M
M8K83_D;G+'GT >B\UOG@["!TY>9M+ZA@KJ=Y;&XAD_\ Y,7T%%<Y)6,DCFW1
MO:'-/B#Q!7SK<8.>X8'U@NH]G%R\LTO QY)DIGF$D^'1<VHREE'3I]LGM9OC
MZR61A:]V05X&3.5B=[X*UTGM7&['+W.U5)<)&;!5OIY0YA]'J%L-)5LJ8@^,
MY\1X+3'RGH["I2U\E%.V2-Q+<^DWQ"O7J=CPRENDWK*[-\"JL.W5T-? )87
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M%HOI-<?PV*:4+1?2:X_AL4HADRJJBJJDE%!W/Z46G[DO\!3B@[G]*+3]R7^
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M1 $1$ 1$0!$1 %"T7TFN/X;%-*%HOI-<?PV*40R95515522B@[E]*+3]R7^
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M9_I/E%0>M+^V?Z3:QN1,J%H?I-<?PV*X:AH">#I/VRL:R5+*N^W">(/[HL8
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< B(@"(B (B( B(@"(B (B( B(@"(B (B(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  H ,D# 2(  A$! Q$!_\0
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M\/KI6N6%S#):$K#*5W+)'V''<>_M7:TE 'GO@G3=3T_QMXCO+[3[B"UU"7?
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M_ EO<6'@_3K&]MI;>YMHMDB2+WR>AZ&L7XK:7J.MZ-:6FE6,UU-'<B5MH
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*4G)*X1BHMV/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
